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INTRODUCTION 
 
 
Proteinuria and Progression 
 
Proteinuria is a frequently present manifestation of glomerular renal diseases. Under normal 
circumstances filtration of circulating proteins is limited as a consequence of the size- and 
charge selective properties of the glomerular basement membrane (GBM). Small molecules 
that still pass the GBM are reabsorbed by the renal tubular cells. For a long time the 
presence of proteinuria was merely considered a consequence of glomerular and/or tubular 
damage. More recently several data suggest that proteinuria has also a more active role: 
substances that pass the GBM may contribute to development of renal damage, particularly 
the development of tubulo-interstitial injury [1,2]. It is not known which components of the 
filtered molecules are the culprit, and also the underlying mechanisms that are responsible 
for tubulo-interstitial damage are still not elucidated. However, there is no doubt that 
proteinuria is associated with an unfavourable renal outcome, independent of the underlying 
renal disease.  
 
 
Tubulo-interstitial damage 
 
In the past decades several investigators have shown that the extent of tubulo-interstitial 
damage, which often accompanies primary glomerular diseases, is significantly correlated to 
renal function. Tubulo-interstitial damage is even more predictive for renal function 
deterioration than glomerular damage [3,4]. 
Several mediators have been mentioned to be involved in the development of tubulo-
interstitial injury. For example potentially damaging antibodies, monocytes, growth factors, 
cytokines, and complement factors seem to play a role in the cascade that results in the 
generation of tubulo-interstitial inflammation and fibrosis [5,6]. 
The presence and severity of tubulo-interstitial injury can be examined non-invasively by 
measuring the urinary excretion of several marker proteins. The most studied markers are 
cellular enzymes like lactate dehydrogenase, N-Acetyl-β-glucosaminidase, alanine 
aminopeptidase and alkaline phosphatase, and low molecular weight proteins like α1-
microglobulin, β2-microglobulin and retinol binding protein. Unfortunately, most of these 
markers mainly reflect proximal tubular cell injury [7,8]. A reliable marker for distal tubular 
injury is lacking. 
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Renal Function 
 
In proteinuric renal diseases the risk to develop renal insufficiency is increased. The golden 
standard to determine the glomerular filtration rate (GFR) is to measure the clearance of 
inulin. However, measurement of the inulin clearance is a laborious and cumbersome 
procedure. In daily practice serum creatinine levels or the calculated creatinine clearance are 
used to determine renal function. In general creatinine clearance overestimates GFR since 
creatinine in not only filtered in the glomerulus but also secreted by renal tubular cells [9]. It is 
not known if the renal handling, particularly the tubular handling, of creatinine is changed in 
patients with severe proteinuria. Thus, it is not clear if serum creatinine levels or creatinine 
clearance are reliable markers for GFR in patients with a nephrotic syndrome.  
 
 
Treatment strategy in patients with idiopathic membranous nephropathy 
 
In the past two decennia we have focussed on the prognosis and treatment of patients with 
proteinuria due to idiopathic membranous nephropathy (iMN). The treatment of patients with 
iMN includes supportive therapy like ace-inhibitors, anti-hypertensive therapy and lipid-
lowering drugs. In some patients there is a role for immunosuppressive treatment, like 
combinations of steroids with alkylating agents, azathioprine or cyclosporine. Consensus with 
regard to the preferred time point to start immunosuppression is lacking [10,11]. Since 40-
50% of the patients will achieve remission of proteinuria spontaneously, we advocate to limit 
this kind of potential toxic treatment to patients who (will) develop renal insufficiency. The 
availability of reliable prognostic markers could be helpful and allow identifying patients with 
an unfavourable prognosis in an early phase of their renal disease. Several assumed 
prognostic markers such as high age, male sex, level and duration of proteinuria, and 
presence of tubulo-interstitial damage lack sufficient sensitivity and specificity to be useful to 
guide treatment [12]. In the past, two small cohort studies in our center revealed that the 
urinary excretion of both β2-microglobulin and IgG were useful to identify patients at risk for 
renal insufficiency with a sensitivity and specificity of about 90% [13,14]. If these results 
could be confirmed these two markers should be suitable to identify those patients in whom 
immunosuppressive therapy is indicated. 
 
The efficacy of immunosuppressive treatment in idiopathic membranous nephropathy has 
been described in several small cohort studies. Treatment with alkylating drugs like 
chlorambucil or cyclophosphamide resulted in favourable effects on proteinuria and renal 
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function. The efficacy of such treatment was supported by a well performed randomized, 
controlled trial carried out by Ponticelli et al. [15]. These Italian investigators studied the 
effects of chlorambucil compared to placebo in patients with iMN, a nephrotic syndrome and 
a normal renal function. 
 
 
OUTLINE OF THE THESIS 
 
Persistent proteinuria in the nephrotic range (>3.5 g /day) is associated with the development 
of renal failure. In our studies we noticed a mother and two daughters with a remarkable 
familial nephropathy, characterized by longstanding proteinuria with preservation of normal 
renal function. To get more insight in this potential harmless proteinuria a detailed analysis of 
urinary proteins was carried out in these patients, which included the selectivity of the 
proteinuria and the presence of β2-microglobulin as marker for tubulo-interstitial damage. 
The results are described in chapter 2. 
 
The above-mentioned markers for tubular function cannot differentiate between proximal or 
distal tubular cell injury. The alpha and pi iso-enzymes of glutathione S transferase (GST) 
are present in respectively proximal and distal tubular cells. We have measured the urinary 
excretion of both GST alpha and GST pi in patients with proteinuria in an effort to determine 
the site of tubular injury. The data are presented in chapter 3. 
 
Activation of complement is suggested to play a role in the development of tubulo-interstitial 
injury. Activated C3 is in the center of the complement cascade. C3d is a breakdown product 
of activated C3, and its measurement thus could provide information on complement 
activation. We have examined the level and source of urinary C3d in patients with tubulo-
interstitial nephritis and in patients with glomerular diseases (chapter 4). 
 
An overload of filtered proteins will be a burden on renal tubular cells. We hypothesized that 
the renal handling, particularly the tubular handling, of creatinine could be changed in 
patients with proteinuria and questioned the reliability of serum creatinine levels and 
creatinine clearance as markers of GFR. In chapter 5 we have compared inulin clearance 
and creatinine clearance in patients with different levels of proteinuria.  
 
We have proposed urinary β2-microglobulin as a marker of tubulo-interstitial injury and 
prognosis in patients with iMN. To be reliable as a marker for tubular cell dysfunction, the 
reabsorption of β2-microglobulin should not be influenced by the presence of other proteins. 
Introduction and Outline of the Thesis 
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Therefore we measured the fractional excretion of β2-microglobulin before and after the 
infusion of albumin in patients with proteinuric renal diseases (chapter 6). 
 
Previous data in patients with idiopathic membranous nephropathy (iMN) revealed that the 
urinary excretion of β2-microglobulin and IgG could be helpful in the identification of patients 
at risk for development of renal insufficiency. A prospective validation study was carried out 
to confirm the prognostic value of these proteins in patients with iMN (chapter 7). We also 
tested the predictive value of other parameters such as serum albumin level and urinary α1-
microglobulin excretion. 
 
The first studies with immunosuppressive treatment in patients with proteinuria and iMN have 
used combinations of steroids and chlorambucil or cyclophosphamide. We also have applied 
both treatment options. We have analyzed the effects of chlorambucil and cyclophosphamide 
in patients with iMN and deterioration of renal function. As described in chapter 8 we 
observed a better efficacy and tolerability of cyclophosphamide compared to chlorambucil. 
Since this observation our standard regimen consists of cyclophosphamide with steroids. We 
have determined the long-term efficacy of immunosuppressive therapy by extended follow-up 
of a cohort of patients with iMN and renal insufficiency (chapter 9).  
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ABSTRACT 
 
Background: Nephrotic syndrome in childhood is mainly due to minimal change nephropathy. 
In general, it is characterized by selective proteinuria, steroid-responsiveness, and 
histologically by podocytic foot process effacement. Familial presentation is rare and mainly 
restricted to one generation.  
Methods: We describe the occurrence of a familial nephropathy in a mother and two 
daughters. An initial diagnosis of minimal change nephropathy was made, but subsequently 
unique features became apparent. During follow-up, detailed studies of renal function and 
urinary protein excretion were performed. Available frozen renal biopsy material was revised 
and processed for immunofluorescence to detect abnormalities in the expression of heparan 
sulfate proteoglycans. The latter results were compared with renal biopsies of a control group 
composed of five adult patients with minimal change nephropathy. 
Results: The mother and two daughters were proteinuric since their early childhood. The 
mother revealed a persistent nephrotic syndrome for more than 20 years despite treatment 
with various immunosuppressive drugs. Likewise, treatment with prednisone was ineffective 
in the daughters. All three patients retained normal renal function during follow-up. Detailed 
measurements revealed that the proteinuria was incredibly selective (selectivity index 
approximately 0.01), and there was no evidence of tubulo-interstitial damage, as reflected by 
a normal excretion of the low-molecular weight proteins β2-microglobulin and α1-
microglobulin. Renal biopsy performed in the mother and one daughter was thought to be 
compatible with minimal change nephropathy. However, histologically, two remarkable 
findings were made. By electron microscopy, there was no evidence of foot process 
retraction; specifically, the foot process width and slit pore diameter were normal. 
Furthermore, in contrast to the control patients, the expression of heparan sulfate 
polysaccharide side chains, as reflected by the staining with monoclonal antibody JM403, 
was normal.  
Conclusion: We propose that this family represents a new familial nephropathy. The 
molecular basis of the permeability defect remains to be identified.  
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INTRODUCTION 
 
Nephrotic syndrome in childhood is most commenly caused by minimal change nephropathy 
[1]. The term minimal change nephropathy is applied because of the absence of glomerular 
abnormalities in light microscopy. However, on more detailed examination by electron 
microscopy, alterations of the glomerular visceral epithelial cells are apparent in the form of 
effacement of the foot processes. It has been suggested that proteinuria in patients with 
minimal change nephropathy is the consequence of a loss of negative charges in the 
glomerular capillary wall [1]. Clinically, patients with minimal change nephropathy present 
with a selective proteinuria, that is, there is a preferential loss of the negatively charged 
albumin when compared with immunoglobulin G (IgG). Most patients quickly respond to 
treatment with corticosteroids, and even if left untreated spontaneous remissions of 
proteinuria do occur and the prognosis is good [1,2]. After years of follow-up, proteinuria 
disappears, and few patients, if any, develop renal insufficiency. Familial occurrence of 
minimal change nephropathy has been reported regularly, although in most families, the 
nephrotic syndrome is restricted to one generation [3,4]. The present study describes a 
mother and two daughters, all three of whom developed a nephrotic syndrome during early 
childhood. Clinical and histologic features initially suggested a minimal change nephropathy. 
However, several arguments favor the idea that these patients represent a new syndrome. 
First, the nephrotic syndrome was present in two generations; second, proteinuria was highly 
selective; third, the nephrotic syndrome was treatment resistant and persisted for more than 
20 years without causing renal failure; fourth, there was no evidence of foot process 
effacement; and finally, we observed a normal expression of glomerular basement 
membrane heparan sulfate polysaccharide side chains, which are thought to play an 
important role in the charge-selective properties of the glomerular capillary wall [5,6]. We 
propose that this familial nephropathy represents a new entity. The pathogenetic mechanism 
involved in the glomerular permeability defect remain to be identified. 
 
 
Case histories 
 
Case 1: The mother.  
Severe proteinuria was discovered in the mother in 1964, at the age of seven years, during 
investigations because of pretibial edema. Her blood pressure was normal, and the urinary 
sediment revealed no abnormalities. From 1966 to 1981, several efforts to reduce the 
proteinuria were unsuccessful. In this 15 year period, the patient was intermittently treated 
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with mevaquine (four months), high and low doses of prednisone and indomethacine for 
several years, a combination of chlorambucil and 6-mercaptopurine for three months, and 
two separate courses of cyclophosphamide (3 and 4 months, respectively). Throughout 
these years, she was regularly seen at the outpatient clinic, and the records show that the 
proteinuria persisted despite these treatment efforts. Urinary protein levels measured in spot 
urine ranged from 1.1 to 12.4 g/L, the variability most likely reflecting differences in urinary 
flow rate. Whenever measured in urine samples collected over 24 hours, proteinuria 
exceeded 3.5 g/24 h (Figure 1). Most important, hypoalbuminemia was present at all times, 
indicative of a persistent nephrotic syndrome (average value 23 ± 2 g/L, range 19 to 27 g/L 
(N=66; Figure 1).  
From 1966 onward, increased levels of total cholesterol (>10 mmol/L) were reported. 
Because of the latter, since 1982, treatment was started with cholestyramine, and after 
several years this was changed to simvastatine. In 1990, she was supplemented with 
levothyroxine because of hypothyroidism. In the period between 1978 and 1983, she was 
pregnant three times. During these pregnancies she had to be treated with methyldopa and 
chlorthalidone because of a slight rise in blood pressure to maximum levels of 150/60 mm 
Hg. No increase of proteinuria was observed, and renal function remained normal. She gave 
birth to two daughters and one son, all born at term. Renal biopsies were performed in 1971, 
1973, and 1978 (discussed later in this article).  
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 1. Time course of serum albumin (closed squares) and 24-hour urinary protein excretion (open 
circles) in patient 1. Serum albumin levels have been persistently below 30 g/L. Urinary protein levels 
measured in spot urines are not shown (discussed in the text). 
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Case 2: The oldest daughter.  
In this girl proteinuria was diagnosed in 1979 in the first year of her life. In 1991, at the age of 
12, she was sent  to a pediatrician by her family doctor because of persistent asymptomatic 
proteinuria. The proteinuria was in the nephrotic range (4.6 to 4.9 g/L) and accompanied by 
hypoalbuminemia (range 27 to 31g/L) and hypercholesterolemia (> 8 mmol/L). Treatment 
with high-dose prednisone (45 mg daily for more than eight weeks) was started. However, 
the therapy was ineffective, and it was decided to perform a renal biopsy (discussed later in 
this article). Subsequently, in 1992, she was treated with a course of cyclophosphamide (2 
mg/kg for 8 weeks). Again, the patient did not respond to this treatment. Because of the 
similarity in presentation between the daughter and the mother, who had a favorable course, 
it was decided not to do more interventions. Since 1995, the patient has been seen yearly by 
the same nephrologist who treated her mother. Laboratory examinations revealed average 
serum albumin levels of 29 g/L (range 28 to 30 g/L) and proteinuria of 2.3 g/24 h (range 2.0 
to 2.6 g/24 h). Blood pressures have always been low, and edema was never noticed  
Detailed clinical studies were done in 1996 and 1999. 
 
Case 3: The youngest daughter.  
In this patient, born in 1982, proteinuria was also first noted in the year after her birth. In 
1991, she went together with her older sister to the pediatrician. Similar to her mother and 
sister, she also had repeatedly elevated cholesterol levels (> 8 mmol/L) and hypo-
albuminemia (28 to 30 g/L). The proteinuria averaged 4.2 g/24 h during measurements in 
1991. Also, she was treated unsuccessfully with high-dose prednisone. A renal biopsy was 
not performed because of the known abnormalities in her mother and sister. From 1995 
onward, she had visited the nephrologist yearly at the outpatient clinic. She infrequently 
observed edema in her hands, but most of the time she was asymptomatic. Serum albumin 
levels averaged 29 g/L (range 28 to 30 g/L), and proteinuria averaged 4.5 g/24 h (range 4.2 
to 4.8 g/24 h). We studied this patient when she accompanied her family members in 1996 
and 1999. 
 
 
METHODS 
 
Clinical studies 
Clinical studies were performed according to a standard protocol. The measurements were 
carried out in the morning after an overnight fast. The evening before the study day the 
patients took 4000 mg of sodium bicarbonate to ensure an urinary pH above 6.0, which is 
needed to prevent degradation of β2-microglobulin. For the studies performed in 1999, the 
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patients also received 1200 mg of cimetidine in the morning in order to block tubular 
secretion of creatinine [7]. Upon arrival at the ward, the patients received 375 to 500 ml of 
tap water to enforce diuresis. The patients remained supine during two hours, except for 
voiding. Timed urine samples were collected, and in the middle of the collection period, a 
blood sample was drawn. Blood and urine samples were used to determine creatinine, the 
low-molecular weight proteins β2-microglobulin and α1-microglobulin, the enzyme β-N-
acetylglycosaminidase (βNAG), and the middle- and high-molecular weight proteins albumin, 
transferrin, and IgG. Blood pressure was recorded using an automatic device (Dinamap), ten 
consecutive readings being done at five-minute intervals. In addition to the timed urine 
samples, the patients also collected 24-hour urine samples for determination of creatinine, 
sodium, and total protein. 
 
Laboratory procedures and calculations 
The concentrations of creatinine, sodium, cholesterol, and urinary total protein were 
measured with standard automated techniques. The concentrations of albumin, transferrin, 
α1-microglobulin, and IgG in serum and urine were measured by immunonephelometry using 
antibodies in which the specificity was checked by Ouchterlony double immunodiffusion and 
immunoelectrophoresis. Details of these nephelometric procedures have been described 
before [8,9]. Urinary β2-microglobulin was measured by an enzyme-linked immunosorbent 
assay (ELISA) method [10].  
Creatinine clearance was estimated from the Cockcroft and Gault formula. In the 1999 
studies, renal function was assessed by calculating the creatinine clearance (ECC), 
measured after administration of cimetidine, by using the formula Ucr*V/Pcr, where Ucr is the 
concentration of creatinine in the urine, V is the urine flow and Pcr is the plasma 
concentration of creatinine. Since cimetidine blocks the tubular secretion of creatinine, the 
creatinine clearance measured during cimetidine administration closely reflects the 
glomerular filtration rate (GFR) [11,12]. The mean arterial pressure was the average of ten 
registered measurements. The protein selectivity index was calculated as the clearance of 
IgG divided by the clearance of albumin. In cases with IgG levels in urine below the detection 
limit of 2 mg/L, the selectivity index and urinary excretion of IgG were calculated using this 
lowest measurable value of 2 mg/L, and the results are expressed as “lesser than”. 
 
Processing of the renal biopsies 
For light microscopy (LM), a portion of the kidney biopsy was fixed in Bouin’s solution, 
dehydrated, and embedded in paraplast (Amstelstad, Amsterdam, The Netherlands). Two 
micrometers sections were stained with hematoxylin-eosin, periodic acid-Schiff (PAS), and 
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silver methenamine. For immunofluorescence (IF), kidney fragments were snap frozen in 
liquid nitrogen, and 2 µm cryostat sections were incubated with fluorescein-labeled antisera 
directed to human IgG, IgM, IgA, C1q, C3, and fibrinogen (DAKO, Copenhagen, Denmark). 
For electron microscopy (EM), a small piece of the biopsy was fixed in 2.5% glutaraldehyde 
dissolved in 0.1 mol/L sodium cacodylate buffer, pH 7.2, for four hours at 4ºC and washed in 
the same buffer. The tissue fragments were postfixed in phosphate-buffered 2% OsO4 for 
two hours, dehydrated, and embedded in Epon 812. Ultra-thin sections were cut in an 
ultratome (LKB Producteer, Bromma, Sweden), and stained with 5% uranyl acetate for 45 
minutes and with lead citrate for two minutes at room temperature. The sections were 
examined using a JEOL 1200 EX2 electron microscope (JEOL, Tokyo, Japan). 
 
Detailed morphometric measurements of the glomerular basement membrane (GBM), the 
podocytic foot processes and the slit-pore diaphragm were done on high-power micrographs 
of EM pictures. The foot process width was determined on x75,000 power micrographs as 
described [13,14]. In brief, the number of foot processes overlying the capillary basement 
membrane was counted and divided by the length of the particular segment of the capillary 
basement membrane. A correction factor of π/4 was used as recommended in the literature 
[13]. For these measurements, five random open capillary loops were used with a total GBM 
length of approximately 100 µm. The thickness of the GBM was measured on x15,000 power 
micrographs [15]. A total of 50 measurements in five loops was done. The slit-pore 
diaphragm was measured on x75,000 power micrographs. The width was measured on the 
level of the slit membrane or at the narrowest point. An average of five to eight slit pores was 
used for the measurements.  
 
Immunofluorescence studies of heparan sulfate proteoglycans 
To assess heparan sulfate proteoglycan (HSPG) staining of the GBM, the following 
antibodies were used (Table 1): (1) goat polyclonal antibody BL31; (2) mouse IgG1 
monoclonal antibody  (mAb) JM72, both directed against the core protein of agrin, which is 
the major HSPG in the GBM [16,17]; (3) mouse IgM mAb JM403  which recognizes a low-
sulfated domain within the heparan sulfate polysaccharide side chain, containing an N-
unsubstituted glucosamine unit [6,18]; and (4) mouse IgG2b mAb 3G10, which is directed 
against heparitinase-generated HS stubs [19]. By heparitinase digestion, a terminal 4,5-
unsaturated uronate residue is formed that is essential for recognition by 3G10. The staining 
of 3G10 can serve as a general HS marker, independent of the extent of HS modification. 
Indirect IF was performed as described before on 2 µm cryostat sections of kidney tissue 
[20]. Sections were fixed in aceton at 4ºC during 10 minutes (except for the sections that 
were digested by heparitinase before staining with mAb 3G10). Primary and secondary 
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antibodies (Table 1) were diluted in phosphate-buffered saline (PBS) containing 1% bovine 
serum albumin (BSA) and 0.05% sodium azide (IF buffer) and incubated for 30 minutes at 
room temperature. After incubation with antibodies, the sections were washed in PBS and 
embedded in Aquamount (pH 7.0; BDH, Poole, UK) and examined with a Zeiss Axioskop 
microscope with an epi-illuminator. For 3G10 staining, nonfixed sections were incubated with 
0.25 U/mL heparitinase (heparan sulfate lyase III; Sigma, St. Louis, MO, USA) in 10 mmol/L 
HEPES and 2 mmol/L CaCl2, pH 7.0, for one hour at 37ºC. Negative controls include the 
whole IF procedure without the incubation of the primary antibodies. All controls were 
negative. 
 
 
Table 1.   Antibodies used for immunohistochemistry 
Primary Antibody Secondary Antibody 
Antigen 
Code Ref. Dilution Code Supplier Dilution
Agrin core BL31 [16]  400 Rabbit anti-goat IgG-FITC De Beer Med. 500 
Agrin core  JM72 [17] 400 Sheep anti-mouse IgG-FITC Cappel 500 
HS JM403 [6,18] 800 Goat anti-mouse IgM-FITC Nordic  75 
HS stub 3G10 [19] 200 Goat anti-mouse IgG2b-FITC Southern 100 
Abbreviations are: Ref., References; HS, heparan sulfate; IgG and IgH, immunoglobulin G and H, 
respectively; FITC, fluorescein isothiocyanate. 
 
 
RESULTS 
 
A pedigree of the family is depicted in Figure 2. Proteinuria was only detected in the mother 
and her two daughters. The parents of the mother, a brother and his daughter, and a son all 
tested negative. In the family’s history, there was no mention of marriages between family-
members.   
 
Figure 2.  Pedigree of the family. The 
proteinuric members are depicted with closed 
symbols. Number II-1 represents our index 
patient (case 1). Numbers III-1 and III-3 are her 
proteinuric daughters (cases 2 and 3). The open 
symbols represent family members without 
proteinuria. The urine of one non-relative case 
was not tested (crossed symbol). 
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Table 2.   Results of repeated clinical studies in the mother and her two daughters 
 Mother Daughter 1 Daughter 2 Normal 
 1996 1999 1996 1999 1996 1999 Range 
Age (years) 39 42 17 20 14 17  
Body weight (Kg) 48.5 56.2 47 53.7 58.9 66.3  
MAP (mm Hg) 90 90 81 72 83 90  
        
Serum levels        
  Creatinine (µmol/L) 41 54 39 52 40 55 50-90 
  Albumin (g/L) 22 24 27 31 30 35 40-50 
  Cholesterol (mmol/L) 8.0 11.2 6.8 7.4 8.1 8.2 4.7-6.5 
  LDL (mmol/L) 5.29 7.8 4.54 5.43 5.64 5.40 <4.7 
  β2m (mg/L) 1.31 1.36 1.09 1.20 1.05 1.17 1.0-2.0 
  ECC (mL/min/1.73 m2) 149 119 185 144 205 152 80-150 
  GFR (mL/min/1.73 m2)  84  112  86 80-130 
        
Urinary Excretion        
  Total protein (µg/min) 2848 3241 250 603 1246 3211 <100 
  Albumin (µg/min) 2497 2237 184  358 1057 2248 <20 
  IgG (µg/min) <13.2 9.1 <2.6 < 3.8 <5.4 < 10.7 <10 
  Transferrin (µg/min) 152 192 13.1  32 84 155 <2 
  β2m (ng/min) 66 50 38 41 87 91 <200 
  α1m (µg/min) 13.2 9.1 2.6 5.7 8.1 <10.7 <10 
        
Selectivity Index <0.02 0.01 <0.08 <0.02 <0.06 <0.02  
Proteinuria (g/24 h) 4.6 5.7 2.0 2.7 3.3 4.3 <0.2 
Abbreviations: MAP = Mean arterial pressure, β2m = β2-microglobulin, α1m = α1-microglobulin. 
 
 
Clinical studies 
The results of the clinical studies performed in 1996 and 1999 are summarized in Table 2. All 
three patients have persistent proteinuria and a stable, normal renal function as reflected by 
the creatinine clearance and serum β2-microglobulin.  
The urine mainly contained  albumin, and in most of the urine samples the levels of IgG were 
below the detection limit. This precluded accurate calculations of the protein selectivity index; 
however, as indicated even when using the lowest detection level of 2 mg/L for urinary IgG, 
proteinuria was highly selective. Exact calculation of the selectivity index was possible in the 
1999 samples of the mother and yielded a value as low as 0.01.  
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In daughter 1, we noticed a discrepancy in albuminuria in the timed urine sample compared 
with the proteinuria measured in the 24-hour urine. This difference in quantity suggested that 
the proteinuria in this patient partially was orthostatic. To exclude the presence of mere 
orthostatic proteinuria, all three family members subsequently collected urine separately 
during the day and night. Also, in the overnight urine collections, overt proteinuria was 
observed with protein:creatinine ratios of 6.0 g/10 mmol (versus 12.2 g/10 mmol at daytime) 
in the mother, 1.2 g/10 mmol (versus 3.2 g/10 mmol at daytime) in the eldest daughter, and 
4.1 g/10 mmol (versus 5.3 g/10 mmol at daytime) in the youngest daughter.  
We measured the urinary excretion of the low-molecular weight proteins β2-microglobulin 
and α1-microglobulin to ascertain tubulo-interstitial injury. As indicated in Table 2, the values 
were normal and did not increase over the three year period. 
 
 
Histological evaluation of the renal biopsies   
The first renal biopsy of the mother was performed in 1971. LM revealed 28 glomeruli that all 
looked normal. In the pars convoluta of the proximal tubular cells, numerous PAS-positive 
granules were observed, mainly at the apical site. The remaining parts of the tubuli, 
interstitium, and blood vessels did not demonstrate abnormalities. No tissue was processed 
for IF or EM. The second biopsy (22 glomeruli) and third renal biopsy (15 glomeruli) 
performed in 1973 and 1978, respectively, showed similar morphology as the first biopsy by 
LM, that is, normal-looking glomeruli and no fibrosis in the interstitium (Figure 3A page 24: in 
color see page 152). Minor (1+) mesangial IgM deposits were seen by IF (4 glomeruli). By 
EM (3 glomeruli), no retractions of the foot processes could be observed in both biopsies 
(Figure 3B).  
 
The biopsy of the daughter, performed in 1991, revealed 19 glomeruli by LM examination 
and disclosed findings similar to the three biopsies of the mother as shown by LM, IF, and 
EM. Thus, in the daughter, granules in tubular cells also were present as a sign of protein 
reabsorption. No foot process retraction was observed by EM, and IF showed mild IgM 
deposits in the mesangium.  
Detailed morphometric measurements of two biopsies of the mother and of the biopsy 
performed in the oldest daughter revealed normal values of the thickness of the GBM, and as 
well as normal values for both the width of the foot processes and the diameters of the slit 
pores (Table 3). 
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Table 3.  Histomorphometric data 
 Biopsy 1973 
Mother 
Biopsy 1978 
Mother 
Biopsy Daughter Normal Range 
[14,21] 
GBM thickness (nm) 485 411 315 221 – 437 
Foot process width (nm) 561 764 605 511 – 963 
Slit pore diameter (nm) 38 37 33 35 – 45 
GBM is glomerular basement membrane. A description of the procedures is in the Methods section. 
 
 
 
Expression of glomerular heparan sulfate proteoglycan 
To study the expression of HSPG in renal tissue, we used various antibodies recognizing 
different domains of the HSPG molecule, including a mAb against the HS polysaccharide 
side chains. Since no renal tissue was available for the daughter, these studies could only be 
done on renal tissue of the mother. For comparison, we processed simultaneously renal 
tissue from five adult patients with a nephrotic syndrome and minimal change nephropathy. 
In our patient, we observed a normal, unchanged linear staining of the GBM with both 
antibodies against agrin core protein (BL31 and JM72). Barely any staining was observed in 
the mesangial regions (Figure 4B page 24: in color see page 152). These results are in 
agreement with our previous findings in normal human renal tissue [16,17]. Staining with 
mAb 3G10 revealed a linear staining of the GBM, including staining of the mesangium in 
accordance with earlier findings. This indicates that in this patient glycanation (the addition of 
HS side chains) of the HSPG core protein proceeded normally. Staining of the HS side 
chains using mAb JM403 revealed a linear staining of the GBM that was not discernible from 
normal renal tissue (Figure 4A). These data show a strictly normal distribution of the various 
antibodies against GBM HSPG and indicate no changes in HSPG expression in our patient. 
In renal biopsies of the five control patients, normal staining with both antibodies against the 
agrin core protein (BL31 and JM72) as well as with 3G10 against the HS stubs was observed 
(Figure 4C). However, the staining for HS with mAb JM403 was almost completely absent in 
three patients and was reduced for about 50 and 80% in the other two patients (Figure 4D). 
This is in contrast to our patient who did not show any reduction in GBM HS staining. 
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Figure 3. Light and electron microscopic pictures of the third biopsy of the mother.  
(A) Normal-looking glomerulus, methenamine silver staining , x350. (B) Electron microscopy 
of a part of a capillary loop. The foot processes of the podocytes reveal no retraction, x12,000. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Immunofluorescence of the third biopsy of the mother (A and B) and  
a biopsy of a patient with classical minimal change nephropathy (C and D).  
Unchanged presence of   (A) heparan sulfate side chains as detected by monoclonal  
antibody (mAb) JM403, and (B) core protein as demonstrated by mAb JM72 of hepa- 
ran sulfate proteoglycan  (HSPG) along the capillary loops. In the biopsy of a patient  
with classical minimal change nephropathy staining of the core protein of HSPG is  
normal (C), while the heparan side chains have completely disappeared (D, x600). 
The original color versions of figures 3 and 4 are depicted on page 152.
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DISCUSSION 
 
This study describes the occurrence of a nephrotic syndrome in a mother and her two 
daughters. This family most likely represents a new syndrome with the following 
characteristics: the presence of proteinuria in two consecutive generations, normal glomeruli 
as shown by LM, highly selective steroid-resistant proteinuria, an absence of effacement of 
the podocytic foot processes, and normal expression of heparan sulfate side chains. 
Initially a diagnosis of minimal change nephropathy was made in these patients. The 
presentation at early childhood, selective proteinuria, and the light microscopical finding of 
normal glomeruli were compatible with such a diagnosis. Unexpectedly, the nephrotic 
syndrome did not respond to treatment with steroids or other immunosuppressive drugs. Few 
patients, if any, with classic “minimal change nephropathy” are treatment resistant. In such 
cases, a diagnosis of focal glomerulosclerosis (FGS) is most likely, and the typical lesions of 
FGS are usually demonstrated in follow-up biopsies [22,23]. Admittedly, even the absence of 
such lesions in the third biopsy of our first patient does not definitely exclude the possibility of 
FGS; however, the clinical course in our patient clearly argues against such a diagnosis, 
since patients with treatment resistant FGS usually progress to renal failure. Most important, 
the finding of normal foot processes is a remarkable observation, as effacement of the 
podocytic foot processes is a characteristic finding in patients with minimal change 
nephropathy as well as in patients with idiopathic FGS [24,25].  
The occurrence of a nephrotic syndrome within a family is not unusual. About 3.4% of 
European children with minimal change nephropathy have affected siblings [3]. However, in 
most families the disease is confined to one generation. In one of the most extended 
overviews of familial nephrotic syndrome, 58 affected families were studied [3]. Only one of 
these families had proven nephrotic syndrome in two consecutive generations, a father and 
daughter, who developed proteinuria at the age of seven and two years, respectively. As 
expected in patients with minimal change nephropathy, their nephrotic syndrome responded 
to treatment with steroids. Familial FGS has also been described, and recently linkage to 
both chromosome 19 and 11 has been suggested [26,27]. In familial FGS, two generations 
are more frequently involved. Clinically, familial FGS is characterized by steroid resistance 
and progression toward end-stage renal disease [28,29]. Finally, two families have been 
reported in whom IgM nephropathy occurred in two generations [30]. In both families, the 
disease ran a progressive course with the development of renal failure, thus bearing striking 
similarity with the described cases of  familial FGS. Some authors consider minimal change 
nephropathy, FGS, and IgM nephropathy to be part of a cluster of related diseases [1,30,31]. 
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The debate on whether these diseases are separate entities will probably continue until the 
pathogenesis of these glomerular disorders is unraveled at the molecular level.  
In our patients, the proteinuria was highly selective; in fact, the value of 0.01 in the mother is 
the lowest value we have ever observed in a patient with nephrotic syndrome. Selective 
proteinuria is indicative of a preferential loss of albumin. Theoretically, preferential loss of 
albumin might be the result of an abnormal charge of the albumin. We excluded this 
possibility by testing urine and serum samples of the mother by agarose-electrophoresis. The 
increased protein loss in our patients may result from alterations in any of the components 
that constitute the glomerular filtration barrier. The highly selective proteinuria observed in 
our patients is generally considered to reflect a defect in glomerular charge selectivity 
[32,33]. The polyanionic coat of the glomerular epithelial cells and particularly the negatively 
charged heparan sulfate side chains in the GBM are the main constituents of the glomerular 
wall negative charge. Removal of sialic acid from the glomerular epithelial cells causes foot 
process fusion [34,35]. Thus, foot process effacement may reflect loss of glomerular 
epithelial cell polyanion. In our patients, podocytic foot processes were not retracted, 
suggesting that the polyanion charge of the visceral epithelial cells has remained unaltered. 
We also found no evidence for changes in HSPGs, which supposedly are involved in minimal 
change nephropathy [20]. 
Our patient demonstrated normal staining with JM403, a mAb directed to the negatively 
charged heparan sulfate polysaccharide side chain. This finding clearly separates the 
disease in our patient from minimal change nephropathy, since all patients in our control 
group showed the loss of heparan sulfate and fusion of podocytic foot processes. Overall, 
there was no evidence of abnormalities in the best known negatively charged components of 
the glomerular filter. Obviously, we cannot  exclude the presence of structural abnormalities 
of heparan sulfate side chains or damage of other charged molecules.  
 
Recently, major progress has been made in identifying proteins involved in maintaining the 
integrity of the slit pore diaphragm. One key component is nephrin, and mutations in the 
nephrin gene on chromosome 19 are held responsible for the congenital nephrotic syndrome 
of the Finnish type [36,37]. Animal studies have indicated that proteins associated with 
nephrin such as CD2-associated protein (CD2AP) may also play a role [38]. CD2AP 
knockout mice develop proteinuria and EM shows effaced foot processes [38]. The finding of 
a normal slit pore width and the presence of normal foot processes in our patients argues 
against abnormalities in nephrin, CD2AP, or other proteins involved in the slit diaphragm. 
Finally, one can speculate on the role of constituents of the GBM. Knowledge of the 
composition of the GBM is rapidly expanding [39]. The GBM subtype of laminin (laminin 11, 
α5β2 γ1) may be involved in proteinuria, since laminin-β2-deficient mice develop minimal 
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change like nephropathy [40]. However, these mice demonstrate foot process fusion, arguing 
against a defect in laminin in our patients. The exact structure of various proteins in GBM 
remains unknown, and probably more components of the GBM remain to be identified. 
Further research might help in identifying abnormalities that can cause proteinuria with 
retainment of the normal podocytic architecture. 
Although proteinuria has been present in the mother for over 30 years now, she has retained 
a normal renal function. It is well known that patients with renal disease and proteinuria are 
prone to develop renal failure. In fact, proteinuria is a major determinant of progressive renal 
failure [41], and it is thought highly unlikely that patients with proteinuria will retain normal 
renal function for more than five years [42]. Proteinuria in itself may contribute to ongoing 
renal injury by causing mesangial and tubulo-interstitial injury [41,43]. No tubulo-interstitial 
injury was observed in the third biopsy in our patient, taken almost 14 years after 
presentation. This absence of tubulo-interstitial lesions seems compatible with the rather 
benign course. We propose that this may be explained by the characteristics of the 
proteinuria, that is, the almost pure loss of albumin. Although in vitro studies have suggested 
that albumin can cause tubular cell injury, in general, this is observed at high albumin levels 
that are not obtained in patients with a nephrotic syndrome [44,45]. Therefore, most likely 
other factors such as growth factors or cytokines are more important in causing progressive 
renal injury. Excretion of these inflammatory mediators may be better reflected by the 
excretion of IgG. In this respect, this would fit with our observations in patients with 
membranous nephropathy where the outcome is predicted by the urinary excretion of IgG 
rather than by total proteinuria [9]. 
In conclusion, we have described a familial nephropathy with several unique characteristics 
that clearly differentiate it from minimal change nephropathy or FGS. The molecular basis of 
the glomerular permeability defect remains to be identified. 
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ABSTRACT 
 
In patients with renal diseases, proteinuria is a major determinant of progressive renal failure, 
probably by causing tubular cell injury. Little is known on extent and site of tubular cell injury 
in patients with proteinuria. Glutathione S transferases (GST) are cytosolic enzymes. The 
alpha isoform is present only in proximal tubular cells, whereas the pi isoform is confined to 
distal tubular cells. We have studied the urinary excretion of both isoenzymes in 56 (38 male 
and 18 female) patients with glomerular diseases and proteinuria. The mean age was 45 ± 
(SD) 16 years, the median creatinine clearance was 80 (range 27-159) ml/min, and the 
median albuminuria was 4.2 (range 0.7-16.9) g/10 mmol creatinine. The excretions of both 
GST alpha (median 35.9 μg/10 mmol creatinine) and GST pi (median 24.8 μg/10 mmol 
creatinine) were elevated as compared with control values (upper limits 10 and 12 μg/10 
mmol creatinine, respectively). The urinary excretion of GST pi, but not that of GST alpha, 
was inversely correlated with the creatinine clearance. The highest levels of GST alpha were 
found in patients with a well-preserved renal function, whereas highest levels of GST pi were 
found in patients with renal failure. In a small number of patients we performed 
immunofluorescent studies of renal tissue. An increased urinary excretion of GST alpha 
correlated with brush border damage and decreased staining of proximal tubules for that 
isoenzyme. Our data suggest that in patients with proteinuria initial injury is apparent at the 
proximal tubules. Measurements of GST alpha and GST pi appear useful to study 
longitudinal timing and site of proteinuria-induced tubular cell injury. 
 
 
GST alpha and pi in Proteinuric Diseases 
 
 33 
 
INTRODUCTION 
 
Proteinuria is a major determinant of the progression of renal failure [1]. Recent studies have 
indicated that proteinuria is not merely a reflection of glomerular damage, but in itself 
contributes to further renal injury, in particular by causing tubulo-interstitial inflammation [2]. 
The mechanisms involved in this latter process are not fully understood. Evidence that 
proteins may cause tubular cell injury either directly (e.g., proximal tubular injury by 
lysosomal overload) or indirectly (e.g. cell injury mediated by complement activation or 
oxygen radical production) has been put forward in several recent reviews [3-5]. Detailed 
information on magnitude and site of tubular cell injury in patients with proteinuria is lacking. 
Thus far, several markers have been used to study tubular cell injury in humans. The best 
known are low molecular weight proteins such as β2-microglobulin, retinol-binding protein, 
and α1-microglobulin, and cellular enzymes such as β-N-acetyl-glucosaminidase (NAG), 
lactate dehydrogenase, and alkaline phosphatase [6-9]. Unfortunately, most of these 
markers mainly reflect proximal tubular cell injury. Reliable markers of distal tubular cell injury 
are lacking. Recent studies have suggested that measurement of the urinary excretion of 
glutathione S transferases (GST) alpha and pi might allow differentiation between proximal 
and distal tubular cell injury [10]. GSTs are cytosolic enzymes involved in the detoxification of 
foreign compounds by the addition of glutathione to a wide variety of xenobiotics [11,12]. 
Several isoforms of this enzyme exists, and in humans four main classes have been 
characterized: alpha, mu, pi, and theta [10]. In the kidney GST alpha and GST pi are the 
main isoforms present: GST alpha is highly expressed in proximal tubular cells, whereas the 
pi isoform is found in distal tubular and collecting duct cells [11,13-15].  
  
In the present cross-sectional study, we have measured the urinary excretions of the alpha 
and pi isoforms of GST in patients with proteinuria. Our data strongly suggest that during the 
early phase of proteinuric renal diseases, proximal tubular cell injury predominates, whereas 
distal tubular cell injury supervenes as the renal function gets compromised. 
 
 
PATIENTS AND METHODS 
 
The study protocol was approved by the hospital ethics committee, and all patients gave 
informed consent. Patients with proven glomerular renal disease and proteinuria >1.0 g/24 h 
were eligible for this study. The evening before the study day, the patients took 4000 mg of 
sodium bicarbonate to ensure a urinary pH above 6.0, which is needed to prevent 
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degradation of β2-microglobulin. After an overnight fast, the patients came to the ward. 
Diuresis was enforced by giving 375-500 ml of tap water. The patients remained supine 
except for voiding. Over the next 2 h urine was collected. 
 
Laboratory Procedures 
The collected urine samples were centrifugated for 10 min at 3000 g, and the supernatant 
was stored at -70 ºC. Urine samples used for the analysis of the GST isoenzymes were 
stored in glass tubes to prevent absorption of enzymes to the wall of plastic tubes [16]. 
Furthermore, these urine samples were supplemented with 10% (v/v) of a storage buffer to 
ascertain a stable pH and to prevent bacterial growth. This storage buffer was a solution of 1 
M HEPES (pH 7.5) containing 5% (w/v) bovine serum albumin, 1% (w/v) sodium azide, 1% 
(v/v) Tween-20 and 10% (v/v) glycerol. 
 
GST alpha 1-1 and GST pi 1-1 were assayed by an ELISA as described recently [17]. The 
concentrations of albumin and IgG in the urine samples were measured by 
immunonephelometry using antibodies the specificity of which was checked by Ouchterlony 
double immunodiffusion and immunoelectrophoresis. Details of the nephelometric 
procedures for the measurement of albumin and IgG have been described before [18,19]. 
Urinary β2-microglobulin was measured by an ELISA method [20]. The antibodies used 
consisted of the immunoglobulin fractions of rabbit antihuman β2-microglobulin; coating: 
code A072, detection (horseradish peroxidase conjugated) code P174 (both Dakopatts, 
Copenhagen, Denmark). NAG was measured by an enzymatic assay according the 
instructions of the manufacturer (Boehringer Mannheim, Germany). Creatinine was 
measured using standard colorimetric methods. 
 
Evaluation and Processing of Renal Biopsy Samples 
We have tried to correlate results of the urinary enzyme measurements with morphological 
evidence of tubular damage. To this end, we have used renal biopsy tissue obtained at a 
time point less than 2 months apart from the day of the urine study. Light microscopical 
slides were reviewed, and whenever possible additional immunofluorescence studies were 
done (see below). 
For light microscopy fragments of kidney biopsy specimens were fixed in Bouin’s solution 
and embedded in paraplast (Amstelstad, Amsterdam, The Netherlands). Sections (2 µm) 
were stained with periodic acid-Schiff.  
For the immunohistological detection of GST alpha, kidney fragments were snap frozen in 
liquid nitrogen, and 2-µm cryostat sections were initially incubated for 60 min with an anti-
GST alpha monoclonal antibody, developed in our laboratory [21], diluted 1:500, followed by 
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a 40-min incubation with a fluorescein isothiocyanate-labeled sheep antimouse IgG, diluted 
1:100 (Dakopatts). After rinsing the sections with phosphate-buffered saline for 15 min, they 
were additionally incubated with TRITC-labeled phalloidin diluted 1:100 (Sigma, Zwijndrecht, 
The Netherlands) for 15 minutes. Phalloidin stains actin and is used as a marker of proximal 
tubular cells due to its prominent staining of brush borders. Thus far, we have not been able 
to perform immunofluorescence studies with anti-GST pi antibodies. The fluorescence 
intensity was low when using these antibodies probably because of the low affinity. 
The sections were examined in a fluorescence microscope (Leitz, Wetzlar, Germany), and 
the staining intensity was recorded semiquantitatively on a scale from 0 to 4+. 
 
Calculations and Statistical Analysis  
The creatinine clearance was calculated by the Cockcroft and Gault formula.  
For the descriptive statistics values are given as means ± SD for parametric data or median 
and ranges for nonparametric data. Comparisons between groups were done using the 
Kruskall Wallis test and the Mann-Whitney test with Bonferroni correction. Linear regression 
was calculated using Spearman's correlation coëfficient. p< 0.05 was considered statistically 
significant.  
 
 
RESULTS 
 
We have studied 56 patients (38 male, 18 female) with a mean age of 45 ± 16 years, a 
median creatinine clearance of 80 (range 27-159) ml/min, and an albuminuria of 4.23 (range 
0.72 - 16.88) g/10 mmol creatinine. The original renal diseases were focal glomerulosclerosis 
(n=16), minimal change nephropathy (n=6), membranous nephropathy (n=19), IgA 
nephropathy (n=8), membranoproliferative glomerulonephritis (n=3), and unspecified 
glomerulonephritis (n=4).  
The overall results of urinary excretion of the parameters are summarized in Table 1. As 
compared with healthy controls our patients had increased urinary excretion of both NAG 
and β2-microglobulin. Also, the excretions of GST alpha and GST pi were increased in 
almost all patients. We observed weak but significant correlations between the urinary 
excretion of GST alpha and the excretion of NAG (r=0.31, p<0.05) and albumin (r=0.33, 
p=0.01), but not with β2-microglobulin, IgG or the creatinine clearance. As compared with 
GST alpha, the excretion of GST pi correlated stronger with the excretion of NAG (r=0.58, 
p<0.001) and albumin (r=0.55, p<0.001), but also with β2-microglobulin (r=0.50, p<0.001) 
and IgG (r=0.58, p<0.001). 
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Table 1.  Urinary excretion of GST alpha, GST pi, β2-microglobulin, and NAG in patients with 
proteinuria 
 Controls (n=10) Patients (n=56) 
GST alpha creatinine ratio  (μg/10 mmol)  
   Median 
   Range 
2.51 
1.17 - 7.48 
35.9 
7.8 – 383 
GST pi creatinine ratio  (μg/10 mmol)  
   Median 
   Range 
5.29 
1.85 - 10.84 
24.8 
6.1 – 756 
β2-microglobulin creatinine ratio  (mg/10 mmol)  
   Median 
   Range 
0.065 
0.06 - 0.08 
1.22 
0.08 – 125 
NAG creatinine ratio  (U/10 mmol)  
   Median 
   Range 
1.68 
1.07 - 1.93 
17.7 
3.6 – 118 
   The levels are corrected for creatinine.  
 
 
Table 2.   Urinary excretion of proteins and enzymes in patients with proteinuria, grouped in quartiles 
according to the creatinine clearance 
 
 
Group 1 
(n=14) 
Group 2 
(n=14) 
Group 3 
(n=15) 
Group 4 
(n=13) 
Creatinine clearance (ml/min)     
   Median 
   Range 
 
140 
112-159 
98 
83-111 
64 
57-77 
47 
27-55 
Urinary Excretion:     
  Albumin (mg/min) 3.54 1.68 3.67 3.77 
  IgG (mg/min) 0.13 0.05 0.20 0.30 
  β2m (µg/min) 0.25 0.18 2.76* 8.48** 
  β-NAG (U/min) 12.9 7.8 19.8 14.2 
  GST alpha (ng/min) 
  GST pi (ng/min) 
68.9 
19.9 
27.7* 
18.3 
21.4* 
27.9 
23.6* 
45.4+ 
 Values are given as medians. For all parameters the Kruskall Wallis test revealed p<0.05. β2m=β2-
microglobuline.  + p = 0.07; * p < 0.05 ;** p < 0.01 versus group 1. 
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A significant negative correlation was found between the urinary excretion of GST pi and 
creatinine clearance (r= -0.37, p<0.001). 
 
In order to try to discern a pattern in the urinary excretion of the GST isoenzymes during the 
progression of renal disease in proteinuric patients, we have divided the patients in quartiles 
according to the creatinine clearance. There was no difference in albuminuria between the 
groups (Table 2). As expected, the urinary excretion of β2-microglobulin increased with 
decreasing renal function. Simultaneously, a slight increase in IgG and NAG excretions was 
observed. We found a clear difference in the pattern of excretion of GST alpha and GST pi; 
for GST alpha the excretion was highest in patients with well-preserved renal function, 
whereas for GST pi the excretion increased with decreasing renal function. As a result, there 
was a significant difference in the urinary GST alpha/GST pi ratio between the quartile 
groups (Figure 1). 
 
 
Figure 1.  GST alpha and pi ratios in the urine of the patients with proteinuria, grouped in quartiles 
according to their endogenous creatinine clearance (ECC; see table 2). Group 1 = ECC range 112-
159 ml/min, group 2 = ECC range 83-111 ml/min, group 3 = ECC range 57-77 ml/min, and group 4 = 
ECC range 27-55 ml/min. *p<0.05 compared to group 1; **p<0.01 compared to group 1. 
 
 
We have analyzed the data according the underlying renal disease. To circumvent the 
effects of renal failure, we have restricted the analysis to patients with a creatinine clearance 
>70 ml/min. Data are given in Table 3. In patients with membranous nephropathy and 
minimal change nephropathy, the urinary excretion of GST alpha was higher than in patients 
with either IgA nephropathy or focal glomerulosclerosis; however, the differences were not 
statistically significant. Overall, the urinary excretion of GST alpha was positively correlated 
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with urinary albumin (r=0.46, p<0.01) and transferrin (r=0.50, p<0.01) excretions and 
negatively with the selectivity index (r= -0.49, p<0.01). It is likely that the relatively high levels 
of GST alpha excretion in the patients with membranous nephropathy and minimal change 
nephropathy are related to the higher selectivity of proteinuria in these patients. 
 
 
Table 3. Urinary excretion of proteins and enzymes in patients with proteinuria and creatinine 
clearance >70 ml/min, grouped according to the underlying renal disease 
 
 
MCD 
(n=6) 
MN 
(n=12) 
FGS 
(n=9) 
IgA 
(n=4) 
Creatinine clearance (ml/min)     
   Median 
   Range 
113 
83-151 
100 
73-159 
111 
73-159 
90 
75-103 
 
Urinary Excretion : 
 
 
 
 
 
 
 
 
   Albumin (mg/min) 4.00 2.93 3.29 1.68 
   GST alpha (ng/min) 
   GST pi (ng/min)  
 
93 
23 
54 
18 
31 
20 
29 
32 
Selectivity index 0.15 0.19 0.24 0.23 
Values are given as medians. MCD, minimal change disease; MN, membranous nephropathy; FGS, 
focal glomerulosclerosis; IgA, IgA-nephropathy. No statistically significant differences were noted. 
 
 
In 12 patients renal biopsies have been done within two months of the urine studies. We 
found a clear negative correlation between the amount of tubular atrophy and the creatinine 
clearance. In 6 patients with normal renal function (creatinine clearance >70 ml/min) the 
degree of interstitial fibrosis amounted to <5% (n=5) or 5-10% (n=1), whereas the biopsy 
specimens of 6 patients with a creatinine clearance < 70 ml/min revealed >10% fibrosis. As 
expected, patients with tubular atrophy had the lowest alpha/pi ratio. In all patients with >10% 
interstitial fibrosis the alpha/pi ratio was below 1.0. Proximal tubular (PT) injury was best 
seen in periodic acid-Schiff stained slides. In patients with an increased excretion of GST 
alpha a more severe proximal tubular damage was seen, as indicated by changes in brush 
border staining and occurrence of membrane blebbing (Figure 2; in color see page 153). 
However, although in most patients with low levels of GST alpha, the proximal tubular injury 
was limited, we sometimes observed membrane blebbing in such patients too. 
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Figure 2.  
Light microscopic pre-
sentation of renal biopsy 
specimens from 2 pat-
ients with IgA nephro-
pathy and differing GST 
iso-enzyme excretion 
Periodic acid-Schiff. x400 
A Specimen from a 
patient with an increased 
urinary level of GST alpha (81 μg/10 mmol creatinine), and a relatively low excretion of GST pi (25 
μg/10 mmol creatinine). Epithelial cells of proximal tubules are damaged (arrows) with loss of brush 
border, whereas distal tubular cells (arrowheads) look normal. B  Specimen from a patient with an 
increased excretion of GST pi (58 μg/10 mmol creatinine) and a slightly elevated level of GST alpha 
(17 μg/10 mmol creatinine). In this patient the distal tubular cells are more severely damaged than the 
proximal tubular cells, as reflected by prominent nuclear and cellular atypia (arrow).  
 
 
Figure 3. 
Immunofluorescence 
double staining for  GST 
alpha  (A,C) and phalloï-
din (B,D) of renal biopsy 
specimens  from  2  pat-
ients.   A,C   Specimens 
from a  patient with focal 
glomerulosclerosis, 
 moderate proteinuria, 
and low levels of both 
GST alpha and pi (17, 
14 μg/10 mmol 
creatinine, respectively). 
The proximal tubules 
can be easily recognized 
by the presence of intact 
brush borders. All 
proximal tubules show 
homogeneous staining of both GST alpha (A: bright green-colored cells) and of phalloïdin (B: bright 
red-colored brush border, arrow).  C,D  Specimens from the patient with IgA nephropathy shown in fig. 
2A. GST alpha excretion was 81 μg/ 10 mmol creatinine. The proximal tubules are damaged as 
A B
A B
C D
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indicated by the irregular and sometimes absent brush border staining (arrow in D). Staining of the 
proximal tubules for GST alpha revealed a variable intensity, with clear loss of staining in most 
proximal tubules (C).  The original color versions of figures 2 and 3 are depicted on page 153.  
 
 
We have studied the presence of GST alpha in proximal tubules by immunofluorescence 
using a double labeling technique. Patients with normal GST alpha and GST pi excretions 
showed a normal phalloïdin staining and a homogeneous staining of the proximal tubules 
(Figure 3). In contrast, in patients with high urinary levels of GST alpha, we frequently 
observed a decrease of brush border staining with phalloïdin. In these patients the intensity 
of staining for GST alpha was quite variable, with a decreased staining intensity occurring in 
many proximal tubules (Figure 3). 
 
 
DISCUSSION 
 
Although it has been suggested that proteinuria might cause tubular cell injury, the site of 
injury is unknown. Studies in humans are hampered by the absence of markers that can be 
used reliably for the detection of distal tubular injury. Recent studies have demonstrated that 
in the kidney GST pi is only present in distal tubules and collecting ducts, whereas GST 
alpha is confined to proximal tubules [11,13-15]. Furthermore, it has been shown that the 
urinary excretion of these isoenzymes was not increased in patients with elevated blood 
levels of GST nor in patients with proteinuria per se [16,22]. We could confirm the latter 
findings in the present study, as we have observed nine patients with proteinuria >3.5 g, in 
whom the excretion of GST alpha or GST pi was normal. Thus, an elevated urinary loss of 
either isoenzyme can only be explained by losses from damaged tubular cells.  
 
The main goal of our study was to disclose a possible relationship between proteinuria and 
extent and site of tubular injury. Therefore, we have included in our study only patients with 
glomerular disease and proteinuria, thus excluding patients with tubulo-interstitial damage 
independent from proteinuria (i.e., patients with chronic pyelonephritis and those with drug-
induced tubulo-interstitial nephritis).  
Overall, both the excretion of GST alpha and that of GST pi were increased in our patients. 
We have tried to correlate the urinary excretion of GST isoenzymes with the extent of tubular 
injury. In agreement with observations by other investigators, we found a negative correlation 
between renal function and percentage of tubulo-interstitial atrophy. Using light microscopy, 
the evaluation of tubular damage proved difficult. Nuclear changes are often considered to 
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be good indicators of cell damage; however, these findings did not correlate with GST 
excretion. Membrane blebbing and loss of brush border seemed better markers; however, 
interpretation and quantitation are hampered by the occurrence of artifacts during 
processing. For future studies, direct fixation should be done. Most promising were the 
results of our immunofluorescence studies. Using a double staining technique, we were able 
to analyze the presence of GST alpha in brush border stained tubules. In patients with 
elevated levels of urinary GST alpha, we observed loss of tubular GST alpha staining.  
There was a clear difference in the pattern of excretion, GST alpha being increased in 
patients with normal renal function and GST pi being increased in patients with renal function 
impairment. Based on these observations it is tempting to speculate that initially in patients 
with proteinuria proximal tubular cell injury prevails, resulting in an increased urinary loss of 
GST alpha. As a result of this initial damage, tubulo-interstitial injury progresses, causing an 
impairment of the renal function. At this point, distal tubular injury becomes evident. The 
decrease in the excretion of GST alpha at this point may reflect tubular atrophy. Since GST 
pi is also present in podocytes [11,13-15], the rise in urinary excretion of GST pi with 
decreasing renal function may reflect more advanced glomerular damage. However, it is 
unlikely that in renal disease podocytic injury is such that these cells lose cytosolic enzymes. 
Admittedly, our data are derived from a cross-sectional study. Longitudinal studies in patients 
with persistent proteinuria are needed to provide details on the time-related changes in 
proximal and distal tubular injury. 
The finding that the highest levels of GST alpha were found in patients with minimal change 
nephropathy deserves further attention. It is unlikely that there are real differences between 
the various types of glomerular disease. Our patients with minimal change nephropathy had 
highest albumin and transferrin excretions and the lowest selectivity index. The excretion of 
GST alpha correlated with all three. The findings at least suggest that loss of GST alpha may 
be the result of tubular toxicity as a consequence of protein overload. This may seem 
unexpected in view of the fact that minimal change nephropathy in general does not cause 
renal failure. However, the development of tubulo-interstitial injury may depend on the 
presence of other filtered factors with toxic properties. Furthermore, in minimal change 
nephropathy proteinuria usually is not long lasting, the exposure time to potentially toxic 
proteins being too short to cause irreversible damage. 
Our data clearly demonstrate that neither the urinary excretion of β2-microglobulin nor the 
excretion of NAG can be used to determine the site of tubular injury. With respect to β2-
microglobulin, the increased excretion in patients with renal failure is explained by the 
increased tubular load, exceeding the threshold of tubular reabsorption. With respect to 
NAG, this lysosomal enzyme is present in proximal as well as in distal tubular cells [23].  
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In conclusion, the urinary excretion of the isoenzymes of GST is increased in patients with 
proteinuria. Our data point to the potential value of the use of urinary GST isoenzymes as 
markers of the site of tubular cell injury. This should be further clarified in longitudinal studies 
during the course of the disease in patients with proteinuria. 
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ABSTRACT 
 
Introduction: Complement-mediated tubular injury may play an important role in the 
progression of renal diseases. C3d is a presumed marker of complement activation. Its 
precursor C3dg has been detected in the urine of patients with membranous nephropathy. 
However, little is known of the renal handling of C3d or its excretion in other renal diseases. 
Methods: We measured the urinary excretion of albumin, IgG, β2-microglobulin (β2m), and of 
complement C3d in patients with tubulo-interstitial nephritis (TIN; n=8), in patients with 
membranous nephropathy (n=35) and in patients with nonmembranous glomerular diseases 
(23 nonproliferative and 21 proliferative). Fractional excretions (FE) were calculated using 
creatinine clearance as marker of GFR.  
Results: C3d was not measurable in the urine of healthy controls, but was detectable in 
seven out of eight of the TIN patients (median excretion 0.11 mU/min, range 0.006-2.4 
mU/min). In these patients the urinary excretion of β2m was clearly elevated (median 26.6 
µg/min, range 1.0-103 µg/min). The FE of C3d correlated with the FE of β2-microglobulin 
(r=0.83, P=0.01), and their ratio amounted to 0.03 (range 0.003-0.06), a value in agreement 
with the expected sieving coefficient. Urine C3d was detectable in all but three of the patients 
with glomerular diseases (median excretion 0.36 mU/min, range 0.004-7.9 mU/min); C3d-
excretion did not differ between the three subgroups of patients with glomerular diseases. 
FEC3d correlated with FEIgG (r=0.88, P<0.01). The ratio FEC3d/FE β2m was 0.78 (range 
0.04-9.99). Selected patients with membranous nephropathy were re-analyzed after (partial) 
remission of proteinuria. Reduction of proteinuria resulted in a decrease of C3d excretion.  
Conclusion: Urinary excretion of C3d is elevated in patients with TIN, most likely as a mere 
consequence of decreased tubular reabsorption. In patients with glomerular diseases urinary 
excretion of C3d is increased and related to proteinuria, independent of the underlying 
glomerular disease. In these patients there is evidence of increased local formation of C3d. 
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INTRODUCTION 
 
There is ample evidence for the pivotal role of tubulo-interstitial damage in the progressive 
renal injury that occurs in patients with proteinuric renal diseases [1,2]. In experimental 
animal models interstitial injury has been related to complement activation. In a murine 
model of glomerulonephritis C3-mRNA up-regulation preceeded the development of 
interstitial inflammation and fibrosis [3]. Complement depletion or inactivation attenuated 
tubulo-interstitial injury in the puromycin aminonucleoside model in rats [4]. In the same 
model tubulo-interstitial injury was less severe in C6-deficient rats compared with 
normocomplementemic control rats [5].  
Few studies have addressed the role of complement in human renal disease. In patients with 
SLE, an auto-immune disease with prominent complement activation, the urinary excretion of  
the complement degradation product C3d correlated with disease activity and predicted the 
presence of active lupus nephritis [6,7]. The urinary excretion of C3dg was measured in 
patients with primary glomerular diseases and found to be elevated in 19 of 44 patients with 
membranous nephropathy, and in four of 40 patients with IgA nephropathy. In three of nine 
patients with focal glomerulosclerosis C3dg was also detectable in the urine [8,9]. In the 
patients with membranous nephropathy, elevated levels of C3dg predicted a worse outcome 
with respect to renal function. These results suggest that the urinary excretion of complement 
degradation products such as C3d could reflect complement activation, related injury and 
renal disease activity. Thus far, the renal handling of complement C3d has received little 
attention. Theoretically there are several ways that could lead to an increased excretion of 
C3d in the urine (Figure 1). C3d is a relatively small molecule of 35 kD, which will be filtered 
to a certain degree. Like other low molecular weight proteins, filtered C3d may be 
reabsorbed by the proximal tubular cells. In such a case, urinary C3d excretion should be 
elevated in patients with tubulo-interstitial diseases. Urinary C3d can also be derived from 
filtered C3. Complement C3 has a high molecular weight (195 kD) and will only pass in the 
urine of patients with glomerular diseases whose glomerular permeability is increased. 
Alternatively, C3 may be locally produced. C3 gene expression has been observed in both 
glomerular epithelial cells and in tubular cells [10-12]. In cell culture tubular cells exposed to 
serum proteins and IL-2 indeed produced C3 [13,14]. Finally, increased local activation of 
complement C3 may occur through amidation of C3 [15]. In the present study we measured 
the urinary excretion of C3d in patients with tubulo-interstitial diseases. The fractional 
excretions (FEs) of C3d and of the low molecular weight protein β2-microglobulin were 
compared and provided evidence for tubular reabsorption of C3d. The excretion of C3d was 
also measured in patients with glomerular diseases. In these patients urinary excretion 
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parallelled proteinuria, and was independent of the underlying glomerular disease. 
Furthermore, the data provided evidence for an increased local generation of C3d. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lane 3: excessive formation of C3d is possible in proteinuric states. Proteinuria will lead to an 
increase of ammonia production (NH3). Next amidated C3 is formed, which can operate as a 
convertase and results in increased C3 degradation. Lane 4: C3d can be derived from locally 
produced C3.  
 
 
METHODS 
 
Patients were recruited from the population seen at our out-patient clinic. We selected 
patients with (suspected) tubulo-interstitial nephritis (TIN) and patients with proteinuria based 
on a primary glomerular disease. Patients who were treated with immunosuppressive drugs 
in the 6 months previous to the measurement of C3d were excluded from the baseline 
analysis. To determine the effect of changes in proteinuria on C3d excretion we selected a 
subgroup of patients with membranous nephropathy who were treated with 
cyclophosphamide and steroids according to our treatment schedule, as previously 
described [16]. In these patients measurements were carried out at baseline before the start 
of immunosuppressive treatment, and again 2 months later. 
 
Measurements 
All measurements were carried out in the morning, after an overnight fast and were 
performed according to a standard protocol. The evening before the study day the patients 
took 4000 mg of sodium bicarbonate to ensure an urinary pH greater than 6.0, which is 
Figure 1.   Possible pathways for the
presence of C3d in urine. CP, Capillary;
GBM, Glomerular Basement
Membrane; PT, Proximale Tubular Cell.
Lane 1:  C3d in urine can be derived
from circulating C3d in plasma. C3d is
filtered in the glomerulus and partly
reabsorbed. The fraction that escapes
from reabsorption will be present in the
urine. Lane 2:  C3d can be derived
from filtered C3 that is converted into
C3d as in plasma. 
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needed to prevent degradation of β2-microglobulin. In the morning the patients received 
1200 mg of cimetidine, in order to block tubular secretion of creatinine [17,18]. Upon arrival 
at the ward the patients received 375-500 ml of tap water to enforce diuresis. The patients 
remained supine for 2 h except for voiding. Timed urine samples were collected, and in the 
middle of the collection period a blood sample was drawn. Blood and urine samples were 
used for the determination of creatinine, complement C3d, the low molecular weight protein 
β2-microglobulin, and the middle and high molecular weight proteins albumin, transferrin, 
and IgG. Blood pressure was recorded using an automatic device (Dinamap, Critikon, Tampa 
FL, USA); 10 consecutive readings being carried out at 5-min intervals.  
 
Laboratory procedures and calculations 
The concentrations of creatinine and urinary total protein were measured with standard 
automated techniques. The concentrations of albumin, transferrin and IgG in serum and 
urine were measured by immunonephelometry using antibodies whose specificity was 
checked by Ouchterlony double immunodiffusion and immunoelectrophoresis. Details of 
these nephelometric procedures have been described previously [19,20]. Urinary β2-
microglobulin was measured by an ELISA method [21].  
Blood- and urine samples for measurement of C3d were collected in 0.005 M EDTA tubes, 
transported in melting ice, and after centrifugation were stored at -70 °C. C3 and C3b 
molecules were precipitated from the samples by 11% PEG 6000 in 0.05 M boric acid, 0.005 
M EDTA for 3 h and subsequently centrifugated at 4 °C at 2900 g. The supernatants were 
measured in the ELISA assay using a coat of rabbit anti-C3d (Dako A063, Glostrup, 
Denmark) and detection with horseradish peroxidase-labelled anti-C3d (Dako P0387). The 
coating antiserum and the conjugate were both tested in crossed immunoelectrophoresis. 
Purified C3c did not show a precipitation arch, whereas with complement-activated plasma 
only a C3d precipitation arch appears (data produced by Dako). The reference material 
serum from the healthy adults was pooled and, in the presence of sodium azide, incubated at 
37 °C for 7 days. This allowed the activation and breakdown of C3 into C3d. This pooled 
activated serum was used as the reference standard and its value was arbitrarily set at 100 
U/l. The reference curve ranged from 0.0005 to 0.01 U/l. The interassay CV was  6.5 %.  
Creatinine clearance (ECC) was calculated by using the formula Ucr*V/Pcr, where Ucr is the 
concentration of creatinine in the urine, V is the urine flow and Pcr is the plasma 
concentration of creatinine. As cimetidine blocks the tubular secretion of creatinine, the 
creatinine clearance measured during cimetidine administration closely reflects the GFR 
[17,18]. The mean arterial pressure was the average of the last six consecutive registrations. 
Protein selectivity index was calculated as the clearance of IgG divided by the clearance of 
transferrin.  
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In patients with glomerular diseases and proteinuria urinary C3d can be derived from filtered, 
non-reabsorbed plasma C3d, and from activated filtered C3 (Figure 1, step 1 and step 2). In 
addition C3d may be formed from locally produced C3 and/or from local activation of C3 
(Figure 1, step 3 and step 4). We have estimated the amount of C3d derived from the first 
two processes. The data obtained from the patients with TIN provided evidence for filtration 
and reabsorption of C3d (see Results). Fractional reabsorption of C3d parallelled the 
fractional reabsorption of β2-microglobulin (see Results). For calculation of the filtration of 
C3d we used a sieving coefficient of 0.01, based on data recently published by Norden et al. 
[22]. These authors estimated glomerular sieving coefficients (GSC) of various proteins in 
vivo in patients with a Fanconi syndrome related to Dent's disease [22]. The amount of 
filtered C3d that is not reabsorbed and will reach the distal tubules can be calculated by the 
formula: filtered C3d – reabsorbed C3d, in which reabsorbed C3d =(1-FEβ2m/100) * filtered 
C3d.  
To calculate the amount of C3d formed in urine from filtered C3 we equated the ratio of 
C3d/C3 in urine to their plasma ratio. We assumed that the filtration of C3 was comparable to 
the filtration of IgG because their molecular weights are in the same range. In our laboratory, 
the normal plasma level of C3 is approximately 1100 mg/l; this standard value was used to 
calculate the C3 excretion. These statements result in the following formula: the amount of 
C3d formed in the urine from filtered C3 = urine C3 *(plasma C3d/plasma C3), in which urine 
C3 = plasma C3* (U IgG/plasma IgG). 
 
Statistical analyses 
To compare the baseline characteristics of the patient groups and to test the changes in 
biochemical parameters, one-way ANOVA was used for parametric data and univariate 
ANOVA in case of nonparametric data. When differences were significant the Bonferroni test 
was performed as adjustment for multiple comparisons. Spearman’s bivariate correlation test 
was used to examine the relation between C3d excretion and proteinuria. Effects of 
treatment in patients with membranous nephropathy were tested with the Wilcoxon signed 
rank test. Results are given as means or medians when appropriate. A P-value of <0.05 was 
considered significant. All statistics were performed using SPSS-software, version 10.0 
(SPSS Inc.,Chicago, IL). 
 
 
RESULTS  
 
We included in our study eight patients with TIN. In four patients the diagnosis was confirmed 
by biopsy. Two patients were not biopsied, but were diagnosed with tubular proteinuria 
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because of a family history of renal disease, with one member who had tubular proteinuria 
and a clinical picture of Dent´s disease being biopsied. The other two patients were 
diagnosed on clinical grounds, presenting with a drug-induced temporary deterioration of 
renal function and markedly elevated urinary β2-microglobulin excretion. We also included 35 
patients with membranous nephropathy, 23 patients with a nonproliferative nephropathy (12 
minimal change nephropathy, 10 focal glomerulosclerosis, and one Alport´s disease), and 21 
patients with a proliferative glomerulonephritis (18 IgA-nephropathy, two Henoch Schönlein 
purpura, one membranoproliferative glomerulonephritis). The renal diagnosis was biopsy 
proven in all patients with membranous nephropathy, and in all but three patients with 
nonmembranous glomerular disease. The diagnosis Alport´s disease was made because of 
a positive familial history, and confirmed by DNA analysis; in the patients with Henoch 
Schönlein purpura the diagnosis was made on the typical clinical presentation with purpura, 
an active urinary sediment, and negative serology.  
Urinary C3d levels measured in six normal healthy controls were undetectable (calculated 
excretion <0.003 mU/min). We studied eight (four male and four female) patients with TIN. 
The mean (±SD) age of these patients was 50 ± 17 years, serum creatinine 178 ± 98 µmol/l, 
serum albumin 42 ± 4 g/l, and proteinuria 0.9 ± 0.1 g/10 mmol creatinine. Renal function as 
measured by creatinine clearance after cimetidine was 46 ± 16 ml/min/1.73 m². By definition, 
urinary β2-microglobulin excretion was increased (median 26.6 µg/min, range 1.0 - 103 
µg/min). C3d was detectable in the urine of seven of the eight patients, with a median 
excretion of 0.11 mU/min (range 0.006 – 2.4 mU/min). There was a strong correlation 
between the fractional excretion of C3d and the fractional excretion of β2-microglobulin 
(Figure 2, r=0.83, P<0.001). 
 
 
Figure 2.  Fractional excretion of C3d (FE C3d) versus fractional excretion of  β2-micro- 
globulin  (FE β2-microglobulin)  in patients with tubulo-interstitial nephritis  (n=8). 
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The ratio of FEC3d/FEβ2m amounted to 0.03 (range 0.003 – 0.06). This ratio, which reflects 
the maximal sieving coefficient of C3d, is in close agreement with the value of 0.01 derived 
from the sieving curve in the paper of Norden et al. [22]. Therefore, the data strongly suggest 
that C3d is filtered and reabsorbed, and reabsorption quantitatively parallels reabsorption of 
β2-microglobulin. In these patients there is no evidence of local production of C3d. 
The baseline characteristics of the three groups of patients with glomerular disease are 
summarized in Tables 1 and 2.  No significant differences were found with regard to age, 
sex, mean arterial pressure and plasma levels of C3d. Renal function was better in the 
patients with membranous nephropathy and other nonproliferative nephropathies compared 
with the patients with proliferative nephropathy. Furthermore, proteinuria was more severe 
and serum albumin lower in the patients with membranous nephropathy and other 
nonproliferative glomerular diseases (Table 2).  
In 77 of the 79 patients C3d was detectable in the urine. There were no differences in urinary 
C3d excretion between the groups, although values were numerically lower in the group of 
patients with proliferative glomerular disease.  
When comparing Figures 2 and 3, it is evident that in patients with glomerular diseases the 
urinary excretion of C3d is higher at comparable levels of β2m-excretion. The ratio of 
FEC3d/FEβ2m amounted to 0.78 (0.04 - 9.99) in this group (P<0.001 compared with the TIN 
patients). These data clearly suggest that altered tubular reabsorption alone cannot explain 
the presence of increased amounts of C3d in the urine of patients with glomerular disease. 
C3d may be simply derived from filtered C3. We have estimated the amount of C3d that 
could reach the urine as a result of filtration and reabsorption of C3d, and of filtration and 
conversion of C3 (see Methods). 
When comparing these estimated values with the actual measured values, the median 
(range) excess of C3d excreted per minute amounted to 0.33 mU/min (0.0 - 7.7 mU/min) in 
the patients with membranous nephropathy, 0.28 mU/min (0.0 - 5.1 mU/min) in the patients 
with nonproliferative nephropathy, and 0.20 mU/min (0.0 - 3.6 mU/min) in the patients with 
proliferative nephropathy. The positive values in all three subgroups with glomerular 
diseases indicate increased C3d formation from activated and/or locally produced C3.  
In six patients with membranous nephropathy, proteinuria decreased more than 50% during 
treatment with a combination of cyclophosphamide and steroids in a schedule, as we have 
described previously [16].  Two months after the start of treatment significant decreases of 
IgG-, albumin-, and C3d-excretion were observed (Table 3). The β2-microglobulin excretion 
decreased in five of the six patients, however, this difference was not statistically significant. 
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Table 1.   Characteristics of patients with membranous nephropathy, nonproliferative and proliferative 
glomerular diseases 
 MN 
n=35 
Nonproliferative 
n=23 
Proliferative 
n=21 
Age (years) 46 ± 14 43 ± 17 40 ± 11 
Sex  (M : F) 26 : 9 10 : 13 14 : 7 
MAP (mm Hg) 90 ± 14 95 ± 11 97 ± 10 
Serum Creatinine (µmol/l) 102 ± 42**  100 ± 46** 145 ± 59 
Serum Albumin (g/l) 27 ± 5** 26 ± 7** 38 ± 5 
Plasma C3d (U/l) 1.59 ± 0.5 1.51 ± 0.4 1.56 ± 0.4 
ECC (ml/min/1.73 m2) 65 ± 22  68 ± 31* 48 ± 21 
Data are mean ± SD. MN, membranous nephropathy; MAP, mean arterial pressure; ECC, 
endogenous creatinine clearance, measured after cimetidine pretreatment. *P<0.05 and **P<0.01 
compared with proliferative nephropathy. 
 
 
 
Table 2.   Urinary protein excretion in patients with membranous nephropathy, nonproliferative and 
proliferative glomerular diseases 
 MN 
n=35 
Nonproliferative 
n=23 
Proliferative 
n=21 
Albumin (mg /min) 3.5*  
(0.5 – 9.3) 
4.3** 
(0.4 – 17.2) 
1.6 
(0.2 – 5.8) 
IgG (µg /min) 120 
(13 – 546) 
99 
(4 – 3363) 
67 
(10 – 546) 
β2m (µg /min) 0.70 
(0.06 – 27.1) 
0.30 
(0.04 – 11.7) 
0.42 
(0.07 – 4.33) 
C3d (mU /min) 0.37 
(0.004 – 7.9) 
0.57 
(0.011 – 5.3) 
0.21 
(0.004 – 3.7) 
Proteinuria 
(g/10 mmol creat) 
6.9** 
(2.2 – 17.2) 
6.4** 
(0.8 – 13.2) 
2.3 
(0.3 – 7.9) 
Selectivity index 0.18 
(0.08 – 0.39) 
0.15**  
(0.01 – 0.38) 
0.26 
(0.12 – 0.59) 
Data are median (range). MN, membranous nephropathy; β2m, β2-microglobulin. *P<0.05 and 
**P<0.01 compared with proliferative nephropathy. 
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In the patients with glomerular disease the FE of C3d correlated significantly with the FE of 
β2m (Figure 3, overall r=0.80,  P<0.001), and with the FE of IgG (Figure 4, r=0.88, P<0.001). 
 
 
 
Figure 3.  Fractional excretion of C3d (FE C3d) versus fractional excretion of β2-microglobulin  (FE 
β2-microglobulin) in patients with membranous nephropathy (n=35; closed circles) nonproliferative 
glomerular diseases (n=23, open squares) and proliferative glomerular diseases (n=21, crosses). 
 
 
 
Figure 4.  Fractional excretion of C3d (FE C3d) versus fractional excretion of the high molecular 
weight protein IgG  (FE IgG) in patients with membranous nephropathy (n=35; closed circles) 
nonproliferative glomerular diseases (n=23, open squares) and proliferative glomerular diseases 
(n=21, crosses). 
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Table 3.  Comparison of urine analysis in 6 patients with membranous nephropathy 
before (baseline) and after 2 months’ treatment with a combination of steroids and  
cyclophosphamide (immunosuppression) 
 Baseline Immunosuppression 
MAP (mm Hg) 93 ± 15 94 ± 13 
Serum Creatinine (µmol/l) 152 ± 69 132 ± 43 
Plasma C3d (U/l) 1.74 ± 0.27 1.55 ± 0.30 
ECC (ml/min/1.73 m2) 47 ± 17 53 ± 22 
   
Urinary Protein Excretion:  
Albumin (mg /min) 6.71 
(3.09 – 9.28) 
3.09* 
(0.28 – 5.40) 
IgG (µg /min) 244 
(159 – 469) 
55* 
(4.1 – 149) 
β2m (µg /min) 12.9 
(3.6 – 18.0) 
8.3 
(0.21 – 35.4) 
C3d (mU /min) 2.79 
(0.46 – 7.9) 
  0.70** 
(0.04 – 4.8) 
Proteinuria 
(g/10 mmol creat) 
8.5 
(5.3 – 15.0) 
3.9* 
(2.1 – 10.2) 
Selectivity index 0.33 
(0.21 – 0.39) 
0.25* 
(0.20 – 0.30) 
Data are in means ± SD or median (range). MAP, mean arterial pressure; β2m,  
β2-microglobulin; ECC, endogenous creatinine clearance, measured after  
cimetidine pretreatment. *P<0.05 and **P<0.01 compared with baseline. 
 
 
DISCUSSION 
 
Our study provides more detailed insight into the renal handling of C3d, a degradation 
product of C3. The data obtained in patients with TIN strongly suggest that in these patients 
the urinary excretion of C3d is merely explained by processes of glomerular filtration and 
tubular reabsorption. The FE of C3d paralleled the FE of β2-microglobulin, a low molecular 
weight protein that is readily filtered by the glomerulus (estimated sieving coefficient >0.9) 
and under normal circumstances was nearly completely reabsorbed by the renal proximal 
tubules. For proteins that behave similarly to β2m the ratio of the FE of the protein and the 
FE of β2m reflects the glomerular sieving. In our patients with TIN this ratio averaged 0.03, a 
value that is in close agreement with the sieving coefficient  for a 35 kD protein, as derived 
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from the sieving curve provided by Norden et al. [22]. Therefore, in the patients with TIN the 
increased urinary excretion of C3d can be readily explained by the filtration of C3d and an 
impairment of the tubular reabsorption. We feel that there is no evidence to consider local 
production or formation of C3d in these patients. 
The situation is clearly more complex in patients with proteinuric renal diseases. In these 
patients urinary excretion of C3d was increased and correlated with the excretion of β2m and 
IgG. The ratio FEC3d/FEβ2m was much higher than in patients with TIN, which indicates that  
the increased excretion of C3d cannot be explained merely by a decrease of tubular 
reabsorption, but also must reflect local production of C3d most likely through activation of 
C3 (Figure 1). It is important to realize that we administered 4 g of sodiumbicarbonate to our 
patients in order to alkalinize the urine, thus allowing an accurate measurement of β2-
microglobulin. We cannot exclude that this alkalinization might have affected, i.e. lowered, 
the urine complement C3d excretion. Morita et al. have demonstrated that treatment with 
sodiumbicarbonate for 2 weeks reduced the urinary excretion of complement activation 
products, at least in patients with established renal insufficiency and metabolic acidosis [23]. 
It is unclear if a similar effect would have occurred when using a single dose of 
sodiumbicarbonate in patients with less severe renal insufficiency. In vitro, lowering of pH 
directly influenced C3 deposition on tubular epithelial cells [24].  
By using a standardized single dose of sodiumbicarbonate we eliminated one factor that 
could have biased our results, thus allowing an even better study of the possible relationship 
between proteinuria and complement excretion. Moreover, the fact that we alkalinized the 
urine and thus may have attenuated C3 activation strengthens further our conclusions that 
C3d must be produced locally in patients with proteinuria.  
Theoretically, urinary C3d could be derived from filtered C3 (Figure 1, steps 2 and 3) or from 
locally produced C3 (Figure 1, step 4). Complement C3 is a molecule with a size comparable 
to IgG. C3 will be filtered in patients with a glomerular permeability defect, and indeed C3 
has been detected by Western blot techniques in the urine of patients with proteinuric renal 
diseases [23]. The strong correlation between FEC3d and FEIgG provides supportive 
arguments for the formation of C3d from filtered C3. However, our calculations indicate that 
in such a case the formation of C3d from C3 in the urine proceeds at a much higher rate than 
in the plasma. This is not unexpected, as it is well known that proximal tubular cells are able 
to activate C3. This process is influenced by ammonia, which leads to formation of amidated 
C3, which operates as a C3 convertase, resulting in cleavage of C3 [15]. In patients with 
proteinuria the production of ammonia is further increased [25]. 
Complement activation may also occur at the site of the visceral epithelial cells, as has been 
shown in models of membranous nephropathy. 
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Although this schedule of events seems highly likely, we cannot exclude that urinary C3d is 
derived from locally produced C3. It is well established that tubular cells are able to produce 
C3. In cell-culture systems using human proximal tubular cells the secretion of C3 was 
increased after exposure to serum proteins, particularly after exposure to transferrin [13,26]. 
We found a definite correlation between urinary C3d and proteinuria, with no differences 
between the various patient groups. Thus, the level of proteinuria, rather than the type of 
renal disease, determines the urinary appearance of C3d. 
In the literature limited data are available concerning C3d measurements in urine of patients 
with renal diseases. Most data are from studies in patients with lupus erythematosus (SLE). 
In patients with SLE, C3d levels in urine were better correlated with the disease activity score 
than serum C3, C4 and C3d [7]. The authors hypothesized that C3d excretion partly was the 
result of local production of C3d in the kidneys, as they were unable to find correlations 
between urine C3d and plasma C3d as well as the C3d/C3 ratio. In another study, urine C3d 
allowed patients with acute lupus nephritis to be distinguished from those without acute lupus 
nephritis [6]. However, both studies did not consider the possibility that the differences in C3d 
excretion between patients with and without active lupus nephritis could be explained by 
differences in proteinuria and/or tubular injury. 
Brenchley et al. have suggested that tubular C3 activation is specific for patients with 
membranous nephropathy [8,9]. Their conclusion was based on the finding of increased 
urinary excretion of C3dg and C5b-9 in the urine of patients with membranous nephropathy 
whereas these complement products were less frequently elevated or even absent in 
patients with IgA nephropathy or patients with other proteinuric renal diseases. However, in 
the latter group of 20 patients only nine had a primary glomerular disease, i.e. focal 
glomerulosclerosis. In these patients with FGS urinary C3dg was present in three (33%). 
Furthermore, the finding of absence of C5b-9 in patients with nonmembranous glomerular 
disease was challenged by data of Ogrodowski et al. [27]. The latter investigators showed 
that the excretion of C5b-9 was increased, even in patients with complement-independent 
renal diseases, and correlated with proteinuria [27]. They hypothesized that the detection of 
C5b-9 in the urine was the result of leakage of complement, but also intratubular complement 
activation; conclusions that are in accordance with our results. In our patients with 
membranous nephropathy immunosuppressive treatment reduced proteinuria and urinary 
C3d excretion. It is generally accepted that a reduction of proteinuria predicts a better 
prognosis. In view of the observation that complement may contribute to the development of 
tubulo-interstitial injury and the relation between proteinuria and complement, it is tempting to 
speculate that lesser activation of complement contributes to the beneficial effects of anti-
proteinuric treatment.  
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Of course, controlled studies are needed to determine the role of complement activation in 
various renal diseases and the prognostic value of complement products in the urine.  
In conclusion: C3d is detectable in the urine of patients with TIN. The observation that the FE 
of C3d correlates with the FE of β2-microglobulin suggests a comparable renal handling of 
C3d, i.e. by processes of glomerular filtration and tubular reabsorption. The increased 
excretion of C3d in patients with proteinuric glomerular diseases cannot merely be explained 
by altered tubular reabsorption. In these patients C3d is formed from filtered or locally 
produced complement C3, a process that is independent of the underlying renal disease. 
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ABSTRACT 
 
Background: In daily clinical practice creatinine clearance is used as marker of glomerular 
filtration rate (GFR). As a result of the tubular secretion process endogenous creatinine 
clearance (ECC) overestimates glomerular filtration rate, particularly in patients with impaired 
renal function. It has been suggested that the tubular handling of creatinine is altered in 
patients with a nephrotic syndrome.   
Methods: Inulin clearance (GFR) and creatinine clearance (ECC) have been simultaneously 
measured in a cohort of 42 patients with proteinuria and 45 healthy controls. The clearance 
of creatinine by tubular secretion (TScreat) can be estimated by ECC–GFR. TScreat was 
calculated in both groups. Regression analysis was performed to identify factors that 
independently influence tubular creatinine secretion. 
Results: The mean age (±SD) of the patients was 41±13 years, serum albumin 26±9 g/l, 
median (IQR) proteinuria 4.5 (3.6-8.2) g/10 mmol creatinine, serum creatinine 103 (84-143) 
µmol/l, ECC 85 (69-118) ml/min/1.73m2, and GFR 54 (36-83) ml/min/1.73m2. Median TScreat 
amounted to 29 (21-36) ml/min/1.73m2. In the healthy controls serum creatinine was 75 (70-
81) µmol/l, ECC 118 (109-125) ml/min/1.73m2, GFR 106 (102-115) ml/min/1.73m2, and 
TScreat 11 (3.5-19) ml/min/1.73m2. By regression analysis serum albumin was identified as 
an independent predictor of tubular creatinine secretion. We divided the patients in two 
subgroups based on serum albumin levels. TScreat was 24 (14-29) ml/min/1.73m2 in patients 
with serum albumin levels >25.8 g/l, and 36 (28-54) ml/min/1.73m2 in patients with serum 
albumin levels <25.8 g/l (P<0.01).  
Conclusion: Serum albumin levels influence tubular creatinine secretion. As a result, the 
endogenous creatinine clearance as well as estimated GFR using a modified MDRD 
equation more pronouncedly overestimate glomerular filtration rate in nephrotic syndrome. 
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INTRODUCTION 
 
Patients with a nephrotic syndrome are at risk to develop renal failure. Accurate assessment 
of renal function is important in the care of these patients. The glomerular filtration rate 
(GFR) can be reliably measured by using filtration markers such as inulin. Since GFR 
measurements with exogenous markers are generally time demanding and costly, in daily 
clinical practice the endogenous creatinine clearance (ECC) is often used. It is well known 
that in normal man the ECC overestimates the GFR as a result of the renal tubular secretion 
of creatinine [1]. In case of a decreased GFR the contribution of tubular secretion to total 
excretion of creatinine is enhanced, and as a result the overestimation of the GFR by the 
ECC will be more pronounced in patients with impaired renal function [2]. It has been 
suggested that the tubular handling of creatinine is also altered in patients with a nephrotic 
syndrome [2,3]. Berlyne et al. have reported four patients with a nephrotic syndrome, in 
whom creatinine clearance markedly overestimated GFR. However, since renal function was 
impaired in some of these patients, firm conclusions cannot be drawn [3]. The study of Carrie 
and colleagues also suggested that the creatinine clearance greatly exceeded the GFR in 
patients with a nephrotic syndrome [2]. However, in the latter study patients with heart failure 
were used as controls.  
Based on the data of the Modification of Diet in Renal Disease (MDRD) study prediction 
equations have been developed that allow a better estimate of GFR in patients with renal 
diseases [4]. Recently, a simplified MDRD equation was published, which used serum 
creatinine as the only serum assay, and which had similar predictive ability as the original 
MDRD equation [5,6]. This simplified equation has already been used in large studies [7]. 
However, the performance of this formula in patients with hypoalbuminaemia is unknown. 
In the present study we have examined the relationship between ECC and GFR in patients 
with proteinuria. Our data indicate that tubular handling of creatinine is dependent on serum 
albumin levels.  
 
 
METHODS 
 
For clinical studies in patients with renal diseases we regularly measured GFR using inulin 
clearances, according to a standardized protocol as described before [8]. All GFR 
measurements were approved by the hospital ethics committee, and all subjects gave their 
informed consent. For the present study we have analysed the data of all patients with a 
glomerular renal disease, and proteinuria >0.5 g/10 mmol creatinine. GFR was measured 
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under baseline conditions. Creatinine and inulin concentrations were measured in all urine 
and blood samples. For comparison we have used data on ECC and GFR measured in a 
group of 45 healthy controls. These healthy controls were recruited from the local population 
and before renal measurements screened for the absence of hypertension, cardiovascular 
disease, renal dysfunction, and microalbuminuria. In the controls medication was not allowed 
except for oral anticonceptives [1].  
 
 
Laboratory Measurements 
In blood and urine samples creatinine was determined according to a modified Jaffé method 
on a Hitachi 747 autoanalyser (Roche, Almere, The Netherlands). Inulin concentrations were 
determined in duplicate by a semi-automatic technique (centrifugal analysis, Multistat) using 
enzymatic degradation of inulin [9]. Albumin was measured in serum by 
immunonephelometry on a BNII nephelometer (Behring, Marburg, Germany) using 
antibodies whose specificity was checked by Ouchterlony double immunodiffusion and 
immunoelectrophoresis (Dako, Gloostrup, Denmark). Urinary protein was measured in 24 h 
urine samples using a turbidimetric method with trichloracetid acid.  
 
 
Calculations and Statistics 
The creatinine clearance was calculated according to the standard formula Ucr*V/Pcr in 
which Ucr is the creatinine concentration in the timed urine portion, V is the volume of the 
timed urine portion, and Pcr is the plasma concentration of creatinine measured in the same 
time period. The GFR was calculated with the same formula, but now using inulin 
concentrations instead of creatinine concentrations. The clearance of creatinine by tubular 
secretion (tubular clearance of creatinine; TScreat) was calculated from ECC-GFR. The 
simplified MDRD equation was used as follows: estimated GFR=186*[Plasma creatinine]-
1.154 *[Age] -0.203 *[0.742 if patient is female] (plasma creatinine in mg/dL). Because all 
patients were Caucasian the correction factor for black people in the formula was eliminated 
[5]. Since serum urea was not regularly measured in our patients we were not able to use the 
extensive MDRD equation [4]. Total proteinuria as measured in 24 h urine samples was 
expressed as grams per 10 mmol creatinine to correct for errors in urine collection.  
Results are given as means (±SD) or medians (interquartile range; IQR) when appropriate. 
For comparisons of means and medians the Student T-test or the Mann-Whitney U-test were 
used respectively. The Spearman correlation test was used to identify individual factors that 
are related to the TScreat.  Next, linear regression analysis was carried out, using a forward 
stepwise procedure, to determine which of these individual factors independently influenced 
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the TScreat. To allow regression analysis non-parametric parameters were transformed. 
TScreat showed a normal distribution after square root transformation, serum creatinine and 
proteinuria after log transformation. The transformed TScreat was defined as the dependent 
variable and the identified factors as result of the univariate analysis were introduced as 
possible predicting variables. A P value <0.05 was considered significant. All statistics were 
performed using SPSS software, version 11 (SPSS, IL, Chicago, USA). 
 
 
RESULTS 
 
Data of 42 patients with proteinuria were available for analysis. The original, biopsy proven 
renal diseases were: membranous nephropathy (n=23), focal glomerulosclerosis (n=9), IgA-
nephropathy (n=4), unspecified glomerulonephritis (n=3), membranoproliferative 
glomerulonephritis (n=2), and M. Alport (n=1). Data about medication was lacking in one 
patient. None of the remaining 41 patients was treated with drugs that interfere with 
creatinine secretion such as cimetidine or trimethoprim. No patient used steroids. Two 
patients were treated with NSAIDs. Twelve patients were treated with an ACE inhibitor or an 
AT1 receptor blocker. Clinical characteristics of the patients are summarized in Table 1. The 
mean age (±SD) of the 45 healthy controls (23 males, 22 females) was 28 ± 6 years, serum 
albumin 44 ± 4 g/l, the median (IQR) serum creatinine 75 (70-81) µmol/l, ECC 118 (109-125) 
ml/min/1.73m2, simplified MDRD 113 (104-125) ml/min/1.73 m2, and GFR 106 (102-115) 
ml/min/1.73m2. 
In the controls TScreat was 11 (3.5-19) ml/min/1.73m2. TScreat was independent from GFR. 
In the patients median (IQR) TScreat was 29 (21-36) ml/min/1.73m2 (P<0.001 vs controls) 
and was also not correlated with GFR (r=0.01, P=0.9). In univariate analysis TScreat was 
significantly correlated with serum albumin (r= -0.52, P<0.001). Weak correlations were 
found with serum creatinine (r= -0.27, P=0.08), and proteinuria (r=0.25; P=0.12). Linear 
regression analysis was performed using the square root transformed TScreat as dependent 
factor and serum albumin, log transformed proteinuria, and log transformed serum creatinine 
as variables. Serum albumin proved the only independent predictor. The relation between 
serum albumin and TScreat and between proteinuria and TScreat are depicted in Figure 1.  
The use of an ACE inhibitor or AT1 blocker did not influence the results. If we restricted the 
analysis to patients not using an ACE inhibitor (n=29) serum albumin proved an independent 
predictor of TScreat. To illustrate the potential magnitude of the effect we have analysed the 
data for patients divided in subgroups based on the median serum albumin level (25.8 g/l).   
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Table 1:   Baseline characteristics of all patients and of groups of patients, ranked according to  
their serum albumin level 
  Serum Albumin 
 
All Patients 
(n=42) 
<25.8 g/l 
(n=21 ) 
>25.8 g/l 
(n=21 ) 
Age (years) 41 ± 13 42 ± 14 40 ± 13 
Sex (M :F) 35 : 7 17 : 4 18 : 3 
NSAID (N) 2 1 1 
ACEi / AT1B (N) 11 / 1 3 / 0# 8 / 1 
Serum albumin (g/l) 26 ± 9 19 ± 5* 33 ± 6 
Serum creatinine (µmol/l) 103 (84-143) 95 (83-156) 108 (92-125) 
ECC (ml/min/1.73m2) 85 (69-118) 82 (63-125) 86 (74-111) 
GFR (ml/min/1.73m2) 54 (36-83) 43 (33-77) 63 (46-89) 
MDRD-GFR (ml/min/1.73 m2) 68 (49-83) 68 (46-90) 67 (56-78) 
TScreat (ml/min/1.73 m2) 29 (21-36) 36 (28-54)* 24 (14-29) 
Proteinuria (g/10 mmol creat) 4.5 (3.6-8.2) 6.0 (4.3-10.5)* 4.0 (2.7-4.9) 
Data are given as means ± SD or median (IQR). NSAID, number of patients treated with an  
NSAID; ACEi/AT1B, number of patients treated with an angiotensin converting enzyme inhibitor  
or angiotensin II type 1-receptor blocker; ECC, creatinine clearance; GFR, glomerular filtration  
rate; MDRD-GFR, GFR calculated by the Modification of Diet in Renal Disease  formula,  
simplified version [5]; TScreat, creatinine clearance by tubular secretion. #P=0.062 and *P≤0.01 
compared to patients with serum albumin >25.8  g/l. 
 
 
Characteristics of the two subgroups are summarized in Table 1. TScreat was highest and 
thus overestimation of the GFR by the ECC was most pronounced in the subgroup of 
patients with the lowest serum albumin level, thus confirming the results of the linear 
regression analysis.  
The relationship between the ECC and GFR for the two subgroups is depicted in Figure 2. It 
is evident that the regression lines are different. To illustrate the consequences of this 
difference for clinical practice, we calculated GFR for a typical patient with a measured ECC 
of 80 ml/min. In healthy controls an ECC of 80 ml/min/1.73m2 represents a GFR of 60 
ml/min/1.73m2; in patients with proteinuria and a serum albumin level >25.8 g/l it represents 
a GFR of 57 ml/min/1.73m2; in patients with a serum level <25.8 g/l an ECC of 80 reflects a 
GFR of 42 ml/min/1.73m2. As expected, we observed a similar difference between the patient 
groups when considering the relationship between calculated GFR using the simplified 
MDRD formula and true GFR (inulin clearance) (Figure 3).  
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Figure 1.  The clearance of creatinine by tubular secretion (TScreat) versus serum albumin (panel A), 
and versus proteinuria (panel B) in patients (n=42) with proteinuria. A significant correlation was only 
observed between TScreat and serum albumin. 
 
 
Figure 2.  Glomerular filtration rate (GFR) 
versus endogenous creatinine clearance  
(ECC) in patients with proteinuria and a 
serum albumin level <25.8 g/l (closed 
circles), and in patients with proteinuria and a 
serum albumin level >25.8 g/l (open 
squares). The overestimation of GFR by 
ECC was more pronounced in patients with 
low serum albumin levels. 
 
 
 
 
Figure 3.  Glomerular filtration rate (GFR) 
versus MDRD-GFR in patients with 
proteinuria and a serum albumin level <25.8 
g/l (closed circles), and in patients with 
proteinuria and a serum albumin level >25.8 
g/l (open squares). In patients with low serum 
albumin levels the GFR was overestimated 
by the MDRD-GFR. 
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DISCUSSION 
 
Our study shows that serum albumin is an independent determinant of the clearance of 
creatinine by tubular secretion. As a consequence overestimation of GFR by ECC is more 
pronounced in patients with a nephrotic syndrome. This conclusion also holds when using 
the simplified MDRD formula instead of ECC as predictor of GFR. 
It is well known that ECC overestimates GFR, due to fact that creatinine is not only filtered 
but also secreted by the renal proximal tubules. Under normal circumstances tubular 
secretion contributes approximately 10-15% to renal creatinine clearance, the ratio of 
ECC/GFR amounting 1.15 in healthy volunteers [1,10]. In patients with a decreased renal 
function the relative contribution of tubular secretion to renal creatinine clearance increases, 
which explains the widely recognized fact that ECC increasingly overestimates GFR at lower 
GFR [10].  
Previous investigators have already pointed to the sometimes marked discrepancies 
between ECC and GFR in patients with a nephrotic syndrome, however, our study is the first 
to demonstrate the independent association between serum albumin levels and tubular 
creatinine handling resulting in a more pronounced overestimation of GFR. Berlyne et al. 
described four patients with a nephrotic syndrome and ECC/GFR ratios ranging form 1.24 to 
2.37 [3]. However, the two patients with the highest ratio had markedly impaired GFR (inulin 
clearance). Carrie et al. studied 38 patients with a nephrotic syndrome. The mean ECC/GFR 
ratio was 1.70 ± 0.11. In these nephrotic patients inulin clearance was impaired. The 
impairment of renal function could not fully explain the increased ratio of ECC/GFR since a 
significantly lower ratio (1.22 ± 0.14) was observed in patients with a comparable GFR. The 
latter group of “control” patients suffered form heart failure, and therefore it remained 
undetermined if tubular creatinine handling was altered in the nephrotic patients or in the 
patients with heart failure [2]. In a study in diabetic patients cimetidine, an inhibitor of 
creatinine transport, more pronouncedly reduced creatinine clearance in patients with 
macroproteinuria [11]; however, again GFR (inulin clearance) was lowest in patients with 
macroproteinuria. In contrast, Anderson et al. did not observe a difference in the ratio 
ECC/GFR between nephrotic and non-nephrotic subjects [12].  
Our observations suggest that alterations in tubular creatinine handling take place as 
consequence of hypoalbuminaemia  which can lead to major errors in the estimation of renal 
function in patients with a nephrotic syndrome.  Our calculations indicate that in patients with 
a nephrotic syndrome roughly a 25% decrease of GFR may occur without any change in 
ECC or serum creatinine. This means that in such patients a fall in GFR will not be noticed, 
even by slight increases of serum creatinine. 
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Our study explains some discrepancies in the literature with respect to renal function 
parameters in patients with proteinuria. Experimental data have unequivocally shown that a 
reduction of albumin causes a decrease in the ultrafiltration coefficient Kf [13]. As a 
consequence GFR and filtration fraction are decreased when measured by precise 
techniques (inulin clearance or comparable methods) in patients with a nephrotic syndrome. 
In contrast, serum creatinine and creatinine clearance are reported as normal in most 
patients with minimal change nephropathy [14,15].  
In recent years new equations have been developed for the estimation of GFR. Based on the 
MDRD data a new formula was developed, which has been validated in patients with renal 
failure [4]. In the MDRD formula parameters included were age, sex, race, serum creatinine, 
serum urea, and serum albumin. Levey et al. have subsequently published a simplified 
formula that included only serum creatinine as serum parameter [5]. Serum albumin and urea 
were excluded since these variables supposedly only contributed <1% to the observed 
variance of the calculations [6]. This simplified formula has been tested also in patients 
without renal diseases [6], and has been applied in recent studies [7]. It is clear from our 
study that the performance of this simplified formula is also dependent on serum albumin 
levels, overestimation of GFR being more prominent in patients with severe 
hypoalbuminaemia. Thus, a formula solely based on serum creatinine as the only serum 
marker should not be used in studies that include patients with severe proteinuria.  
Unfortunately, serum urea levels were only available in 11 of our patients. Application of the 
original MDRD formula in this subgroup suggested a better performance of the original 
formula (data not shown). However, the paucity of data does not allow firm conclusions and 
larger studies are needed to validate the original MDRD formula particularly in patients with 
proteinuria. 
It is difficult to speculate on the mechanism that may cause the altered tubular handling of 
creatinine in patients with low serum albumin levels. Apparently, tubular creatinine secretion 
is increased in patients with low serum albumin levels. Of note, serum albumin and not 
proteinuria was independently related to tubular creatinine handling. One mechanism could 
be that low serum albumin levels reflect lesser transport of albumin bound molecules that 
normally compete with creatinine for tubular transport. 
We would like to point out an alternative explanation. We feel that our findings may be 
compatible with a decrease in creatinine reabsorption. In patients with a nephrotic syndrome 
and severe hypoalbuminaemia proximal sodium reabsorption is reduced [16]. As such, 
creatinine reabsorption as a passive process will be influenced by changes in water and 
sodium reabsorption. The findings of Carrie et al. with low ECC/GFR ratio in patients with 
heart failure also are compatible with such an idea, since in these patients creatinine 
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reabsorption will be increased. Admittedly, creatinine reabsorption has only been 
demonstrated in some animal species [17]. There are data available in human studies 
suggesting the presence of tubular reabsorption of creatinine, particularly in patients with low 
rates of urine flow, however proof is lacking [18-20]. Although studies in humans are difficult, 
we feel that such a process cannot be excluded. 
In conclusion, the present data indicate that serum albumin levels influence tubular handling 
of creatinine. As a result GFR is more pronouncedly overestimated by ECC in patients with a 
nephrotic syndrome. In patients with a nephrotic syndrome a normal serum creatinine should 
not be regarded as evidence of a normal GFR. 
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ABSTRACT 
 
Most filtered proteins are reabsorbed by the renal proximale tubule by a mechanism that 
involves binding to the brush border membrane and endocytosis. Under normal conditions 
the low molecular weight protein β2-microglobulin (β2M), which is used to detect tubular 
injury, is reabsorbed almost completely. However, in proteinuric patients an increased urinary 
excretion of β2M may not simply reflect tubular damage but might also result from a 
decreased tubular reabsorption due to competitive mechanisms. To examine the magnitude 
of such an effect we have studied the renal effects of albumin infusion (40 g in 2 h of a 20% 
solution) in 10 patients with a glomerular disease and proteinuria >3.5 g/24 h. Before, during 
and after albumin infusion the GFR (inulin clearance), RPF (PAH clearance), blood pressure 
and the urinary excretion of albumin, IgG, transferrin, and β2M were measured. Albumin 
infusion resulted in a slight decrease of the GFR (72±11 ml/min before and 67±10 ml/min 
after infusion), an increase of the RPF (379±66 ml/min before and 445±83 ml/min after), a 
decrease of the filtration fraction (0.20 before and 0.17 after), and hemodilution. After 
infusion the urinary excretion of albumin increased from 4.5±0.7 to 8.4±1.6 mg/min (p<0.05). 
The urinary excretion of IgG and transferrin increased, probably reflecting a change in 
glomerular size-selectivity. In contrast, the urinary excretion of β2M did not change 
significantly (baseline 12±5 μg/min, end 13±6 μg/min, percentage change 16.8±11%). To 
correct for changes in tubular load we calculated the fractional reabsorption of β2M. The 
initial rise in albuminuria during infusion did not affect fractional tubular reabsorption (Δ%: 
0.72±0.52%, median 0.005%). In the period after infusion a slight decrease was noted 
(median -0.33%, p<0.01). A decrease in the fractional reabsorption was particularly observed 
in patients with pre-existing tubular damage.  
In conclusion: infusion of albumin in proteinuric patients has no clinically relevant effect on 
the tubular reabsorption of β2M.  Therefore, β2M is useful as a parameter to detect tubular 
injury and alterations in tubular handling of proteins in patients with proteinuria and 
glomerular diseases. 
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INTRODUCTION 
 
Proteinuria is a common finding in renal diseases. An increased excretion of proteins can 
result from a loss of the glomerular barrier function, a decrease of the tubular protein 
reabsorption, or a combination of both. In general, glomerular injury is characterized by 
urinary losses of high molecular weight (HMW) proteins such as albumin, transferrin, and 
IgG. In contrast, tubular disorders are characterized by increased urinary losses of low 
molecular weight (LMW) proteins like β2-microglobulin (β2M). β2M is a 11,800-kD protein 
which is nearly completely filtered through the glomerulus and very efficiently reabsorbed by 
the proximal tubules. Because of these properties the urinary excretion of  β2M has been 
found very useful in the detection of tubular injury [1,2].  
Already 20 years ago, Schainuck et al. [3] demonstrated that the development of renal 
insufficiency in patients with renal diseases correlated better with tubulo-interstitial changes 
on renal biopsy than with glomerular changes. In line with these observations, we have 
recently  demonstrated that an increased excretion of β2M predicted the future development 
of renal insufficiency in patients with membranous nephropathy [4]. Similar observations 
were done by Bazzi et al. [5]. These investigators used SDS-PAGE electrophoresis to 
analyze urinary proteins. The presence of LMW proteins of 10 kD (i.e. β2M) predicted the 
development of chronic renal failure in their patients with focal glomerulosclerosis, 
membranous nephropathy or membranoproliferative glomerulonephritis. Furthermore, the 
presence of increased levels of β2M in the urine is also suggestive for treatment failure in 
patients with an idiopathic nephrotic syndrome [6]. Therefore, measurement of urinary β2M 
might be of particular value in predicting prognosis and in guiding treatment of patients with 
proteinuric renal diseases.  
However, it is unclear if the urinary excretion of β2M is merely dependent on the extent of 
tubulo-interstitial injury. It has been suggested that HMW proteins may interfere with the 
tubular reabsoption processes of LMW proteins. Intravenous injection of albumin in rats 
abruptly increased the urinary excretion of β2M, most likely the result of a competitive 
inhibition [7]. Thus far there are no convincing data in the literature on the direct effects of 
albumin on the tubular reabsorption of β2M in man. Therefore, we have studied the effects of 
an intravenous infusion of albumin on the urinary excretion of β2M in patients with nephrotic 
range proteinuria (>3.5 g/24 h). Our data demonstrate that such an increased load of albumin 
has no major impact on tubular β2M reabsorption. 
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PATIENTS AND METHODS 
 
The study protocol was approved by the hospital ethics committee. All participants gave 
informed consent before study entrance. Ten patients with proteinuria >3.5 g/24 h and stable 
renal function were selected from our outpatient clinic. The patients were instructed to refrain 
from smoking and coffee drinking during the last 8 h and from alcohol during the last 24 h 
before the study. On the day of investigation the patients came to the ward at 08:30 h. 
Venous catheters were inserted in both forearms; one for continuous infusion of an inulin 
(Poly-fructosan, Inutest, Laevosan Ges., Linz, Austria) and PAH solution, as described 
before [8], and the other catheter for blood sampling. The patients remained supine except 
for spontaneous voiding. Blood pressure (BP) was monitored every 30 min with a 
sphygmomanometer. During the measurements, diuresis was maintained by an oral water 
load of 110 ml every hour and a continuous infusion of a 5% glucose solution, 100 ml/h. The 
administered albumin solution contained 145 mmol/l sodium. To achieve a constant sodium 
intake during the whole measurement, an 1.5% NaHCO3 solution was infused, 81.5 ml/h, in 
the periods before and after the albumin infusion. The NaHCO3 infusion also contributed to 
an urinary pH >6.0. This is a requirement to determine β2M in a reliable way, because ß2M 
is unstable in acid urine. After a 90-min equilibration period, two 45-min clearance periods 
were scheduled for baseline measurements. Thereafter, an infusion of 200 ml of a 20% 
solution of human albumin (total dose 40 g) was given over a 120-min period. Four clearance 
periods were scheduled from the start of the albumin infusion; two periods of 60 min during, 
and two periods of 45 min after albumin infusion, respectively. Blood and urine samples were 
collected at the beginning and at the end of each clearance period. The freshly voided urine 
samples were centrifuged and stored at -70°C. In blood and urine samples the 
concentrations of albumin, IgG and transferrin were measured by immunonephelometry 
using antibodies whose specificity was checked by Ouchterlony double immunodiffusion and 
immunoelectrophoresis. Details of the nephelometric procedures for the measurement of 
albumin, transferrin and IgG have been described before [9,10]. Serum and urinary β2M 
were measured by RIA (Pharmacia, Uppsala, Sweden). Inulin, PAH and creatinine were 
measured using standard colorimetric methods. 
 
 
Calculations and statistical analysis 
The glomerular filtration rate (GFR) was estimated by inulin clearance and effective renal 
plasma flow (RPF) by PAH clearance. The filtration fraction (FF) was calculated by 
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GFR/RPF. The percentage of tubular reabsorption of β2-microglobulin (β2M) was calculated 
as:  
 
(Serum level β2M x GFR)  -  Absolute urinary excretion of β2M 
X 100 
(Serum level β2M x GFR) 
 
Unless otherwise indicated, results are expressed as mean ± SEM. The values obtained 
during and after albumin infusion were compared with baseline data using a two-tailed paired 
Wilcoxon test with Bonferroni correction. A probability value <0.05 was considered 
statistically significant. Exponential trendlines to determine the relationship between the 
urinary excretion of albumin and β2M were generated using Excel software (Excel 5.0, 
Microsoft Corp.). 
 
 
RESULTS 
 
We have studied 10 patients (9M, 1F) with a mean (±SD) age of 33 ± 14 years. The original 
renal disease was primary focal glomerulosclerosis (n=4), IgA nephropathy (n=2), 
membranous nephropathy (n=1), membranoproliferative glomerulonephritis (n=1),  
amyloidosis (n=1), and Alport’s disease (n=1). Mean serum creatinine was 133 ± 49 μmol/l, 
mean serum albumin 27 ± 3.7 g/l, and proteinuria 7.1 ± 2.3 g/24 h. The baseline urinary β2M 
excretion was normal (< 0.340 μg/min) in three, slightly increased (ranging from 0.51 to 1.16 
μg/min) in three, and highly elevated in four patients (range 12.8 - 38.1 μg/min). 
Infusion of albumin increased plasma volume as reflected by a change in hematocrit from 
0.37 ±0.02 l/l at baseline to 0.35 ± 0.02 l/l during, and 0.34 ±0.02 l/l after the infusion 
(p<0.01). The systemic and renal hemodynamic parameters as measured before, during, and 
after albumin infusion are given in Table 1. The infusion of albumin did not significantly alter 
blood pressure or pulse rate. Also, urinary flow rate and fractional sodium excretion remained 
unchanged. After the infusion of albumin a slight decrease of the GFR was observed,  
simultaneously with an increase of the RPF, resulting in a significant decrease of the filtration 
fraction.  
As expected, serum albumin increased (Table 2). As a result of the increased plasma 
volume, serum levels of the high molecular weight proteins IgG and transferrin decreased, 
thus mimicking the change in hematocrit. In contrast, the serum levels of β2M did not change 
during the study period (Table 2). 
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Table 1.  Systemic and renal hemodynamic effects of albumin infusion in patients with proteinuric 
renal diseases (n=10) 
 Albumin Infusion 
 Baseline During After 
SBP  (mm Hg) 132 ± 10 133 ± 9 137 ± 9 
DBP  (mm Hg) 84 ± 4 85 ± 4 87 ± 5 
HR (beats/min) 61 ± 3 60 ± 3 63 ± 4 
GFR (ml/min) 72 ± 11 69 ± 10 67 ± 10 
RPF  (ml/min) 379 ± 66 401 ± 70 445 ± 83* 
FF 0.20 ± 0.02 0.18 ± 0.02 0.17 ± 0.02* 
    
Urine Flow (ml/min) 7.3 ± 1.3 6.1 ± 0.8 7.2 ± 0.6 
FE Na ( % ) 3.1 ± 0.9 2.8 ± 0.6 3.7 ± 0.8 
Abbreviations:  SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; GFR 
= glomerular filtration rate; RPF = renal plasma flow; FF = filtration fraction; FE Na = fractional 
excretion of sodium.  Values are given as means ± SEM, * p < 0.05 compared to baseline. 
Blood pressure measurements were available in 8 subjects. 
 
 
 
Table 2.  Effects of albumin infusion on serum protein levels and urinary protein excretion 
 Albumin Infusion 
 Baseline During After 
Serum    
   Albumin  (g/l) 27 ± 3.7 34 ± 3.6* 35 ± 3.6* 
   IgG  (g/l) 5.7 ± 0.8 5.1 ± 0.8* 4.9 ± 0.8* 
   Transferrin (g/l) 1.9 ± 0.2 1.7 ± 0.1* 1.6 ± 0.1* 
   β2M (mg/l) 3.4 ± 0.5 3.3 ± 0.5 3.3 ± 0.5 
    
Urinary excretion    
   Albumin (mg/min) 4.5 ± 0.7 5.5 ± 1.1* 8.4 ± 1.6* 
   IgG (μg/min) 311 ± 74 282 ± 65 351 ± 87 
   Transferrin (μg/min) 369 ± 82 333 ± 73 384 ± 69 
   β2M (μg/min)  12 ± 5 10 ± 4 13 ± 6 
Values are given as means ± SEM, * p < 0.01 compared to baseline values. 
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Values of the urinary excretion of the various proteins at baseline and in response to the 
infusion of albumin are given in Table 2. We observed an immediate increase in the urinary 
excretion of albumin already apparent in the period during the infusion of albumin, with a 
further rise occurring in the period thereafter. The absolute urinary excretion of IgG and 
transferrin did not change significantly. However, fractional excretions of IgG and transferrin 
both increased significantly (IgG: 0.18 ± 0.07% before vs. 0.23 ± 0.09% after infusion of 
albumin; transferrin: 0.54 ± 0.19% before vs. 0.71 ± 0.25 % after infusion; both p<0.01). 
 
Overall, there was no change in the absolute urinary excretion of β2M (Table 2). Compared 
to baseline values, the median change in the β2M excretion was +5.3% after albumin 
infusion. The increase amounted to > 30% in only two (71 and 79%, respectively) of the ten 
patients. To account for changes in the tubular load of β2M, we next calculated the fractional 
tubular reabsorption of β2M. At baseline the fractional tubular reabsorption of β2M ranged 
from 73.1 to 99.89% (median 99.52%). Tubular reabsorption of β2M was approximately 
normal in 6 patients in whom fractional reabsorption averaged 99.73% (range 99.39 to 
99.89%), and abnormal in four with values ranging from 73.06 to 92.32%. Fractional 
reabsorption of β2M remained unchanged during the infusion of albumin, at a time point that 
the urinary albumin excretion had increased from 4.5 ±0.7 to 5.5 ±1.1 μg/min. In the period 
after the infusion of albumin, the fractional reabsorption of β2M decreased slightly but 
significantly with a median percentage decrease of -0.33% (p<0.01). A closer look at the data 
revealed that the fractional tubular reabsorption of β2M hardly decreased in the six patients 
with normal baseline values (from 99.73 to 99.59%), whereas an apparent decrease was 
observed in the four patients with evidence of a disturbed tubular reabsorption of β2M at 
baseline (percentage decrease: -1.12 to -10.76%). To better assess the amount of albumin 
present at the site of the putative transport in the individual tubules, we have analyzed the 
data after factoring the albumin excretion by the GFR. These data, expressed as mg albumin 
per 100 ml GFR, and their relationship with the fractional β2M excretion are depicted in 
Figure 1. At baseline, highest values for urinary excretion of β2M were seen in patients with 
the highest levels of albuminuria, a finding compatible with an interference of albumin with 
the tubular reabsorption of β2M. However, from Figure 1 it is evident that when the tubular 
load of albumin is increased by the infusion, this does not result in an increase in the 
fractional excretion of β2M. 
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Figure 1. The relationship between the urinary excretion of albumin expressed per 100 ml  
GFR and the fractional excretion of β2M at baseline (♦), and after (Ο) infusion of albumin. 
Lines  A and  B  represent the respective trendlines (exponential fit, Excel Software). 
The paired values before and after albumin infusion of the 4 patients with the highest  
excretion of both albumin and β2M are connected with lines. 
 
 
DISCUSSION 
 
Most filtered proteins are reabsorbed by the proximal tubules. This process of reabsorption is 
governed by binding of the proteins to the brush border membrane and subsequent 
endocytosis [11]. Based on data derived from animal experiments it has been suggested that 
albumin could interfere with the tubular reabsorption of low molecular weight proteins such 
as β2M or lysozyme [7,12]. To address this particular question in humans, we increased the 
tubular load of albumin in patients with proteinuria, and studied the effects on the urinary 
excretion of β2M. As expected, after the infusion of albumin an increase of the albuminuria 
was observed. This increase is not only due to the increased serum levels of albumin. The 
infusion of albumin and the resulting volume expansion also causes an enhancement of the 
defect in the glomerular size-selectivity as has been demonstrated by Shemesh et al. [13]. In 
accordance with such a defect in glomerular permeability, we observed an increase in the 
fractional excretions of IgG and transferrin. 
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Since the sieving coëfficient of β2M is close to 1.0, the tubular reabsorption of this low 
molecular weight protein can be precisely calculated, and corrected for changes in GFR and 
serum levels. The infusion of albumin and the ensuing albuminuria slightly attenuated the 
fractional reabsorption of β2M. At first sight these findings might seem compatible with an 
interference of albumin with the tubular reabsorption of β2M via a competitive mechanism. In 
such a case, the magnitude of this effect is rather small and clinically irrelevant. Admittedly, 
we cannot exclude that an effect of albumin on the reabsorption of β2M would become 
apparent at levels of albumin in the tubular fluid that exceed the maximaum capacity of the 
transporter protein in the brush border. Our data indicate that this might be the case in 
situations when the quotient albumin/100 ml GFR exceeds 50, a value which reflects a daily 
proteinuria of 80 g, a value not readily obtainable in patients.  
 
Our data argue against a direct competitive effect of albumin on the tubular reabsorption of 
β2M. First, the initial increase of albuminuria did not attenuate the tubular reabsorption of 
β2M. A decrease of the fractional reabsorption of β2M was observed in the post-infusion 
period and occurred predominantly in patients with evidence of tubular injury. In these 
patients the increased excretion of β2M might reflect protein-induced lysosomal and tubular 
damage of already vulnerable tubules. Secondly, we did not observe a relationship between 
(the increase of) albuminuria and the urinary excretion of β2M (Figure 1).  
Data in the literature also argue against an important effect of albumin on the tubular 
reabsorption of low molecular weight proteins. Several authors have reported normal urinary 
excretion of β2M in patients with minimal change nephropathy and profound albuminuria 
[2,6,14]. Harrison et al. [15] found that in patients with glomerulonephritis and heavy 
proteinuria, lysozyme excretion was not necessarily elevated. Also in another study [16], no 
relationship was observed between the excretion of high molecular weight proteins and the 
presence in the urine of low molecular weight proteins as analyzed by SDS-PAGE 
electrophoresis.  
In animal studies different approaches have been used to study the interaction between 
albumin and the tubular reabsorption of low molecular weight proteins. Results have been 
contradictory. The strongest support for the concept that albumin interferes with the tubular 
reabsorption of β2M via a competitive mechanism comes from two studies [17,18]. In in vitro 
experiments, Simonnet et al. [17] demonstrated that the binding of β2M to brush border 
membranes decreased upon increasing the concentration of albumin in the incubation 
medium. Bernard et al. [18] infused albumin in rats and observed an increase in the excretion 
of β2M [18]. However, it should be recognized that the results of the above-mentioned 
studies may not be applicable to the human situation. In fact both Bernard et al. [18] and 
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Simonnet et al. [17] have seen the effects mentioned in particular when using bovine serum 
albumin in rats, whereas the effects of human and rat albumin were less clear. It seems quite 
likely that the specific characteristics of bovine albumin determine the potency to inhibit 
tubular protein reabsorption. This might explain the limited effects of albumin on the urinary 
excretion of β2M in humans.  
In conclusion: our data indicate that there is no major effect of albumin on the tubular 
reabsorption of β2M. Therefore, the urinary excretion of β2M can be used as a reliable 
parameter to detect tubular damage in patients with proteinuria. Also, measurements of the 
urinary excretion of β2M can be used to determine if agents influence proteinuria by altering 
glomerular protein leakage, tubular protein reabsorption or both. 
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ABSTRACT 
 
An accurate prediction of the prognosis of patients with idiopathic membranous nephropathy 
(iMN) should allow restriction of immunosuppressive treatment to patients who are at highest 
risk for ESRD. On the basis of retrospective studies, it has previously been suggested that 
the urinary excretions of β2-microglobulin (Uβ2m) and IgG (UIgG) are useful predictors of 
renal insufficiency in patients with iMN. The threshold values of 0.5 µg/min (Uβ2m) and 250 
mg/24 h (UIgG) have been validated in a new and larger patient cohort. 
From 1995 onward, 57 patients with iMN (38 men,19 women; age 48±16 yr), a nephrotic 
syndrome, and a serum creatinine level ≤1.5 mg/dl were studied prospectively. At baseline, a 
standardized measurement was carried out to determine renal function and protein excretion. 
The end point renal death was defined as a serum creatinine exceeding 1.5 mg/dl or a rise of 
serum creatinine of >50%. Mean (±SD) follow-up was 53 ± 23 mo. Thus far, 25 (44%) of the 
patients have reached the end point renal death. Multivariate analysis confirmed Uβ2m as 
the strongest independent predictor for the development of renal insufficiency. Sensitivity and 
specificity were 88% and 91%, respectively, for Uβ2m, and both were 88% for UIgG. When 
the excretions of both proteins were combined, specificity improved to 97%. It is concluded 
that the present data validate the accuracy of Uβ2m and of UIgG in predicting renal outcome 
in patients with iMN. These markers can be used to guide decisions on the start of 
immunosuppressive treatment. 
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INTRODUCTION 
 
Idiopathic membranous nephropathy (iMN) is one of the most frequent causes of the 
nephrotic syndrome in adults [1]. If left untreated, up to 40% of patients will progress to end 
stage renal disease (ESRD) [2-4]. The efficacy of immunosuppressive therapy has been 
demonstrated in a randomized, controlled trial [4]. Although this study provided arguments to 
treat all patients with iMN and a nephrotic syndrome, most authors advocate restricting 
immunosuppressive treatment to patients who are at highest risk for developing ESRD [5,6]. 
It is well established that deterioration of renal function is a powerful predictor of ESRD [7,8]. 
Therefore, a trial of immunosuppressive therapy is warranted in patients with iMN and 
established renal insufficiency. However, it is evident that immunosuppressive treatment 
started at a relatively late time point may be less effective in attaining normal renal function 
[9]. Moreover, we and others have noted that the use of immunosuppressive agents in 
patients with renal insufficiency was associated with more frequent and more severe side 
effects than in patients who are treated in an earlier phase of their disease [10-12]. 
Therefore, it would be ideal if treatment could be optimized by identifying high-risk patients at 
an earlier time point. In patients with iMN, various risk factors for the development of renal 
failure have been identified [13]. However, the sensitivity and specificity of most of these 
factors (e.g. age, gender, glomerular injury, tubular interstitial fibrosis) are too low to justify 
their use to guide decisions on the start of immunosuppressive therapy. Thus far, the level 
and the duration of proteinuria are the best predictive factors in a model introduced by the 
Toronto Glomerulonephritic Registry [14]. This model requires a minimal observation period 
of 6 to 18 mo.  
On the basis of data derived from small patient cohorts, we demonstrated previously that the 
urinary excretion of β2-microglobulin (Uβ2m) and IgG (UIgG), assessed in a single urine 
sample, independently predicted the development of renal insufficiency in patients with iMN 
[15,16]. Our data suggested high sensitivities and specificities, which ranged from 80 to 90%. 
We now have validated these results in a prospectively studied, new and larger patient 
cohort. 
 
 
METHODS 
 
In our center, patients with proteinuria are evaluated using a standard protocol. In all of these 
patients, standardized urine and blood measurements are carried out as described below.  
For the validation study, we prospectively studied patients with biopsy-proven iMN, evaluated 
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from 1995 onward. In the analysis, we included only patients with a baseline serum 
creatinine ≤1.5 mg/dl and proteinuria ≥2.7 g/g creatinine and/or serum albumin ≤3.0 g/dl. We 
excluded patients who had been treated with immunosuppressive drugs other than oral 
prednisone. Patients were also excluded when the interval between renal biopsy and the 
baseline measurement exceeded 3 years. 
 
Standardized Measurement of Urinary Proteins 
Patients come to the ward after an overnight fast. Patients are instructed to take 4000 mg of 
sodium bicarbonate on the evening before to ensure that urinary pH exceeds 6.0, which is 
mandatory for the measurement of Uβ2m. On the morning of the measurement, patients are 
not allowed to take diuretics. Upon arrival, 375 to 500 ml of tap water is given to enforce 
diuresis. The patients remain supine during 2 h except for voiding. Blood pressure 
measurements are done using an automatic device, and 10 consecutive readings are 
registered with an interval of 5 minutes (DINAMAP, Criticon, Tampa FL). Timed urine 
samples are collected, and in the middle of the collection period, a blood sample is drawn. In 
addition, two 24-h urine samples are collected for assessment of daily excretion of total 
protein and creatinine. 
 
Laboratory Measurements 
In the blood samples, we assessed the following parameters: creatinine, cholesterol, β2m, 
albumin, IgG, and transferrin. In the timed urine samples, we measured creatinine, β2m, α1-
microglobulin, albumin, IgG, and transferrin. The concentrations of serum creatinine, serum 
cholesterol, urinary total protein, and urinary creatinine were measured with standard 
automated techniques. The concentrations of albumin, transferrin, α1-microglobulin, and IgG 
in serum and urine were measured by immunonephelometry on a BNII nephelometer 
(Behring, Marburg, Germany) using antibodies whose specificity was checked by 
Ouchterlony double immunodiffusion and immunoelectrophoresis (Dako, Glostrup, 
Denmark). Urinary and serum β2m were measured by ELISA as described before [17]. 
 
Calculations 
Endogenous creatinine clearance (ECC) was calculated according to the formula Ucr x 
V/Pcr, where Ucr is the concentration of creatinine in the urine, V is the urine flow, and Pcr is 
the plasma concentration of creatinine, and was corrected for body surface area. Because 
24-h urine samples were not collected regularly during follow-up, we estimated creatinine 
clearances using the Cockcroft and Gault formula. In addition, we calculated GFR for 
patients who reached the end point renal death by applying the recently developed 
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Modification of Diet in Renal Disease (MDRD) formula using serum creatinine, age, gender, 
race, serum albumin and serum urea [18]. The mean arterial pressure was the average of 
the last six out of 10 registered measurements.  
The amounts of β2m, α1-microglobulin, IgG, transferrin, and albumin in the timed urine 
samples are expressed as excretion per unit time (minute or 24 h).  
Protein selectivity index was calculated as the clearance of IgG divided by the clearance of 
transferrin. The total protein excretion in the 24-h urine samples was expressed as g / g 
creatinine to correct for sampling errors. 
 
Statistical Analysis 
For the validation study, we calculated renal survival using Kaplan-Meier statistics. Renal 
death was defined as an increase of serum creatinine >50% or an increase of serum 
creatinine >1.5 mg/dl. Survival was calculated using the date of the baseline study at t=0. We 
compared renal survival using log-rank test for patients with low and high Uβ2m and UIgG. 
We used the threshold values established in our previous studies [15,16]. The threshold level 
for β2m excretion was 0.5 µg/min and for IgG was 250 mg/24 h. Using these threshold 
levels, we calculated sensitivity, specificity, true positive predictive value, and true negative 
predictive value. 
Because the use of a fixed serum creatinine value as end point, irrespective of the baseline 
value, might have introduced a bias (a subtle increase in serum creatinine could have been 
defined as failure), we performed a subanalysis in a group of patients with a baseline serum 
creatinine <1.2 mg/dl. 
Using the data of the present patient cohort, we also studied the effect of other parameters in 
predicting renal outcome. Univariate analysis and multivariate analysis using the Cox 
proportional hazard model with a forward stepwise procedure was performed to identify 
independent predictive parameters. Receiver operating characteristics (ROC) curves were 
made to determine the area under the curve (AUC), and to calculate the sensitivity and 
specificity using the most discriminative thresholds. The following parameters were plotted 
into ROC curves: β2m excretion, IgG excretion, α1-microglobulin excretion, transferrin 
excretion, albumin excretion, selectivity index, ECC, serum creatinine, serum albumin, and 
total proteinuria per 24 h. The parameters with the highest AUC were selected and used as 
covariates in the Cox regression analysis. All values are given as means (±SD) or medians 
(range) when appropriate. All statistics were performed using SPSS software, version 11.0 
(Chicago, IL). P <0.05 was considered significant. 
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RESULTS 
 
From 1995 to 2002, we studied 57 patients who had iMN and fulfilled the inclusion criteria. In 
90% of the patients, the baseline measurement was performed within 1 yr after renal biopsy. 
Baseline characteristics are given in Table 1. Two patients had been treated with prednisone. 
Patients have been followed for 53 ± 23 mo.  
 
Table 1.  Baseline characteristics of patients with iMN (n=57)  
Gender   (M/F) 38/19 
Age (yr) 48 ± 16  
MAP (mm Hg) 98 ± 16 
ECC 24 h (ml/min/1.73 m2) 88 ± 26 
Serum creatinine  (mg/dl) 1.00 ± 0.23 
Serum β2m (mg/l) 2.8 ± 1.1 
Serum albumin (g/dl) 2.4 ± 0.5 
Cholesterol (mg/dl) 329  ±  76 
Interval Bx – Measurement (mo) 2 (0–33) 
Follow-upa (mo) 
 
 53 ± 23  
 
Timed urine sample:  
   Albumin excretion (mg/min) 3.8 (0.3–16) 
   IgG excretion (mg/24h)  197 (18–3597) 
    β2m excretion (µg/min)b 0.38 (0.05–68.4) 
    α1m excretion (µg/min)  29 (4–418) 
   Transferrin excretion (µg/min) 283 (17–1455 ) 
   Selectivity Index 0.18 (0.06–0.39) 
   Proteinuria (g/g creatinine) 5.8 (1.7–13.3) 
Data are means ± SD or medians (range). iMN, idiopathic membranous  
nephropathy; MAP, mean arterial pressure; ECC 24 h, creatinine clearance,  
calculated from 24 h urine; β2m, β2-microglobulin; Bx, renal biopsy. aFrom  
baseline measurement until end of follow-up. bIn case of β2m excretion: n=56;  
in one patient, β2m was not measurable because pH urine was too low (<6.0). 
 
Thus far, 25 (44%) patients have reached the predefined end point of renal death. The 
reason for renal death was a serum creatinine >1.5 mg/dl in 21 patients and a rise of >50% 
of serum creatinine in 4 patients. Overall renal survival was 81% at 6 mo, 68% at 1 yr, and 
54% at 3 yr. Thus, in most patients progressive disease was apparent within 3 years after the 
baseline study. In this new patient cohort, the use of the previously established threshold 
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values of Uβ2m and UIgG excretion allowed an accurate prediction of renal outcome. Renal 
survival curves are depicted in Figures 1 and 2.  
 
 
Figure 1.  Renal survival in patients with idiopathic membranous nephropathy with urinary β2-
microglobulin excretion (β2m) <0.5 µg/min and ≥0.5 µg/min. Renal death was defined as an  
increase of serum creatinine to values >1.5 mg/dl or an increase of serum creatinine >50%. 
 
 
Figure 2.  Renal survival in patients with idiopathic membranous nephropathy and  
an IgG excretion <250 mg/24 h versus patients with an IgG excretion ≥250 mg/24 h. 
 
Our calculations confirmed the high sensitivity and specificity (Table 2). We evaluated the 
possible bias of using the fixed serum creatinine value of 1.5 mg/dl as end point. To this end, 
Chapter 7 
 92
we assessed the extent of the deterioration of renal function. In the 25 patients who reached 
the predefined end point of renal death, serum creatinine had increased by an average of 
46% from 1.15±0.2 to 1.65±0.24 mg/dl. Calculated creatinine clearance (Cockcroft and Gault 
formula) was 76±22 ml/min/1.73m2 at baseline and 52±13 ml/min/1.73m2 at the end point. 
The absolute decrease of creatinine clearance averaged 45 ml/min/1.73m2/yr. For 
comparison, in the nonfailure group, the average change of calculated creatinine clearance 
was 1.7 ml/min/1.73m2/yr. When we estimate GFR using the recently developed MDRD 
formula, the severity of renal dysfunction is even more manifest: the MDRD GFR at the 
predefined end point (and thus at the start of immunosuppressive therapy) was 37±9 
ml/min/1.73m2. Of note, because we did not calibrate serum creatinine values against the 
standard of the MDRD reference laboratory, our calculated MDRD GFR may underestimate 
true GFR by 5 ml/min/1.73m2. 
The difference in course of renal function between patients with high and low Uβ2m can be 
appreciated by comparing the slopes of 1/serum creatinine: in patients with low Uβ2m, the 
slope was –0.012 dl/mg per yr (interquartile range, –0.04 to 0.014); in patients with high 
Uβ2m, the slope was –0.42 dl/mg per yr (interquartile range, -0.91 to -0.16; P<0.01).  
A subgroup analysis limited to 44 patients with an initial serum creatinine <1.2 mg/dl resulted 
in similar conclusions: renal survival was 93% at 6 mo, 79% at 1 yr, and 67% at 3 yr. In this 
subgroup, 14 (32%) patients reached the end point of renal death; at baseline, their serum 
creatinine was 1.00±0.14 mg/dl and increased by 63% to 1.64±0.31 mg/dl before start of 
immunosuppressive therapy. In this subgroup analysis, both Uβ2m and UIgG predicted 
prognosis. Renal survival was 33% at 1 yr in patients with high Uβ2m and 97% in patients 
with low Uβ2m. Calculated sensitivity and specificity were 79 and 97% for the Uβ2m and 79 
and 90% for the IgG excretion. The specificity improved to 100% when the β2m and IgG 
excretion were combined.  
 
We also explored our data using all available parameters. In the initial multivariate analysis, 
α1-microglobulin was not included in view of the very high correlation between Uβ2m and 
urinary α1-microglobulin. In univariate analysis, the following parameters were significantly 
related to renal outcome: serum creatinine (P<0.001), serum albumin (P<0.001), ECC 
(P<0.01), proteinuria (P<0.001), selectivity index (P<0.001), and urinary excretion of albumin, 
β2m, α1-microglobulin, transferrin and IgG (all P <0.001). Multivariate analysis revealed that 
Uβ2m was the strongest independent predictive factor (relative risk, 1.030; 95% confidence 
interval, 1.017 to 1.043; P<0.001), indicating that the risk for renal insufficiency increased by  
3.0% for every 0.1 µg/min increase of Uβ2m.  
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After Uβ2m, serum albumin was identified as the second independent predictive factor 
(relative risk, 0.786; 95% confidence interval, 0.691 to 0.894 P<0.01).  
We calculated sensitivity and specificity for the various parameters (Table 2). When 
combining parameters, specificity can be somewhat increased (Table 2). ROC curves, as 
depicted in Figure 3, confirmed the best performance of Uβ2m, as reflected by the AUC. 
 
 
Figure 3.  Comparative efficacy of serum creatinine and the urinary excretion of several proteins for 
predicting renal death in patients with iMN (n=57). Receiver operating characteristics curves of β2-
microglobulin excretion (β2m-exc; area under the curve (AUC) 0.947), α1-microglobulin excretion 
(α1m-exc; AUC 0.956), IgG excretion (IgG-exc; AUC 0.876), proteinuria per day (AUC 0.898), and 
serum creatinine concentration (s.creatinine; AUC 0.833). 
 
 
 
We specifically evaluated urinary α1-microglobulin excretion in comparison with β2m 
excretion. There was a high correlation between these parameters (r=0.80, P<0.001). In fact, 
it is evident from Table 2 and Figure 3 that urinary α1-microglobulin excretion and Uβ2m give 
comparable results. 
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DISCUSSION 
 
We have validated the performance of Uβ2m and UIgG as predictors for renal insufficiency in 
patients with iMN. To this end, we tested the threshold values developed in our previous 
studies in a new, prospectively studied patient cohort. Our data clearly demonstrate that 
Uβ2m and UIgG predict with high accuracy renal outcome in patients with iMN. In fact, the 
calculated sensitivities and specificities are nearly identical to the values obtained in our 
previous studies [13]. Thus, our data indicate that the model parameters are robust. 
Our study may be criticized because we used a fixed value of serum creatinine of 1.5 mg/dl 
as end point for defining renal death. However, it is evident from calculated creatinine 
clearance and MDRD GFR that renal function was severely disturbed at the end point. The 
slope of 1/serum creatinine proved that there was a clear loss of renal function. Adopting a 
doubling of serum creatinine or 50% decrease of GFR as end point would have resulted in 
even longer withholding of immunosuppressive treatment. 
We used a restrictive treatment policy in our patients, initiating immunosuppressive treatment 
as renal failure was evident. On the basis of the results of the randomized study conducted 
by Ponticelli et al. [4], one might ask whether delay of treatment is justified especially in 
patients with a nephrotic syndrome. Our treatment policy was based on our preliminary 
findings that immunosuppressive treatment with cyclophosphamide is effective in patients 
with established renal failure. We recently extended these observations and also 
demonstrated that a restrictive treatment policy results in excellent patient and renal survival 
rates [9,12]. 
In our previous study, we noted that the UIgG was the only variable that was independently 
associated with renal function deterioration. This superiority of UIgG over Uβ2m was 
explained by one patient in whom results of UIgG and Uβ2m did not concur. In this patient, 
who developed renal insufficiency, UIgG exceeded the threshold value of 250 mg/day 
whereas Uβ2m was below the threshold [16]. In our present, larger study cohort, Uβ2m was 
the most significant independent predictive factor. It has been well established that Uβ2m 
reflects the severity of tubulo-interstitial injury [19,20]. Thus, our findings are in good 
agreement with studies that have unequivocally shown that in patients with glomerular 
diseases, renal outcome is more related to the presence and extent of tubulo-interstitial injury 
than to glomerular pathology.  In general, there was a good agreement between Uβ2m and 
UIgG. When both parameters were combined, specificity even increased to a value of 97%.  
How can we explain that UIgG and Uβ2m accurately predict renal failure? We propose that 
UIgG reflects the severity of glomerular damage, whereas Uβ2m is a marker of tubulo-
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interstitial injury. It has been suggested that IgG or other high molecular weight proteins 
cause tubular cell activation or injury that results in tubulo-interstitial inflammation, the final 
step toward renal insufficiency.  
Thus far, only one model for the identification of patients who have iMN and are at risk for the 
development of chronic renal failure has been validated. The model was developed with data 
derived from the Toronto Glomerulonephritis Registery. In the first study, the duration and the 
level of proteinuria proved to be fairly accurate predictive factors. The best performance was 
found using a level of proteinuria >8 g/day for >6 mo. Calculated sensitivity was 66%, and 
specificity was 88% [13,14]. In the validation study, roughly similar figures were reported with 
a sensitivity of 58% and a specificity of 93% [21]. In addition, the Toronto group extended the 
model by calculating a risk score on the basis of the data of a selected 6-mo interval with the 
worst sustained proteinuria. In this model are included the minimum amount of proteinuria in 
that 6-mo interval, the initial creatinine clearance, and the slope of the creatinine clearance 
during the 6-mo period. The risk score model was validated in three different populations and 
proved quite good with sensitivities varying from 60 to 89%, specificities from 86 to 92%, and 
an overall accuracy of 79 to 87% [21]. Obviously, this model has a very good performance. 
However, there are several disadvantages, particularly the need to have an observational 
period that exceeds a period of 6 mo and the necessity of multiple, accurate 24-h urine 
collections. Our model is based on the collection of a single timed urine sample collected in 
the morning period. 
Furthermore, it is unproved whether the Toronto model can be applied to patients with newly 
diagnosed iMN. The model has been validated and applied to a group of patients with well-
defined follow-up. This suggests that a long observation period was used to define the 6-mo 
period with the worst sustained proteinuria. In more than one quarter of the patients, the 6-
mo period started >12 mo after renal biopsy. Therefore, the model may not be applicable to 
patients with a follow-up after biopsy of <12 to 18 mo. 
In the present study, we specifically analyzed the value of urinary α1-microglobulin, a low 
molecular weight protein like β2m. In routine clinical practice, measurement of urinary α1-
microglobulin is easier in view of its relative stability at pH<6.0. We observed a very high 
correlation between Uβ2m and urinary α1-microglobulin. Sensitivities and specificities were 
also comparable, although, admittedly, the threshold values used for α1-microglobulin should 
be validated in a second population. Our data confirm and strengthen the conclusion of Bazzi 
et al. [22]. In a small cohort of 19 untreated patients with iMN, a nephrotic syndrome, and 
normal renal function, these authors found that urinary α1-microglobulin predicted the 
development of chronic renal failure with a sensitivity and specificity of 100%. We have 
applied their threshold value of 33.5 mg/g creatinine to our study cohort of 57 patients and 
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calculated a sensitivity of 88% and a specificity of 78%. Bazzi et al. also reported the 
predictive value of UIgG. Using a threshold value of 110 mg/g creatinine, sensitivity was 
100% and specificity was 69%. Applying this threshold value to our study cohort, we 
calculated a sensitivity of 92% and a specificity of 63%. We used a higher cutoff value (250 
mg/day, approximately 180 mg/g creatinine), thereby increasing specificity. We believe that a 
high specificity should be pursued to be able to avoid unnecessary immunosuppressive 
therapy in patients with iMN. 
The data of our secondary analysis suggest that serum albumin may have added value as 
prognostic marker. Admittedly, this needs confirmation in another patient cohort. Can we 
avoid unnecessary immunosuppressive treatment by using Uβ2m and UIgG as prognostic 
markers? From our data, it can be calculated that when used in the present population with a 
failure rate of 44% (which is in close agreement with literature data), our established 
threshold values would have resulted in the unnecessary treatment of one patient (1.8% 
overall, 4.8% of all treated patients), whereas 31 patients rightly would not have received 
treatment.  
Conclusion: We have validated the performance of Uβ2m and UIgG as prognostic markers in 
patients with iMN. Urinary α1-microglobulin can replace Uβ2m. Use of these markers will 
allow identification of high-risk patients at an early stage. We propose that these markers 
may help to guide the time of start of immunosuppressive treatment in individual patients. 
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ABSTRACT 
 
We treated patients with idiopathic membranous nephropathy (iMN) and renal insufficiency, 
using: (I) (n=15) monthly cycles of steroids (1 g methylprednisolone i.v. on three consecutive 
days, followed by oral prednisone 0.5 mg/kg/day months 1, 3, and 5) and chlorambucil (0.15 
mg/kg/day month 2, 4, and 6); or (II) (n=17) oral cyclophosphamide (1.5 - 2.0 mg/kg/day for 1 
year) and steroids in a comparable dose. The groups were comparable in age, renal function 
and levels of proteinuria. During the 6 months preceding treatment, serum creatinine levels 
increased from 148±50 to 219±73 μmol/l in the chlorambucil group and from 164±86 to 
274±126 μmol/l in the cyclophosphamide group. Median (range) follow-ups were: 
chlorambucil 38 months (8-71); cyclophosphamide 26 months (5-68) (NS). Renal function 
improved in both groups, but the improvement was short-lived in the chlorambucil group; 12 
months after starting treatment, mean serum creatinine was 6.3 μmol/l lower in the 
chlorambucil group and 121 μmol/l lower in the cyclophosphamide group (p<0.01). Four 
chlorambucil-treated patients developed ESRD, and five needed a second course of therapy, 
whereas only one cyclophosphamide-treated patient developed ESRD (p<0.05). Remissions 
of proteinuria occurred more frequently after cyclophosphamide treatment (15/17 versus 
5/15; p<0.01). Side-effects necessitated interruption of treatment in six patients on 
cyclophosphamide and in 11 on chlorambucil (p<0.05). 
In our patients, oral cyclophosphamide was better tolerated than oral chlorambucil. The 
suggested greater efficacy of the oral cyclophosphamide regimen needs to be ascertained by 
longer follow-up. 
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INTRODUCTION 
 
In the majority of patients with idiopathic membranous nephropathy (iMN), the renal disease 
runs a benign course; about 50% of nephrotic patients with iMN will spontaneously enter a 
partial or complete remission. However, up to 40% of the patients will develop end-stage 
renal failure [1]. There is no consensus about the treatment of patients with iMN [2]. Most 
clinicians tend to follow the recommendations of Cattran, who recently suggested that 
treatment with immunosuppressive drugs should be considered only in patients with 
longstanding proteinuria and/or evidence of deteriorating renal function [3]. Both chlorambucil 
and cyclosporine were mentioned as treatment options. However, information on the 
tolerability and efficacy of immunosuppressive treatment in patients with iMN and renal 
insufficiency is limited to small, non-randomized studies. Positive effects have been 
described for chlorambucil [4,5], oral cyclophosphamide [6,7], azathioprine [8,9], and 
cyclosporine [10]. Formal comparisons of immunosuppressive drug regimens have not been 
reported. Over the past 10 years, we have used immunosuppressive therapy in patients with 
iMN and renal insufficiency [11,12]. We developed treatment schedules with chlorambucil 
and oral cyclophosphamide, both combined with corticosteroids. At the end of 1996, we 
analysed the long-term outcome of all patients treated with chlorambucil [13]. The results 
were less favourable than expected. Most remarkable was the high incidence of side-effects, 
often necessitating interruption or premature withdrawal of chlorambucil treatment. These 
results prompted us to analyse the results of treatment with oral cyclophosphamide and to 
compare them with those for chlorambucil treatment. 
 
 
PATIENTS AND METHODS 
 
From 1986 onwards, we have used immunosuppressive therapy in patients with 
membranous glomerulopathy. To be eligible for such treatment, patients were required to 
have biopsy-proven membranous nephropathy, nephrotic syndrome and deteriorating renal 
function. Patients younger than 18 years or with evidence of secondary types of 
membranous nephropathy were excluded. In 1986, we treated one patient with chlorambucil 
and prednisone in a pilot phase. From 1989 onwards, patients were randomized for 
treatment with either chlorambucil and corticosteroids (n=9) or intravenous boluses of 
cyclophosphamide and methylprednisolone. Intravenous cyclophosphamide proved an 
ineffective treatment modality [12]. Therefore, we conducted a pilot study in which we treated 
all eligible patients with oral cyclophosphamide and prednisone (n=7). From 1994 till 1996, 
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patients were then asked to participate in a randomized trial in which we compared 
chlorambucil and corticosteroids with oral cyclophosphamide and corticosteroids. Patients 
unwilling to participate in this study were treated with the oral cyclophosphamide treatment 
regimen. Our interim analysis revealed a particularly high frequency of side-effects with 
chlorambucil treatment [13]. Therefore, we decided in 1996 to stop this randomized study 
prematurely. Meanwhile, five patients were included in each treatment group and in parallel 
with the study, another five patients were treated with oral cyclophosphamide. At start of the 
present analysis the cumulative number of patients that had been treated with chlorambucil 
and prednisone was 15, whereas 17 patients had received oral cyclophosphamide and 
prednisone.  
  
Treatment regimens 
Patients assigned to chlorambucil treatment were treated according to the scheme originally 
described by Ponticelli et al. [14], although we used a lower dose of chlorambucil in view of 
the more severe side-effects of this drug in patients with renal insufficiency [4,11]. In brief, 
the patients received three cycles of steroids consisting of intravenous pulses of 
methylprednisolone, 1 g on 3 consecutive days, followed by oral prednisone 0.5 mg/kg of 
body weight per day for 27 days. Each cycle was followed by 1 month of treatment with oral 
chlorambucil (0.15 mg/kg per day). The total duration of treatment was six months. Patients 
treated with oral cyclophosphamide received this drug in a daily dose of 1.5 to 2 mg/kg body 
weight for 1 year. In the pilot phase (in which seven patients were treated) concomitant 
treatment consisted of oral prednisone 60 mg/day or 125 mg every other day for at least 8 
weeks (mean cumulative dose 8400 mg, range 4200-13650 mg). The last 10 patients 
received intravenous pulses of methylprednisolone, 1 g each on 3 consecutive days at the 
beginning of the first, third and fifth month, and oral prednisone 0.5 mg/kg every other day for 
6 months. The latter schedule precisely matches the corticosteroid dose given to 
chlorambucil treated patients.  
 
All patients received diuretics and antihypertensive drugs if required. Clinical examinations, 
biochemical profiles and full blood counts were done every one or two weeks during the first 
months of treatment, and at regular intervals thereafter. The end-point was defined as 
deterioration of renal function requiring a second course of immunosuppressive therapy or 
the development of end-stage renal disease. A second course of immunosuppressive 
therapy was offered to patients who experienced a rise of serum creatinine of >50 % over the 
lowest value reached after the first immunosuppressive treatment. Otherwise patients were 
followed until July 1997. 
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For calculations of renal survival, the time of renal death was defined as the time of the start 
of a second course of immunosuppressive treatment or the time of start of renal replacement 
therapy. We have used the reciprocal of serum creatinine (1000/serum creatinine level) to 
assess the effects of treatment on the progression of renal insufficiency. Changes in this ratio 
parallel changes in endogenous creatinine clearance. For the calculations, 1000 μmol/l was 
used as the serum creatinine level in patients on renal replacement therapy. To correct for 
inappropriate 24-hr urine collections, the amount of urinary protein was adjusted for the 
amount of urinary creatinine (protein-creatinine index). A complete remission of proteinuria 
was defined as a reduction of the protein-creatinine index to less then 0.2 g/10 mmol 
creatinine, and a partial remission as a protein-creatinine index of between 0.2 and 2.0 g/10 
mmol creatinine.  
 
Statistics 
Changes in biochemical parameters were analysed with repeated measures ANOVA, and 
post-test according to Newman-Keuls. Comparisons between groups were done by Fisher’s 
test, Mann-Whitney U test, or unpaired t-test where appropriate. Probabilities of survival were 
calculated by the Kaplan-Meier method and for comparison of survival curves the log rank 
test was used. Results are given as means ± SD, or medians and range when appropriate. A 
p value < 0.05 was considered significant. 
 
 
RESULTS 
 
The baseline characteristics of both treatment groups are summarized in Table 1. All but two 
patients were male. Both treatment groups were comparable with respect to age, blood 
pressure, renal function, proteinuria, and the interval between renal biopsy and start of the 
immunosuppressive treatment. In four patients of the chlorambucil group and in five of the 
cyclophosphamide group, this interval was more than 2.5 years. All patients had evidence of 
renal function deterioration. In the 6 months before the start of treatment, serum creatinine 
levels of patients in the chlorambucil group increased from 148±50 μmol/l to 219±73 μmol/l; 
in the cyclophosphamide group, serum creatinine increased from 164±86 μmol/l to 274±126 
μmol/l (chlorambucil versus cyclophosphamide: p=NS). Six patients in the chlorambucil 
group had received prednisone therapy in an earlier phase of the disease, whereas in the 
cyclophosphamide group, eight patients had been treated previously (four with prednisone 
and four with prednisone and chlorambucil). Seven patients in the chlorambucil group and 
nine patients in the cyclophosphamide group were treated with an angiotensin-converting 
enzyme inhibitor. 
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Table 1.  Baseline characteristics 
 Chlorambucil Cyclophosphamide  
Number of patients 15 17 
Sex  (M/F) 15/0 15/2 
Age (years) 51 ± 12 53 ± 14 
Time from kidney biopsy to start of 
treatment (months) 
 
14 (1 - 120) 
 
11 (1 - 157) 
Blood pressure (mm Hg) 
           Systolic 
           Diastolic 
 
145 ± 18 
85 ± 9 
 
151 ± 29 
89 ± 10 
Proteinuria (g/10 mmol creat)      9 ± 2.6 11 ± 5.3 
ECC (ml/min) 46 ±17 43 ± 23 
Values are given as means (±SD) or medians (range). 
 
During the course of the follow-up the blood pressures of the patients in the chlorambucil 
group did not differ significantly from the blood pressures in the cyclophosphamide treated 
patients (systolic blood pressure at month 12; 140±11 versus 135±20 mm Hg (NS), at month 
24; 136±17 versus 137±18 mm Hg, diastolic blood pressure at month 12; 89±8 versus 83±8 
mm Hg, at month 24; 87±17 versus 85±16 mm Hg. 
Short-term effects of treatment are given in Table 2. Both treatment regimens reversed the 
deterioration of renal function, as evidenced by the decrease of serum creatinine. In most 
patients, improvement of renal function was already apparent after 1 month of therapy.  
 
 
Table 2. Short-term effects of immunosuppressive treatment on renal function and proteinuria 
   0 months  3 months  6 months 12 months 
Serum creatinine 
(μmol/l) 
CA 
CP 
 219 ± 73 
 274 ± 126 
165 ± 56** 
171 ± 82*** 
166 ± 54** 
165 ± 80*** 
216 ± 99 
  174 ± 78*** 
 
Serum albumin 
(g/l) 
 
CA 
CP 
 
  22 ± 5.6 
  22 ± 6.0 
 
 26 ± 6.0** 
  29 ± 5.1*** 
 
 31 ± 6.2*** 
 34 ± 5.2*** 
 
   32 ± 6.8*** 
   40 ± 4.7*** 
 
Proteinuria 
(g/10 mmol creat) 
 
CA 
CP 
 
  9.1 ± 2.6 
11.2 ± 5.3 
 
 8.3 ± 5.9 
   4.9 ± 2.3*** 
 
 6.5 ± 3.9* 
  3.0 ± 2.3*** 
 
 6.8 ± 4.4 
   2.0 ± 3.0** 
CA, Chlorambucil group; CP, Cyclophosphamide group. Values are means ± SD. 
Treatment was started at 0 months.  *p<0.05, ** p<0.01, *** p<0.001 versus 0 months. 
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Overall, renal function improved or stabilized in 13/15 patients on chlorambucil, and in all 
patients on cyclophosphamide. The improvement of renal function was also evident from 
significant changes in the slope of 1000/serum creatinine. In the chlorambucil group the 
slope of 1000/Screat changed from -0.38 (95%CI -0.48 to -0.29) in the 6 months before start 
of treatment to 0.29 (95%CI 0.13 to 0.44) in the 6 months after start of treatment. In the 
cyclophosphamide group, values were -0.53 (95%CI -0.75 to -0.30) and 0.40 (95%CI 0.21 to 
0.58), respectively. However, in the chlorambucil treated patients the improvement in renal 
function was short-lasting. In these patients a decline in renal function was already apparent 
at 12 months after start of treatment, which contrasts with the findings in the cyclo-
phosphamide treated patients: at 12 months serum creatinine levels had changed by -6.3 
μmol/l (95%CI: -65 to 52 μmol/l) in the chlorambucil group and by -121 μmol/l (95%CI: -166 
to -76 μmol/l) in the cyclophosphamide group (p<0.01). This difference is also reflected in the 
slope of 1000/Screat from 6 to 12 months (chlorambucil -0.16, 95%CI -0.24 to -0.08 versus 
cyclophosphamide 0.00, 95%CI -0.11 to 0.11, p<0.05). 
 
Long-term follow-up  
The median duration of follow-up was 26 months (range 5-68) in the cyclophosphamide 
group and 38 months (range 8-71) in the chlorambucil group (NS). Eleven of the 
cyclophosphamide treated patients and 14 of the chlorambucil treated patients were followed 
for at least 24 months (NS). Pertinent data for the individual patients of both treatment 
groups are given in Tables 3 and 4. In the chlorambucil group, four patients progressed to 
ESRD, whereas in 5 other patients a second course of therapy was given because of 
deterioration of renal function. Thus far, only one of the cyclophosphamide treated patients 
has developed ESRD. The difference in renal survival between the groups is significant 
(p<0.05). 
There was a striking difference in the cumulative incidence of the occurrence of a complete 
or partial remission of proteinuria (Figure 1). Overall, a partial remission of proteinuria was 
observed in 5 (33%) patients after chlorambucil treatment and in 15 (92%) patients after 
cyclophosphamide treatment (p<0.01). Of these latter patients, six developed a complete 
remission, whereas none of the chlorambucil treated patients did (p<0.01). At the end of 
follow-up, two patients in the chlorambucil group and 11 patients in the cyclophosphamide 
group were still in remission. The median interval between start of treatment and 
development of partial remission was 6 months (range 1 - 24) in the chlorambucil treated 
patients and 12 months (range 1 - 24) in the cyclophosphamide treated patients. Four 
patients in the cyclophosphamide group had previously been treated with chlorambucil. 
Exclusion of these patients did not alter the results, as remissions still occurred more 
frequently in the cyclophosphamide group (11/13 versus 5/15, p<0.01). 
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To further exclude as much as possible any bias because of a difference in the year of 
treatment start, we have analysed separately the data of patients treated from 1992 onward, 
and excluding the patients who received cyclophosphamide as retreatment. Results are 
given in Table 5. This analysis confirmed the superiority of cyclophosphamide treatment. 
 
 
Figure 1. Cumulative incidence of partial remissions of proteinuria (i.e. proteinuria < 2 g/10 mmol 
creatinine) in patients treated with either chlorambucil or cyclophosphamide. 
 
 
From Tables 3 and 4, it is evident that side-effects were observed regularly. Side-effects 
included leukopenia, anaemia, thrombocytopenia, infectious complications and nausea, and 
occurred more frequently in the chlorambucil group. Overall, only one patient in the 
chlorambucil group did not experience side-effects as compared to nine patients in the 
cyclophosphamide group (p<0.01). It is unlikely that the differences in side-effects are related 
to the use of methylprednisolone. As indicated in Table 4, the incidence of infectious 
complications was similar in patients treated with or without pulses methylprednisolone. 
 
 
Table 5. Analysis of data of patients treated from 1992 onward 
 
 
Chlorambucil 
(n=8) 
Cyclophosphamide 
(n=12) 
p 
Follow-up duration (months) 25 ± 14 19 ± 11  
Serum creatinine month 0 170 ± 45 215 ± 83  
Rise of creatinine >50% 5 0 <0.01 
Proteinuria month 0 9.3 ± 2.8 10.7 ± 5.9  
Partial Remission 3 11 <0.02 
Complete Remission 0 5 0.055 
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Treatment had to be reduced, temporarily interrupted, or prematurely stopped in 11/15 
chlorambucil treated patients and in 6/17 cyclophosphamide treated patients (p<0.05). 
As a result, patients have used a lower cumulative dosage (9.8±4.1 mg/kg) of chlorambucil 
than initially scheduled (13.5 mg/kg). For cyclophosphamide, this difference is less clear; the 
median daily dose amounting to 1.56 mg/kg. 
 
 
DISCUSSION 
 
In iMN, immunosuppressive therapy should be reserved for patients at high risk for 
developing ESRD [3]. Thus far, a steady rise in serum creatinine is the best predictor of 
future development of ESRD [15,16]. Therefore, it has been recommended that 
immunosuppressive therapy should be delayed until renal insufficiency becomes apparent. 
However, little is known on the efficacy of immunosuppressive treatment when it is initiated 
at this stage of the disease, and comparisons between the various immunosuppressive 
drugs are lacking. We have compared oral chlorambucil- and oral cyclophosphamide-based 
regimens, which have been used successfully in previous, smaller studies [4,7]. Our study 
confirms that immunosuppressive treatment is indeed effective, and able to preserve or even 
improve renal function when initiated in patients with moderately to severely impaired renal 
function. Furthermore, our data suggest that oral cyclophosphamide is more effective than 
chlorambucil, in preserving renal function as well as in inducing remissions of proteinuria. 
Admittedly, in the cyclophosphamide treated patients a longer follow-up is needed to 
ascertain that renal function will remain stable for a longer time period. However, we 
observed a very high rate of remissions of proteinuria in this group, and it is generally 
accepted that the development of remissions of proteinuria is associated with a good 
prognosis [17]. Treatment with cyclophosphamide was reasonably well tolerated. In contrast, 
chlorambucil caused side-effects more frequently, often necessitating interruption of therapy. 
 
Although our study was not fully randomized, it seems unlikely that the observed differences 
between both drugs are caused by a selection bias. All patients were treated prospectively; 
the majority of patients as part of a randomized study, or in parallel with one of the 
randomized studies. Moreover, both groups had similar baseline characteristics, in particular 
with respect to risk factors such as baseline serum creatinine, rate of renal function 
deterioration and the amount of proteinuria. Furthermore, the cumulative dose of steroids 
was comparable in both treatment groups. Subgroup analysis also suggested a higher 
efficacy of cyclophosphamide treatment, thus confirming and strenghtening our overall 
conclusions. 
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It is quite possible that the better efficacy of cyclophosphamide is fully explained by the 
longer duration of cyclophosphamide therapy (12 versus 6 months) and the lesser need to 
interrupt treatment. However, it is also possible that cyclophosphamide is a more effective 
drug than chlorambucil. A review of the available literature provides support for this latter 
explanation. Thus far, six other studies have addressed the effects of cyclophosphamide or 
chlorambucil in patients with iMN and deteriorating renal function [4,7,18,19]. The results of 
these non-randomized, small studies and the current study are summarized in Table 6. From 
this table, it is evident that remissions of proteinuria are more frequent during treatment with 
cyclophosphamide, a complete remission occurring in 16/41 patients after cyclophosphamide 
and in 2/39 patients on chlorambucil (p<0.001). A similar significant difference is observed 
when counting the number of complete and partial remissions (Table 6). The differences 
remain present after exclusion of the data of the present study, complete remissions 
occurring in 11/24 patients on cyclophosphamide and in 2/24 patients on chlorambucil 
(p<0.01). Admittedly, with respect to the effects on renal function, the differences are not 
significant. 
 
The available literature data do not allow meaningful conclusions on the efficacy of oral 
cyclophosphamide in comparison with immunosuppressive drugs such as azathioprine and 
cyclosporine. We are aware of only one study in which patients with iMN and renal failure 
were treated with cyclosporine [10]. In this study, only 9 patients were included, and although 
renal function was preserved, the results are somewhat disappointing since neither 
improvement of renal function nor sustained remissions of proteinuria were observed. Two 
groups of investigators have reported on the effects of azathioprine [8,9]. The initial data, on 
only 10 and 6 patients, respectively, showed an improvement of renal function after start of 
azathioprine. In the short term, sustained remissions of proteinuria were rare, occurring in 
only 3/16 patients. However, with longer follow-up, results seem more favourable. Bone and 
colleagues recently reported 10-year follow-up data for 21 patients treated with azathioprine 
[20]. In most patients there was a permanent improvement of renal function, and a partial or 
complete remission of proteinuria occurred in up to two third of patients [20]. These data 
show that treatment with azathioprine has favourable effects. It should be noted however, 
that these results were obtained with continued, possibly lifelong treatment with low-dose 
azathioprine and prednisone. Longer follow-up of our cyclophosphamide treated patients is 
needed to see whether limited duration of treatment with this drug has similar effects in the 
long run. 
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For chlorambucil therapy, we have adapted the treatment protocol developed by Ponticelli et 
al. for patients with iMN and normal renal function [14]. In their patients, side-effects were 
uncommon (occurring in 10% of patients). Although we have used a lower dosage, we 
observed a very high incidence of side-effects. Similar observations were made by 
Mathieson and Warwick [4,5]. This suggests that patients with renal insufficiency are more 
sensitive to the side-effects of chlorambucil. An even lower dose might have been better 
tolerated [19], but the efficacy of such low doses has not been proven. A formal comparison 
of the efficacy of oral chlorambucil and cyclophosphamide can best be performed in patients 
with normal renal function. 
  
In conclusion, immunosuppressive treatment preserves renal function and can result in 
complete remission of proteinuria in patients with iMN and renal insufficiency. In view of its 
efficacy and tolerability, we prefer oral cyclophosphamide over chlorambucil for the treatment 
of these patients. 
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ABSTRACT 
 
Background: Up to half of the patients with idiopathic membranous nephropathy (iMN) will 
develop renal failure. Preferably, immunosuppressive treatment should be restricted to 
patients at risk for the development of end-stage renal disease. However, the evidence that 
immunosuppressive treatment is effective in patients with iMN and renal insufficiency is weak 
and based on few studies with short follow-up in a limited number of patients.  
Methods: We have analyzed the efficacy of immunosuppressive treatment in a large number 
of patients with membranous nephropathy and renal insufficiency. Since 1991, we have 
prospectively treated 39 patients (31 M, 8 F) with membranous nephropathy and evidence of 
deterioration of renal function. Treatment consisted of oral cyclophosphamide, 1.5-2.0 mg/kg 
body weight for 12 months, and corticosteroids for 6 months. At regular intervals blood 
pressure, serum creatinine, serum albumin, and proteinuria were measured. Adverse events 
were recorded.  
Results: Average follow-up is 32 months (range 6-104), 18 patients have been followed for 
more than three years. Mean age of the patients was 55±12 years. In the six months before 
start of therapy, serum creatinine increased from 150±74 to 226±108 µmol/l. After start of 
treatment renal function rapidly improved, serum creatinine at 12 months averaging 143±62 
µmol/l. Proteinuria decreased from 10.3±4.9 g/10 mmol creatinine at baseline to 2.2±2.4 g/10 
mmol creatinine at month 12. These initial favorable effects have persisted. Overall, 12 
patients have developed a complete remission of proteinuria (persistent in 11), and an 
additional 19 have developed a partial remission of proteinuria (persistent in 15). Thus far, 
only one treated patient has developed end-stage renal disease. Side effects are a major 
drawback of the treatment, with 7 patients being admitted, mainly for the treatment of 
infectious complications.  
Conclusions: Cyclophosphamide is effective in the treatment of patients with idiopathic 
membranous nephropathy and deterioration of renal function. The favorable effects are 
maintained well beyond the one-year treatment period. Therefore, we propose that in 
patients with iMN immunosuppressive therapy can be restricted to patients at high risk for 
end-stage renal disease. 
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INTRODUCTION 
 
About 40% of patients with idiopathic membranous nephropathy (iMN) and nephrotic range 
proteinuria will finally develop end-stage renal disease (ESRD). In their large placebo-
controlled, randomized study, Ponticelli et al. showed that treatment with a combination of 
chlorambucil and steroids improved renal survival and increased the number of complete and 
partial remissions of proteinuria [1]. This favorable outcome was still present after a follow-up 
of 10 years [2]. More recently, the same investigators have documented that 
cyclophosphamide is as effective as chlorambucil [3]. In these Italian studies, treatment was 
initiated in patients with iMN at an early stage. Most patients had normal renal function and a 
short duration of the disease. Since 33% of their untreated patients spontaneously developed 
a complete of partial remission of proteinuria, the treatment policy as adopted by the Italian 
investigators can been criticized for being too aggressive. Several recently published reports 
recommend restricting immunosuppressive treatment to patients with iMN who are at high 
risk for the development of ESRD [4,5]. However, the long-term efficacy of 
immunosuppressive treatment in patients with iMN and renal insufficiency remains to be 
proven.  
The short-term efficacy of immunosuppressive therapy has been suggested in a number of 
small, non-randomized studies, in which various (combinations of) drugs were used such as 
chlorambucil, cyclophosphamide, cyclosporine or azathioprine [6-16]. Over the last 15 years 
we have adopted a policy restricting immunosuppressive drugs to patients with iMN and 
evidence of deterioration of renal function. We initially have used corticosteroids combined 
with either chlorambucil for 6 months or cyclophosphamide for 12 months. When comparing 
these drug regimens we observed that cyclophosphamide was better tolerated and on the 
short-term more effective than chlorambucil [17]. Ever since, a cyclophosphamide based 
regimen has become our treatment of choice in patients with iMN and renal insufficiency. 
Patients eligible for this therapy have been prospectively studied. Therefore, we are now able 
to present data on the long-term efficacy of cyclophosphamide treatment in our patient 
group. Our data indicate that cyclophosphamide treatment is indeed effective in patients with 
iMN and renal insufficiency.  
 
 
METHODS 
 
Since 1986, we have prospectively treated patients with biopsy-proven iMN and renal 
insufficiency with immunosuppressive drugs. From 1986 till 1993, we have used a 
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combination of chlorambucil and corticosteroids [15]. In 1991 we started to use a 
combination of oral cyclophosphamide and steroids, and this treatment has been the 
treatment of choice after a comparison of the data indicated that cyclophosphamide was 
more effective and better tolerated [17].  
 
Our treatment regimen has been described in detail before [17]. Briefly, cyclophosphamide 
was administered orally during one year in a target dose of 1.5 to 2 mg/kg body weight per 
day. The majority of patients received intravenous pulses of methylprednisolone, 1 g each on 
3 consecutive days at the beginning of the first, third, and fifth month, and oral prednisone 
0.5 mg/kg bodyweight every other day for 6 months. As methylprednisolone was initially not 
included in the treatment regimen the first 7 patients only received oral prednisone in a 
different schedule of 125 mg every other day, or 60 mg/day for at least 8 weeks [17].  
Eligible patients had to present with evidence of deterioration of renal function defined as a 
serum creatinine of >130 µmol/l, an increase of the serum creatinine >50%, or a calculated 
Ccr<70 ml/min. Previous immunosuppressive treatment was not an exclusion criterion. Renal 
biopsies were not repeated before start of therapy. Clinical examinations, biochemical 
profiles and full blood counts were done every one or two weeks during the first months of 
treatment, and at regular intervals thereafter. Blood pressure was repeatedly measured by 
use of a mercury sphygmomanometer. The presence of hypertension was defined as a 
systolic blood pressure ≥140 mm Hg and/or a diastolic blood pressure ≥90 mm Hg. The use 
of antihypertensive drugs, diuretics, ACE inhibitors, angiotensin II receptor blockers and lipid 
lowering drugs was allowed during the study period as required. 
In the present study we have analyzed the effects of cyclophosphamide therapy in patients 
who have been treated and followed for at least 6 months.  
 
Calculations and statistics 
The Ccr was calculated according to the standard formula Ucr x V/Pcr, in which Ucr reflects 
the urinary creatinine concentration and V the volume of a 24-hour urine sample, and Pcr the 
serum creatinine level. The reciprocal of serum creatinine (1000/serum creatinine level) has 
been used to assess the effects of treatment on the progression of renal insufficiency. 
Changes in this ratio parallel changes in Ccr. For the calculations, 1000 µmol/l was used as 
the serum creatinine level in patients on renal replacement therapy. To correct for incomplete 
24-hour urine collections during the follow-up, the amount of urinary protein was adjusted for 
the amount of urinary creatinine (protein-creatinine index). A complete remission of 
proteinuria was defined as a reduction of the protein-creatinine index to less then 0.2 g/10 
mmol creatinine, and a partial remission as a protein-creatinine index between 0.2 and 2.0 
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g/10 mmol creatinine. Patients with a stable remission were defined as those having a 
remission at the end of follow-up. 
For descriptive statistics, results are given as means ±SD, or medians and range when 
appropriate. Changes in biochemical parameters were analyzed with repeated measures 
ANOVA, with adjustment for multiple comparisons by Bonferroni correction. Probabilities of 
survival were calculated by the Kaplan-Meier method. A Cox regression analysis was 
performed to examine if a specific set of variables could predict the occurrence of remission 
of proteinuria. To select variables worth including as co-variates in the regression analysis, 
initially variables were tested univariate using Kaplan Meier survival curves. The log-rank test 
was used to compare the survival curves. The following variables were considered relevant: 
sex, age, the slope of the plotted reciprocal of serum creatinine in the 6 months previous to 
start of treatment, previous immunosuppressive treatment, serum creatinine level, serum 
albumin level, and proteinuria at start of treatment, blood pressure during the year of 
treatment, use of an ACE inhibitor or angiotensin II receptor blockers during at least 80% of 
the time period before reaching a partial remission of proteinuria, and total dose of 
cyclophosphamide. Cox regression analysis was restricted to variables with a P-level <0.20. 
For the performance of the test a forward-step procedure was used, in which the cut-off 
value to be entered in the equation was defined as <0.10.  A P-value <0.05 was considered 
significant. All statistical procedures were done using SPSS software (SPSS version 9.0, 
Chicago, Illinois). 
 
 
RESULTS 
 
From January 1991 until April 1999, 46 patients with iMN and renal failure came to our 
attention. Two patients refused immunosuppressive treatment. Five patients were treated 
with chlorambucil in the period 1991-1993 as part of a controlled study [17]. The remaining 
39 patients that have received cyclophosphamide form the basis of this report. In 18 patients 
the duration of the follow-up has exceeded 36 months. Baseline characteristics of the 
patients are summarized in Table 1. Five patients were previously treated with steroids only, 
another 4 with a combination of chlorambucil and steroids, one patient with cyclosporine A, 
and one patient was previously treated with a short course of cyclophosphamide because of 
severe proteinuria with absence of renal failure. In all these 11 patients, deterioration of renal 
function occurred that led us to consider cyclophosphamide treatment. The median interval 
between the end of the previous treatment and the start of cyclophosphamide therapy was 
30 months (range 8 – 133). At baseline, 27 patients were hypertensive, and 26 patients were 
on treatment with an ACE inhibitor or angiotensin II receptor antagonist. All patients had 
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evidence of deterioration of renal function. In the 6 months before the start of treatment, 
serum creatinine levels increased from 150±74 µmol/l to 226±108 µmol/l. In all patients but 
one, proteinuria exceeded the nephrotic level of 3.5 g/10 mmol creatinine.  
 
 
Table 1.  Baseline characteristics of the patients 
  All patients Patients followed 
 for >36 months 
Number (N) 39 18 
Sex (M/F) 31/8 16/2 
Age (yrs) 55 ± 12 53 ± 13 
Time from kidney biopsy to start 
of treatment (months) 
11 (0 – 158) 14 (1 – 158) 
Previous immunosuppressive treatment (N) 11 9 
Blood pressure (mm Hg) 
        Systolic 
        Diastolic 
 
149 ± 26 
  84 ± 10 
 
149 ± 25 
  87 ± 10 
Proteinuria (g/10 mmol creatinine) 10.3 ± 4.9 10.7 ± 5.9 
Ccr (ml/min)   45 ± 21   42 ± 23 
Follow-up (months) 32 (6 - 104) 49   (37 - 104) 
Values are given as means ± SD or median (range). 
 
 
After start of the immunosuppressive treatment the serum creatinine level decreased (n=37) 
or stabilized (n=2) in all patients (Table 2 and Figure 1). The decrease of serum creatinine 
became notable within one month after start of treatment and the lowest level was reached 
within the first 6 months in 35 patients. 
 
 
Table 2.  Short-term effects of cyclophosphamide on renal function and proteinuria 
 0 months 
(n=39) 
3 months 
(n=39) 
6 months 
(n=39) 
12 months 
(n=35) 
Serum creatinine  (µmol/l)                    226 ± 108 145 ± 66* 142 ± 64* 143 ± 62* 
Serum albumin (g/l)        23 ± 7 29 ± 6*  33 ± 6*#  38 ± 5*# 
Proteinuria (g/10 mmol creatinine)     10.3 ± 4.9  4.9 ± 3.9*    3.2 ± 2.8*#    2.2 ± 2.4*# 
Values are means ± SD. Treatment was started at 0 months. *P<0.01 vs. 0 months, 
#P<0.01 vs. month 3. 
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The median decrease in serum creatinine was 38% (9-67%). Subanalysis in patients with a 
follow up of > 36 months revealed a stable improvement of renal function on the long-term as 
depicted in Figure 1. Serum creatinine levels in this subgroup amounted 277±125, 168±75, 
183±87, and 187±95 µmol/l at month 0, 12, 24, and 36, respectively. Thus far, serum 
creatinine has increased by more than 50% over the lowest value in 4 cyclophosphamide-
treated patients, and only one patient has developed end-stage renal disease.  
Treatment also resulted in a significant decline in proteinuria, and an increase of the serum 
albumin level (Table 2). The effects were stable during prolonged follow up (Figure 2).  
 
 
Figure 1.  Serum creatinine levels 
before, during and after immuno-
suppressive treatment of all patients 
(n=39, dashed line), and of the 
subgroup of patients with a follow-up 
>36 months (n=18, straight line). 
Cyclophosphamide was administered 
from month 0 to month 12. In both 
groups the creatinine levels from 
month 3 onward significantly differ from 
the levels at month 0 (P<0.01) 
 
 
In the 18 patients with follow up >36 months, levels of proteinuria and serum albumin at 
month 36 amounted to 1.6±2.1 g/10 mmol creatinine and 40±7 g/l, respectively.  
 
 
 
Figure 2.  The effects of 
immunosuppressive treatment of 
proteinuria in patients with a follow-up 
of >36 months (n=18). Proteinuria is 
corrected for creatinine levels in the 
urine and expressed as g per 10 mmol 
creatinine. All levels from month 3 
onward are significantly lower than 
baseline levels (P<0.01). 
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Partial remission of proteinuria occurred in 31 of the treated patients, and 12 patients further 
improved to complete remission. The cumulative remission rates are depicted in Figure 3. 
 
 
 
 
Figure 3.  Cumulative incidence of 
partial remission of proteinuria (i.e. 
proteinuria ≤2g / 10 mmol creatinine) 
in patients treated with 
cyclophosphamide. 
 
 
 
 
 
 
The median interval between start of treatment and development of partial or complete 
remisson was 12 months (range 1-24) and 21 months (range 2-36), respectively. In all 
patients complete remission was reached within one year after the onset of partial remission. 
At the end of follow-up 26 patients were still in remission, including 11 patients with a 
complete remission. In 7 patients relapses of proteinuria (defined as proteinuria > 2.0 g/10 
mmol creatinine) were noticed (overall relapse rate 23%); two of these came in remission for 
a second time. In general, in patients who relapsed, remissions had been of short duration 
(<1 year). The occurrence of a relapse was not related to the length of the interval from start 
of therapy to the time when remission was reached: relapses were noticed in patients with 
early as well as late remissions. 
 
We have evaluated whether the outcome with respect to the development of remissions 
could be predicted. All variables tested in univariate analysis are listed in Table 3. The 
likelihood of developing a partial remission of proteinuria tended to be higher in patients with 
lower levels of proteinuria and lower diastolic blood pressure. In the Cox regression analysis 
no factor really proved significant. In patients with a stable remission the likelihood of renal 
failure was significantly less than in patients with persistent or relapsing proteinuria (0% vs 
33% p<0.01). 
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Table 3.  Results of univariate survival analysis: the influence of several parameters on remission 
of proteinuria 
 Values N Remission at 36 
months (%) 
P 
Sex  M 
F 
30 
8 
95 
75 
 
0.83 
Age  (years) < 59 
≥ 59 
18 
20 
91 
92 
 
0.30 
1000/S.creatinine (µmol.l-1.yr-1)  < -1.7 
≥ -1.7 
17 
17 
87 
92 
 
0.21 
Previous immunosuppressive therapy  (N) Yes 
No 
10 
28 
90 
93 
 
0.99 
S.creatinine at start of therapy (µmol/l) < 184 
≥ 184 
19 
19  
100 
89 
 
0.22 
S.albumin at start of therapy (g/l) < 23 
≥ 23 
19 
19 
86 
94 
 
0.86 
Proteinuria (g /10 mmol creat) < 10 
≥ 10 
21 
17 
100 
78 
 
0.09 
SBP year 1  (mm Hg) < 134 
≥ 134 
19 
16 
89 
92 
 
0.70 
DBP year 1  (mm Hg) < 80 
≥ 80 
17 
18 
100 
83 
 
0.06 
ACE-inhibitor (N) Yes 
No 
24 
14 
94 
88 
 
0.16 
Dosage cyclophosphamide  
(mg/Kg BW/day) 
< 1.35 
≥ 1.35 
20 
18 
83 
100 
0.73 
 
One patient is not included because he had a proteinuria at start of treatment of < 2.0 g/10 mmol 
creatinine. 1000/S.creatinine represents deterioration of renal function in the 6 months preceding  
start of treatment. S=serum, SBP=systolic blood pressure, DBP=diastolic blood pressure. Systolic  
and diastolic blood pressures are the means of the measurements during the first year of treatment.  
ACE-inhibitor is the use of an ACE-inhibitor / AIIA receptor blocker during >80% of the time untill  
the remission of proteinuria is achieved. 
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During treatment all adverse events were registered. The majority of patients experienced 
side effects, which resulted in therapy interruption in 12 patients (Table 4).  
 
 
Table 4.  Therapy related side-effects 
 Number of patients 
 (N) 
Without side effects 15 
> 1 side effect 8 
Leukopenia            10 (7 / 0) 
Anemia             5  (0 / 0) 
Infections:   Respiratory 
                   Oral candidiasis 
                   Herpes Zoster 
                   Bursitis 
                   Campylobacter 
                   Febris e.c.i. 
            7  (3 / 5) 
           1  (0 / 0) 
           1  (1 / 0) 
           1  (0 / 0) 
           1  (0 / 0) 
           1  (0 / 1) 
Nausea/Vomiting/Malaise            6  (6 / 1) 
Numbers in brackets represent patients in which the side effect  
necessitated interruption of treatment / hospital admission. 
 
 
Therefore, the calculated daily dose of cyclophosphamide used throughout the treatment 
period was slightly lower than the target dose, and the median dose amounted 1.4 mg/kg/day 
(range 0.5 – 2.2). Seven patients were admitted mostly for treatment of infections; however 
no serious, life-threatening events were observed. Thus far, malignancies have not been 
observed in any of the patients.  
 
 
DISCUSSION 
 
Our descriptive study is the largest reported thus far on immunosuppressive treatment in 
patients with idiopathic MN and renal insufficiency. The data clearly indicate that treatment 
with cyclophosphamide and steroids is effective in inducing a remission of proteinuria, and a 
stable improvement of renal function in the majority of such patients. Thus far, only one 
patient has developed end-stage renal disease and calculated renal survival at 5 years after 
start of treatment is 89%. Although our study was not controlled, we feel that the data 
strongly suggest that patients with iMN and renal failure can benefit from immunosuppressive 
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treatment. This conclusion is supported by literature data that indicate that patients with iMN 
who present with renal function deterioration have an unfavorable prognosis [12,18-24]. In 
such patients, development of end-stage renal disease is the rule, with less than 10% of the 
patients demonstrating a spontaneous improvement [18,24]. 
Average blood pressures in our patients exceeded the value of 125/75 mm Hg, the current 
target value for patients with overt proteinuria. Nowadays we strongly advocate such blood 
pressures in order to attenuate deterioration of renal function. However, we feel that it is 
highly unlikely that the improvement of renal function that we observed in our patients could 
have been obtained merely by more aggressive antihypertensive treatment. Moreover, in 
about a quarter of our patients renal function decreased despite blood pressure values below 
125/75 mmHg. 
The present data support and extent our previous observations on the short-term efficacy of 
cyclophosphamide in the treatment of patients with iMN [17]. In our latter study we observed 
that the cyclophosphamide schedule was more effective and better tolerated than the 
chlorambucil regimen. However, the number of patients included in our previous study was 
small and follow-up was limited. Likewise, most data on the effects of immunosuppressive 
treatment in patients with iMN and renal insufficiency in the literature come from small, non-
randomized studies (reviewed in [17]). Most studies have suggested that both 
cyclophosphamide and chlorambucil can attenuate deterioration of renal function [6-11,15-
17]. When analyzing these literature data, we observed a significant difference in the 
remission rate of proteinuria in favor of the use of cyclophosphamide. Also, the use of 
chlorambucil was associated with a higher incidence of side effects [15,17].  
The efficacy of cyclosporine in the treatment of patients with iMN and renal insufficiency has 
been evaluated in one controlled study [12]. Cyclosporine significantly decreased the rate of 
renal function deterioration. However, the number of treated patients was small (n=9), and in 
none of the patients was a sustained remission of proteinuria or real improvement of renal 
function observed. The latter findings certainly are in contrast with our experience with 
cyclophosphamide. Also, the lack of data in larger patients groups and the well-known 
nephrotoxicity of cyclosporine argue against the routine use of cyclosporine in patients with 
iMN and renal insufficiency.  
Data on the efficacy of azathioprine in patients with iMN and renal insufficiency are 
equivocal. In 3 studies, positive effects of azathioprine on renal function and proteinuria in 
patients with moderate to severe renal impairment were reported [14,25,26]. In most patients 
an improvement of renal function was observed, and at the end of the follow-up few patients 
still had proteinuria in the nephrotic range. These favorable effects of azathioprine have – in 
one recent study - not been confirmed [27]. In the latter study a comparison was made 
between treated and untreated patients. However, patients were not randomized, and the 
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control group had better renal function and lower proteinuria (although no significant 
differences were noted). Most importantly, therapy was not restricted to patients with 
deterioration of renal function. The inclusion of patients with a good prognosis, even if left 
untreated, certainly makes it difficult to find differences in small sized studies.  
To determine if immunosuppressive therapy can be restricted to patients with evidence of 
renal function deterioration, our data must be compared to the results obtained by the Italian 
group of investigators, who have unequivocally demonstrated that immunosuppressive 
therapy improves renal survival in patients with iMN [1,2,24]. As noted before, in the Italian 
studies all patients with iMN were treated at a time when their renal function was still normal. 
In the initial studies, immunosuppressive treatment consisted of a combination of 
chlorambucil and prednisone [1]. Recently, similar results were obtained with a combination 
of cyclophosphamide and prednisone [3]. Duration of treatment was 6 months, and the 
cumulative dose of cyclophosphamide amounted 17 g. Notably, in the latter study the total 
number of side effects was less in the cyclophosphamide-treated group, thus supporting our 
data in patients with renal impairment [17]. In this study, 43 patients with iMN were treated 
with cyclophosphamide and prednisone and followed for 42 months (range 12 – 72 months) 
[3]. The cumulative incidence of a first partial remission of proteinuria amounted 93%, with 
37% of patients entering a complete remission. The relapse rate was 24%. Two patients 
(5%) have developed end-stage renal disease. Data after a 10-year follow-up are available 
for patients treated with chlorambucil and prednisone [2]. Cumulative incidence of remission 
was 88%, and 10-year renal survival was 92%. We feel that our figures in patients with renal 
insufficiency compare favorably, with a calculated remission rate of 92% at 5 years and a 
renal survival of 89%. Although we have no formal renal survival data of 10 years’ follow-up, 
we feel that the prospects are good since the majority of patients has developed a stable 
remission of proteinuria. Our present data as well as other studies indicate that achievement 
of a stable remission is associated with a good prognosis [28,29]. Side effects are a major 
draw-back of our cyclophosphamide therapy. Obviously, the most dreaded side effect is 
development of malignancies, in particular bladder carcinoma. The development of such 
malignancies is dose-dependent and has been mainly reported in patients with Wegener’s 
granulomatosis who had received a cumulative dose of more than 100 g, or were treated for 
more than a year with a daily dose of 2.0 mg/kg BW [30,31]. In patients with non-Hodgkin’s 
disease, an increased risk for bladder malignancies has been observed with a lower 
cumulative dosage of 20-50 g. However, these patients were simultaneously treated with 
other chemotherapeutics and radiation [32]. In our cyclophosphamide schedule we remain 
far below the dosage of 100 g (e.g. bodyweight 75 kg; ≤55 g). The most noted side effects 
were leukopenia, anemia and infections. In many patients it was necessary to reduce the 
cyclophosphamide dose or to temporarily interrupt treatment. Also, several patients needed 
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in-hospital treatment for infectious problems. Apparently, side-effects are encountered more 
frequently when using immunosuppressive drugs in patients with renal insufficiency [15]. 
Several approaches can be taken to reduce the number of side-effects. First, we currently 
have introduced once daily cotrimoxazole as prophylaxis for infectious complications. 
Second, one could consider reducing the dosage of cyclophosphamide treatment in line with 
the above mentioned schedule designed by Ponticelli et al. [3]. Future studies need to 
assess the efficacy of a lower dose cyclophosphamide in patients with iMN and renal failure. 
Third, side effects may occur less frequently if treatment is started earlier. Patients at risk for 
the development of ESRD can be identified at an early stage by using the proteinuria criteria 
of Pei et al. [33], or by quantitating urinary IgG or β2-microglobulin excretion [34,35].  
In conclusion: combination therapy of oral cyclophosphamide and steroids is effective in 
patients with iMN and renal insufficiency. Treatment results in persistent improvement of 
renal function and remission of proteinuria. We recommend using immunosuppressive 
treatment only in patients with iMN and evidence of renal dysfunction. 
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SUMMARY AND CONCLUSIONS 
 
Proteinuria is a strong predictor of progressive renal insufficiency. The precise mechanisms 
to explain this relationship are still unknown, although many experimental studies have 
shown that proteinuria may induce tubulo-interstitial injury. Many investigators have observed 
that tubulo-interstitial injury better reflects renal insufficiency than glomerular injury. Indeed, 
in pilot-studies we have demonstrated that the urinary excretion of the low molecular weight 
protein β2-microglobulin, a marker of tubulo-interstitial injury, predicts the development of 
chronic renal insufficiency in patients with idiopathic membranous nephropathy. It remains 
unknown which components in proteinuric urine are responsible for the induction of tubulo-
interstitial injury. Identification of these components should enable to develop more specific 
therapeutic interventions and to identify patients at risk for chronic renal insufficiency with 
higher specificity and at an earlier stage. Therefore, we have initiated studies in patients with 
proteinuria to evaluate tubulo-toxic injury and possible mediators. We specifically have 
focussed on patients with membranous nephropathy, the most common cause of the 
nephrotic syndrome in adults. In these patients we also have evaluated the efficacy of 
immunosuppressive therapy.  
 
 
In chapter 2 we describe the course of a familial nephropathy in a mother and her two 
daughters. In all three family members the proteinuria was discovered in early childhood. The 
mother had a persistent proteinuria, exceeding the nephrotic level of 3.5 g/day for more than 
20 years despite treatment with several immunosuppressive drugs. Likewise, in both 
daughters treatment with prednisone was ineffective. In view of the relation between 
proteinuria and tubular cell damage we expected that the persistent nephrotic range 
proteinuria should have led to the development of tubulo-interstitial damage and loss of renal 
function. Remarkably, in these patients there was no evidence of tubulo-interstitial injury, as 
expressed by the low excretion of β2-microglobulin, and all maintained normal renal function. 
Analysis of the proteinuria revealed that the patients had a very selective proteinuria, albumin 
being the main constituent of urinary proteins. Based on the observations in this family we 
can conclude that urinary albumin per se does not cause renal tubular cell damage. 
 
 
In chapter 3 data are presented of a study that was aimed at analysing the site of tubular 
injury in patients with a nephrotic syndrome. Most markers that have been used to assess 
tubular cell injury provide solely information on proximal tubular cells or do not allow 
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differentiating between various tubular segments. Glutathione S transferases (GST) are 
cytosolic enzymes involved in the metabolism of glutathione. Several iso-forms are known, 
with different distribution in the kidney. GST alpha is mainly present in proximal tubular cells, 
whereas GST pi is found in distal tubular cells and collecting ducts. We have measured the 
urinary excretion of both GST alpha and GST pi in 56 patients with glomerular diseases and 
proteinuria. The excretion of both enzymes was elevated compared to values measured in 
healthy controls. The urinary excretion of GST pi was inversely correlated with the creatinine 
clearance, a measure of renal function. The highest levels of GST alpha were found in 
patients with well-preserved renal function. Histological studies confirmed that in these 
patients the GST alpha staining in the proximal tubules was decreased. The data suggest 
that in patients with proteinuria initial injury is localized in the proximal tubules as reflected by 
the increased excretion of GST alpha. However, loss of renal function is characterized by 
increased injury of the distal tubules, as reflected by increased excretion of GST pi. 
Longitudinal studies are needed to confirm this time course of tubular cell injury. 
 
 
Based on experimental data we hypothesized that complement activation may have a 
prominent role in proteinuria-induced tubular cell injury. We questioned if measurement of 
C3d, a degradation product of complement C3, could provide a valuable marker of 
complement activation. As described in chapter 4 we performed a study to evaluate the 
urinary excretion of C3d in patients with various renal diseases. Theoretically, C3d in the 
urine can be derived from locally activated C3. However, urinary C3d excretion may also be 
governed by glomerular filtration of circulating C3d and decreased tubular reabsorption. To 
evaluate the tubular reabsorption of C3d we have measured urinary C3d in 8 patients with 
tubulo-interstitial nephritis (TIN). Patients with TIN have markedly injured tubular cells, which 
results in a decreased reabsorption of proteins. We have used urinary β2-microglobulin as a 
marker of the tubular reabsorption process. We observed that urinary C3d was highly 
correlated with urinary β2-microglobulin, thus indicating that C3d is indeed reabsorbed by the 
proximal tubular cells. We next measured urinary C3d in 79 patients with glomerular 
diseases and proteinuria. In these patients urinary C3d levels were clearly elevated. A 
mathematical analysis suggested that the increased C3d excretion in patients with 
proteinuria was the result of both an increased filtration as well as an increased local 
production of C3d. 
 
 
In the next study, chapter 5, we evaluated the reliability of the creatinine clearance as marker 
of GFR in patients with nephrotic syndrome. In normal daily practice the creatinine clearance 
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is routinely used as marker of GFR. However, creatinine is not only filtered in the glomeruli, 
but also secreted by renal tubular cells. As a consequence creatinine clearance usually 
overestimates glomerular filtration, particularly in patients with impaired renal function. It is 
not known if the tubular handling of creatinine is changed in patients with nephrotic 
syndrome. Therefore we compared in 42 patients with proteinuria the creatinine clearance 
with the clearance of inulin, the golden standard of GFR. The data show that in our patients 
tubular secretion of creatinine was independently related to serum albumin levels. As a 
consequence, creatinine clearance overestimated GFR more markedly in patients with the 
lowest serum albumin levels. Thus, in patients with a recurrent nephrotic syndrome a 
decrease of GFR is not always reflected by an increase of serum creatinine. 
 
 
In chapter 6 we describe the effect of albumin on the tubular reabsorption of β2-microglobulin 
(β2M). Most filtered proteins are reabsorbed by the renal proximal tubular cells after binding 
to ligands in the brush border membrane. The low molecular weight protein β2M is normally 
completely reabsorbed by the proximal tubular cells. Even subtle tubular cell injury is 
reflected by a decreased reabsorption and thus an increased urinary excretion of  β2M. As 
such, urinary β2M excretion was proposed as marker of tubulo-interstitial injury and predictor 
of prognosis in patients with proteinuric renal diseases. However, it was undetermined if 
other urinary proteins could affect tubular reabsorption of β2M merely by competitive 
inhibition at the level of the brush border membrane. We have evaluated the possible role of 
albumin. To increase the tubular load, we administered 40 g albumin intravenously in 10 
patients with a nephrotic syndrome and measured urinary β2M excretion. Although albumin 
excretion increased considerably, we did not observe major changes in urinary β2M 
excretion. Thus, in patients with a nephrotic syndrome urinary β2M can be reliably used as a 
marker of tubular injury. 
 
 
Based upon data from pilot experiments we proposed urinary β2M and IgG as predictors of 
progressive renal failure in patients with idiopathic membranous nephropathy (iMN). 
Previously, high sensitivities and specificities, ranging from 80 to 90% were found, using a 
threshold level of 500 ng/min for β2M-excretion (Uβ2M), and 250 mg/day for the IgG-
excretion (UIgG). In a validation study (chapter 7) we prospectively tested the accuracy of 
Uβ2m and UIgG to predict the renal outcome. We measured Uβ2M and UIgG in 57 patients 
with iMN, proteinuria and normal renal function, and followed these patients prospectively. At 
the end of follow-up 44% of the patients had reached the end point “renal death” which was 
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defined as a rise of serum creatinine of >50%, or a serum creatinine >135 mmol/l (1.5 mg/dl). 
Multivariate analysis confirmed that Uβ2M was the strongest independent factor to predict 
the development of renal insufficiency. Sensitivity and specificity were 88% and 91%, 
respectively, for Uβ2M, and both were 88% for UIgG. When the excretions of both proteins 
were combined, specificity improved to 97%. We conclude that these markers can be used to 
guide decisions on the start of immunosuppressive treatment. 
 
 
There is no consensus with regard to the optimal treatment schedule in patients with 
idiopathic membranous nephropathy (iMN). In chapter 8 we have compared the efficacy of 
two treatment strategies in patients with iMN and renal insufficiency. Fifteen patients were 
treated with oral prednisone (0.5 mg/kg/day, month 1, 3 and 5) in combination with 
chlorambucil (0.15 mg/kg/day, month 2, 4 and 6), and 17 patients were treated with 
prednisone (0.5 mg/kg every other day during 6 months) and oral cyclophosphamide (1.5-2.0 
mg/kg/day during 1 year). In both groups also 3 cycles of methylprednisolone were 
administered intravenously. The groups were comparable in age, renal function, and level of 
proteinuria at start of therapy. Renal function improved in both treatment groups, however 
the improvement was less sustained in the chlorambucil-group. One year after start of 
treatment mean serum creatinine was only 6.3 mmol/l below baseline in the chlorambucil-
group as compared to 121 mmol/l lower in the cyclophosphamide-group (P<0.01). Four 
chlorambucil- and one cyclophosphamide-treated patients developed end-stage renal 
disease. Remissions of proteinuria (<2.0 g/10 mmol creatinine) were observed in 15 of the 
cyclophosphamide treated patients and in 5 chlorambucil treated patients (P<0.01). Of 
course, the better efficacy of the cyclophosphamide regimen could be explained by the 
longer duration of treatment. However, elongation of the treatment period with chlorambucil 
is hardly an option since in 11 of the 15 treated patients chlorambucil had to be stopped 
prematurely because of side effects. From these data we concluded that cyclophosphamide 
was better tolerated and more effective than oral chlorambucil. 
 
 
In chapter 9 we present our extended experience with prednisone and cyclophosphamide 
treatment in 39 patients with idiopathic membranous nephropathy, proteinuria and renal 
insufficiency. The average follow-up was 32 months. Eighteen patients have been followed 
for more than three years. As described in detail above, all patients were treated with 
prednisone during 6 months and cyclophosphamide during 1 year. After start of treatment 
renal function rapidly improved: serum creatinine decreased from 226±108 mmol/l at 
baseline to 143±62 mmol/l after 12 months of treatment. This favourable effect was 
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maintained during the extended follow-up. In 31 patients a partial remission of proteinuria 
(<2.0 g/10 mmol creatinine) was noted, which in 12 patients further improved to a complete 
remission (<0.2 g/10 mmol creatinine). Thus far a relapse of proteinuria occurred in 7 
patients. Side effects of immunosuppressive treatment occurred in the majority of the 
patients, however no serious life-threatening events were observed. Based on the results of 
this study we concluded that treatment with cyclophosphamide and steroids is effective both 
on the short- and long-term in patients with idiopathic membranous nephropathy and renal 
insufficiency. The high incidence of side effects supports our opinion to restrict this treatment 
to patients at risk for end-stage renal disease. 
  139
Chapter 11 
Samenvatting en Conclusies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 11 
 140
 
SAMENVATTING EN CONCLUSIES 
 
Proteïnurie is een goede voorspeller van progressief nierfunctieverlies. Het hoe en waarom 
van deze relatie is niet geheel verklaard, alhoewel meerdere experimentele studies hebben 
aangetoond dat proteïnurie tubulo-interstitiële schade kan induceren. Diverse onderzoekers 
hebben vastgesteld dat tubulo-interstitiële schade een betere maat is voor nierinsufficiëntie 
dan glomerulaire schade. Daarmee in overeenstemming zijn de bevindingen van onze 
pilotstudies waaruit bleek dat de excretie van het laag moleculaire eiwit β2-microglobuline, 
een marker voor tubulo-interstitiële schade, de ontwikkeling van nierinsufficiëntie voorspelde 
bij patiënten met een idiopathische membraneuze nefropathie. Het is nog onbekend welke 
specifieke componenten in eiwitbevattende urine verantwoordelijk zijn voor het induceren 
van tubulo-interstitiële schade. Identificatie van deze componenten zou kunnen leiden tot de 
ontwikkeling van een meer gerichte behandeling. Ook wordt het dan mogelijk om al in een 
vroege fase van de ziekte met grote specificiteit die patiënten te identificeren die een 
verhoogd risico hebben om chronische nierinsufficiëntie te ontwikkelen. Daarom zijn we 
gestart met onderzoeken bij patiënten met proteïnurie met als doel tubulo-interstitiële schade 
te kwantificeren en de mogelijke mediatoren te identificeren. We hebben ons met name 
gericht op patiënten met een membraneuze nefropathie, de meest voorkomende oorzaak 
van het nefrotisch syndroom bij volwassenen. Bij deze patiënten hebben we tevens de 
effectiviteit van immunosuppressieve therapie geëvalueerd. 
 
 
In hoofdstuk 2 beschrijven we het beloop van een familiaire nefropathie bij een moeder en 
haar twee dochters. Bij allen werd proteïnurie ontdekt op de vroege kinderleeftijd. De moeder 
had gedurende meer dan 20 jaar een proteïnurie van meer dan 3.5 g/dag ondanks 
behandeling met diverse immunosuppressieve middelen. Ook bij beide dochters bleek 
behandeling met prednison niet effectief. Vanwege de sterke relatie tussen proteïnurie en 
tubuluscelschade hadden we verwacht dat de persisterende proteïnurie zou hebben geleid 
tot de ontwikkeling van tubulo-interstitiële schade en verlies van nierfunctie. Opmerkelijk is 
echter dat deze patiënten geen tekenen hadden van tubulo-interstitiële schade, getuige de 
lage uitscheiding van β2-microglobuline. De nierfunctie was volstrekt normaal gebleven. Bij 
nadere analyse bleek dat er sprake was van een zeer selectieve proteïnurie, met albumine 
als de belangrijkste component van het eiwit in de urine. Op grond van onze bevindingen in 
deze familie kunnen we concluderen dat albumine in de urine niet zonder meer renale 
tubuluscelschade veroorzaakt. 
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In hoofdstuk 3 worden de gegevens gepresenteerd van een studie die als doel had het 
analyseren van de plaats van de tubulusschade bij patiënten met een nefrotisch syndroom. 
De meeste markers die worden gebruikt om tubulusschade te beoordelen geven alleen 
informatie over de proximale tubuluscellen, of maken het niet mogelijk om te differentiëren 
tussen verschillende tubulussegmenten. Glutathione S transferases (GST) zijn cytosolische 
enzymen die betrokken zijn bij het metabolisme van glutathion. Er zijn diverse isovormen 
bekend, met verschillende distributie in de nier. GST alpha is hoofdzakelijk aanwezig in de 
proximale tubuluscellen, terwijl GST pi beperkt is tot distale tubuluscellen en de 
verzamelbuizen. Wij hebben de uitscheiding in de urine van zowel GST alpha als GST pi 
gemeten bij 56 patiënten met glomerulaire nierziekten en proteïnurie. Zowel van GST alpha 
als GST pi was de uitscheiding verhoogd. De excretie van GST pi was omgekeerd evenredig 
gecorreleerd met de creatinine klaring, een maat voor de nierfunctie. De hoogste GST alpha 
waarden werden waargenomen bij patiënten met een goede nierfunctie. Histologisch 
onderzoek bevestigde dat bij deze laatstgenoemde patiënten de GST alpha kleuring in de 
proximale tubuluscellen was verminderd. De bevindingen suggereren dat in de beginfase bij 
patiënten met proteïnurie de schade is gelocaliseerd in de proximale tubuluscellen, met als 
gevolg een verhoogde uitscheiding van GST alpha. Echter, bij verlies van nierfunctie blijkt er 
meer sprake van schade van distale tubuluscellen, zoals gereflecteerd door de verhoogde 
uitscheiding van GST pi. Er zijn longitudinale studies nodig om dit beloop van 
tubuluscelschade in de tijd te bevestigen. 
 
 
Op basis van gegevens verkregen uit experimenteel onderzoek lijkt het logisch te 
veronderstellen dat complementactivatie een prominente rol speelt bij proteïnurie-
geïnduceerde tubuluscelschade. Wij stelden de vraag of C3d, een degradatieproduct van 
complement C3, in de urine een goede marker zou zijn voor complementactivatie. We 
hebben de uitscheiding van C3d in de urine bepaald bij patiënten met verschillende 
nierziekten (hoofdstuk 4). Theoretisch kan C3d in de urine terechtkomen door activatie van 
locaal aanwezig C3. C3d kan echter ook in de urine terecht komen door glomerulaire filtratie 
van C3d en/of een verminderde tubulaire reabsorptie. Om een indruk te krijgen van de 
tubulaire reabsorptie hebben we C3d gemeten in de urine van 8 patiënten met een tubulo-
interstitiële nefritis (TIN). Patiënten met een TIN hebben evidente tubuluscelschade hetgeen 
leidt tot een verminderde tubulaire reabsorptie van eiwitten. Als marker voor het tubulaire 
reabsorptie proces hebben we de uitscheiding van β2-microglobuline gebruikt. De 
uitscheiding van C3d was sterk gecorreleerd met de uitscheiding van β2-microglobuline 
hetgeen suggereert dat C3d inderdaad wordt gereabsorbeerd door de tubuluscellen. 
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Vervolgens hebben we C3d gemeten in de urine van 79 patiënten met glomerulaire 
nierziekten en proteïnurie. In deze patiënten was de concentratie van C3d in de urine 
duidelijk verhoogd. De resultaten van een mathematische analyse suggereerden dat de 
toegenomen uitscheiding van C3d in de urine van patiënten met proteïnurie het resultaat was 
van zowel toegenomen filtratie als toegenomen locale productie van C3d. 
 
 
In het volgende onderzoek, beschreven in hoofdstuk 5, hebben we de betrouwbaarheid van 
de creatinine-klaring als maat voor de GFR bestudeerd in patiënten met een nefrotisch 
syndroom. In de normale dagelijkse praktijk wordt de creatinine-klaring routinematig gebruikt 
als maat voor de GFR. Creatinine wordt echter niet alleen gefiltreerd door de glomeruli, maar 
ook gesecreteerd via de tubuluscellen. Het gevolg hiervan is dat de creatinine-klaring in het 
algemeen de GFR overschat, met name bij patiënten met een gestoorde nierfunctie. Het is 
niet bekend of het tubulaire transport van creatinine is veranderd in patiënten met een 
nefrotisch syndroom. Daarom hebben we bij 42 patiënten met proteïnurie de creatinine-
klaring vergeleken met de inuline-klaring, de gouden standaard voor de GFR. De tubulaire 
secretie van creatinine bleek op onafhankelijke wijze gerelateerd aan het serum albumine, 
met als gevolg dat de overschatting van de GFR door de creatinine-klaring meer 
uitgesproken was bij patiënten met het laagste serum albumine. Een afname van de GFR bij 
patiënten die een nefrotisch syndroom ontwikkelen wordt dus niet zonder meer weerspiegeld 
door een gelijktijdige stijging van het serum creatinine. 
 
 
In hoofdstuk 6 beschrijven we het effect van albumine op de tubulaire reabsorptie van β2-
microglobuline (β2M). De meeste gefiltreerde eiwitten worden, na binding aan een ligand in 
de brush border membraan, gereabsorbeerd door de renale proximale tubuluscellen. Het 
laag moleculaire eiwit β2M wordt onder normale omstandigheden volledig gereabsorbeerd 
via de proximale tubuluscellen. Zelfs minimale schade aan de tubuluscellen wordt al 
weerspiegeld door een verminderde reabsorptie en dus een verhoogde excretie van β2M. 
Als zodanig wordt de uitscheiding van β2M in de urine beschouwd als een marker voor 
tubulo-interstitiële schade en een voorspeller ten aanzien van de prognose bij patiënten met 
nierziekten en proteïnurie. Het was echter niet duidelijk of andere eiwitten in de urine in staat 
waren de tubulaire reabsorptie van β2M via een competitief mechanisme op het niveau van 
de brush border membraan te beïnvloeden. We hebben de mogelijke rol van albumine 
onderzocht. Om het tubulaire aanbod te vergroten, hebben we intraveneus 40 g albumine 
toegediend aan 10 patiënten met een nefrotisch syndroom en het effect hiervan op de 
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uitscheiding van β2M onderzocht. Ondanks een aanzienlijke toename van de uitscheiding 
van albumine, zagen we geen grote veranderingen in de uitscheiding van β2M. Uit deze 
resultaten kunnen we concluderen dat bij patiënten met een nefrotisch syndroom urine β2M 
kan worden gebruikt als betrouwbare maat voor tubulusschade. 
 
 
Gebaseerd op de resultaten van pilotstudies hebben wij gesuggereerd dat β2-microglobuline 
en IgG in de urine voorspellende factoren zijn voor de ontwikkeling van progressief nierfalen 
bij patiënten met idiopathische membraneuze nefropathie (iMN). In deze eerdere studies 
bedroegen de sensitiviteit en specificiteit 80 tot 90%, uitgaande van een drempelwaarde van 
500 ng/min voor β2-microglobuline (Uβ2m), en 250 mg/24 uur voor IgG (UIgG). In een 
validatiestudie, beschreven in hoofdstuk 7, hebben we de betrouwbaarheid van de 
voorspellende waarde van Uβ2m en UIgG voor nierfunctieverlies getest. We hebben Uβ2m 
en UIgG gemeten in 57 patiënten met iMN, proteïnurie en normale nierfunctie en deze 
patiënten prospectief gevolgd. Aan het einde van de follow-up had 44% van de patiënten het 
eindpunt van nierfalen, gedefinieerd als een stijging van het serum creatinine >50% of een 
serum creatinine >135 µmol/l, bereikt. Multivariaat analyse bevestigde dat Uβ2m de sterkste 
onafhankelijke voorspellende factor voor de ontwikkeling van nierinsufficiëntie was. De 
sensitiviteit en specificiteit bedroegen respectievelijk 88% en 91%. Indien de uitscheiding van 
β2m en IgG werden gecombineerd, verbeterde de specificiteit tot 97%. Op basis van deze 
studie concluderen wij dat Uβ2m  en UIgG kunnen worden gebruikt voor het bepalen van de 
noodzaak tot het starten van immunosuppressieve therapie. 
 
 
Er bestaat geen consensus over de optimale behandeling van patiënten met een 
idiopathische membraneuze nefropathie (iMN). In hoofdstuk 8 hebben we de effectiviteit 
vergeleken van twee behandelschema’s toegepast bij patiënten met iMN en 
nierinsufficiëntie. Vijftien patiënten werden behandeld met oraal prednison (0.5 mg/kg/dag, 
maand 1, 3 en 5), in combinatie met chloorambucil (0.15 mg/kg/dag, maand 2, 4 en 6), en 17 
patiënten werden behandeld met prednison (0.5 mg/kg om de dag, gedurende 6 maanden)  
en oraal cyclofosfamide (1.5-2.0 mg/kg/dag, gedurende 1 jaar). Beide groepen ontvingen 
daarnaast methylprednisolon intraveneus gedurende 3 cycli. De patiënten groepen waren 
vergelijkbaar wat betreft leeftijd, nierfunctie en ernst van de proteïnurie op het moment van 
de start van de behandeling. De nierfunctie verbeterde in beide groepen, echter de 
verbetering was minder uitgesproken in de chloorambucil-groep. Eén jaar na start van de 
behandeling was het gemiddelde serum creatinine slechts 6.3 µmol/l lager dan de 
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uitgangswaarde in de chloorambucil-groep en 121 µmol/l lager in de cyclofosfamide-groep 
(P<0.01). Bij vier van de met chloorambucil behandelde patiënten en één met cyclofosfamide 
behandelde patiënt ontwikkelde zich een terminale nierinsufficiëntie. Een remissie van 
proteïnurie (<2 g/10 mmol creatinine) werd waargenomen bij 15 van de met cyclofosfamide 
behandelde patiënten en bij 5 van de met chloorambucil behandelde patiënten (P<0.01). 
Natuurlijk kan het zo zijn dat de betere effectiviteit van cyclofosfamide is toe te schrijven aan 
de langere duur van deze behandeling. Verlenging van de behandeling met chloorambucil is 
echter nauwelijks een optie aangezien bij 11 van de 15 patiënten de behandeling met 
chloorambucil voortijdig moest worden gestopt wegens bijwerkingen. Op grond van deze 
gegevens concluderen wij dat cyclofosfamide beter wordt verdragen en effectiever is dan 
chloorambucil. 
 
 
In hoofdstuk 9 beschrijven we onze langere termijn ervaringen met de combinatietherapie 
prednison en cyclofosfamide gebaseerd op gegevens van 39 patiënten met een 
idiopathische membraneuze nefropathie, proteïnurie en nierinsufficiëntie. De gemiddelde 
follow-up duur was 32 maanden. Achttien patiënten hadden een follow-up van meer dan 3 
jaar. Zoals in detail in het voorgaande beschreven, werden alle patiënten behandeld met 
prednison gedurende 6 maanden en cyclofosfamide gedurende 1 jaar. Na start van de 
behandeling verbeterde de nierfunctie al snel: het serum creatinine daalde van 226±108 
µmol/l bij het begin tot 143±62 µmol/l na 12 maanden behandeling. Dit gunstige effect bleef 
aanwezig gedurende de follow-up. Bij 31 patiënten ontstond een partiële remissie van de 
proteïnurie (<2.0 g/10 mmol creatinine), en bij 12 uiteindelijk een complete remissie (<0.2 
g/10 mmol creatinine). Tot nu toe namen wij bij 7 patiënten een recidief van de proteïnurie 
waar. De meeste patiënten ontwikkelden bijwerkingen als gevolg van de 
immunosuppressieve behandeling, al was de ernst hiervan meestal beperkt. Gebaseerd op 
de resultaten van deze studie mogen we concluderen dat behandeling met cyclofosfamide 
en prednison effectief is, zowel op de korte als de langere termijn, voor patiënten met een 
idiopatische membraneuze glomerulopathie en nierinsufficiëntie. De hoge incidentie van 
bijwerkingen ondersteunt onze mening dat deze behandeling beperkt moet blijven tot die 
patiënten met een verhoogd risico op ontwikkeling van een terminale nierinsufficiëntie. 
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DANKWOORD 
 
Na een lange weg is het er toch van gekomen: het proefschrift is klaar. Dit was niet mogelijk 
geweest zonder de hulp en inspanning van vele mensen, inclusief alle patiënten die hebben 
meegewerkt. Het is onmogelijk om alle betrokkenen in dit dankwoord te vermelden; daarom 
aan allen die mijn pad de afgelopen jaren hebben gekruist en een bijdrage hebben geleverd 
aan het volbrengen van mijn onderzoekstaken en opleiding hierbij mijn welgemeende dank.  
 
Een aantal mensen wil ik natuurlijk toch nog expliciet met naam noemen. Ik ervaar dit 
dankwoord als bijzonder omdat de eerst genoemde persoon ook de laatst genoemde zal zijn.  
Jack (Prof. Wetzels), met respect en bewondering heb ik jou als onderzoeksleider jaren 
kunnen volgen. Je bent enorm gedreven in je werkzaamheden. Je (literatuur)kennis, inzicht 
en snelheid van werken zijn door weinigen te overtreffen. Dank voor je steun en begeleiding.  
Beste Rob (Prof. Koene), toen ik in 1992 bij de afdeling nierziekten begon, was je het hoofd 
van deze afdeling. Ik had een moeizame start bij het verwezenlijken van mijn doelen. Je hebt 
in de loop der jaren een enorme sleutelrol gespeeld zodat ik toch de route kon volgen om 
internist te worden en promotieonderzoek te doen; ik ben je veel dank verschuldigd voor alle 
steun en vertrouwen. 
Beste Jo (Prof. Berden), in 1992 was jij degene die naar Mierlo belde met de vraag of ik 
interesse had in een baan als AGNIO. Jij was het startpunt van mijn “nefro-loopbaan” en 
hebt me tot aan het einde van het onderzoek de mogelijkheid geboden het werk af te maken, 
mijn dank hiervoor.  
Overige (ex-)stafleden van de afdeling nierziekten (Roland, Andries, Frans, Henk, Ine, 
Luuk, Ruud, Gerald, inmiddels ook Heinrich): jullie hebben mij in de loop der jaren 
begeleid bij onderzoek en patiëntenzorg. Ik dank jullie voor de inhoudelijke begeleiding, maar 
met name ook voor de gemoedelijke, prettige sfeer die de afdeling nierziekten al jarenlang zo 
karakteriseert.  
Alle meewerkende internist-nefrologen: de hieronder genoemde collegae hebben in de 
afgelopen jaren patiënten naar Nijmegen verwezen voor proteïnurie analyse en deelname 
aan een van de onderzoeken in dit proefschrift : 
 
Amsterdam, St. Lucas Andreas Ziekenhuis: Dr B. Potter van Loon 
Apeldoorn, Gelre Ziekenhuizen locatie Lucas: Dr J. Barendregt 
Arnhem, Rijnstate Ziekenhuis: Dr F. Bosch, Dr R. van Leusen, Dr K. Parlevliet, Dr L. 
Reichert 
Beverwijk, Rode Kruis Ziekenhuis: Dr G. Schrijver 
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Breda, Amphia Ziekenhuis: Dr P. Stijnen, Dr G. Verburg 
Doetinchem, Slingeland Ziekenhuis: Drs G. Bruinings, Dr E. Muller 
Ede, Ziekenhuis Gelderse Valei: Dr G. Feith, Drs M. den Hartog 
Eindhoven, Maxima Medisch Centrum: Dr A. Lieverse 
Enschede, Medisch Spectrum Twente: Drs R. Brouwer 
Geldrop, St. Anna Ziekenhuis: Drs R. Smeets 
Heerlen, Atrium Medisch Centrum: Dr L. Frenken 
’s-Hertogenbosch, Jeroen Bosch Ziekenhuis: Dr J. Beutler, Dr A. Hollander, Dr J. Jansen, 
Dr M. Koolen 
Nijmegen, Canisius Wilhelmina Ziekenhuis: Dr M. ten Dam, Dr I. Go, Dr M. Schuurmans 
Roermond, Laurentius Ziekenhuis: Drs W.Grave, Dr J. Wirtz 
Roosendaal, Ziekenhuis Franciscus: Drs D. de Gooyer, Drs T. Noordzij, Drs H. van 
Roermund 
Tiel, Ziekenhuis Rivierenland: Dr P. Bleeker 
Tilburg, St. Elisabeth Ziekenhuis: Dr A. Apperloo, Dr P. Rensma 
Tilburg, TweeSteden Ziekenhuis: Dr P. Spooren 
Veghel, Ziekenhuis Bernhoven: Dr L. van Hulsteijn 
Veldhoven, Maxima Medisch Centrum: Dr P. Gerlag, Dr A. van den Wall Bake 
Venlo, VieCuri Medisch Centrum: Dr W. van Kuijk, Dr A. Luik, Dr V. Verstappen 
Zwolle, Isala Klinieken: Dr G. Kolsters, Dr J. Offerman 
 
De jarenlange studies bij patiënten met proteïnurie konden alleen worden uitgevoerd dankzij 
de medewerking van U/jullie allen. Het verwijzen van patiënten voor de “2-uurs metingen”, 
het doorsturen van de benodigde data en de gastvrije ontvangst als ik data wilde komen 
verzamelen zijn van essentieel belang geweest om te komen tot het huidige resultaat. Ik 
hoop dat deze goede werkrelatie tussen de perifere centra en de academische afdeling 
nefrologie te Nijmegen een lange toekomst heeft, naar tevredenheid van alle partijen. 
Beste Peggy (du Buf-Vereijken), destijds als nefroloog in opleiding raakte je betrokken bij het 
proteïnurie-onderzoek bij patiënten met membraneuze glomerulopathie. Je enthousiasme 
lijkt vaak nauwelijks te temperen. Met bewondering heb ik gezien hoe je de drukke weg naar 
de  promotie hebt afgelegd. Ik heb onze samenwerking erg gewaardeerd en het is plezierig 
om de promotiedag samen met jou en Gerard te kunnen vieren. Beste Gerard (du Buf),  je 
bent zeer waardevol en onmisbaar geweest bij het verwezenlijken van een wens die ik al 
jaren had: een Accessbestand voor de data van het proteïnurieonderzoek. Je hebt daar op 
vrijwillige basis (samen met Peggy!) erg veel tijd ingestoken, en het resultaat mag er zijn. 
Ook ben je behulpzaam geweest bij het drukklaar maken van “het (dit) boekje”. Mijn dank 
hiervoor. Beste Iris (Kremer) en Marijke (Rodermond), jullie staan aan de basis van de 
  
 147 
uitvoering van de “2-uurs urinemetingen”. Jullie hebben veel werk verricht bij het begeleiden 
van de patiënten tijdens de vele metingen en de registratie/opslag van al het materiaal. Als ik 
weer eens iets in de procedure wilde wijzigen hielpen jullie mij zonder gemopper; dank voor 
jullie goede inzet.  
Beste Annemiek (Wellesen-Polman), Simone (Mooren) en Yvonne (Hooghof), jullie hebben 
de uitvoering van de metingen sinds een aantal jaren overgenomen. In deze laatste jaren 
was ik zelf steeds minder op de functiekamer en verliep het overleg regelmatig per e-mail. 
Vanaf het begin heb ik er het volste vertrouwen in gehad dat de metingen en alles wat daar 
bij komt bij jullie in goede handen was en is.  
Vanaf 1995 zijn er vele honderden bloed- en urinemonsters naar de laboratoria gegaan voor 
diverse eiwit-, enzym, en complement bepalingen. Voor al het werk dat daaraan verbonden 
was (en is) wil ik alle medewerkers van het voormalige immunochemisch laboratorium 
onder leiding van Ina Klasen hartelijk bedanken. Wilbert Peters, Theo Mulder en Hennie 
Roelofs van het laboratorium MDL wil ik bedanken voor hun inzet bij de verwezenlijking en 
uitvoer van de bewerkelijke GST-bepalingen.  
Voor diverse onderzoeken was het nodig om PA van nierbiopten opnieuw te beoordelen en 
en/of voor publicaties tot mooie afbeeldingen te verwerken. Van de afdeling pathologie wil ik 
voor hun vakkundige inzet en prettige contact danken Karel Assmann en Henry Dijkman. 
Jaap van den Born wil ik bedanken voor zijn belangrijk aandeel in het onderzoek naar de 
expressie van heparan sulfaat proteoglycanen zoals beschreven in hoofdstuk 2.  
In de loop der jaren heb ik diverse kamergenoten gehad, collega-onderzoekers en collega 
arts-assistenten: aan allen mijn dank voor het delen van ervaringen en leuke contacten. 
 
Beste Ilse en Camiel, al meer dan 10 jaar zijn jullie door dik en dun goede vrienden. Jullie 
zijn een enorme steun, alleen al doordat ik weet dat ik altijd bij jullie aan kan kloppen. Ik hoop 
op nog vele jaren van goede vriendschap. Ilse en Erik, het is fijn dat jullie als mijn 
paranimfen naast mij staan op deze voor mij zo bijzondere dag; dank voor jullie 
aanwezigheid en inzet.  
Lieve pap en mam, als kleuter zei ik al dat ik “dokteres” wilde worden. Een droom die jullie 
altijd hebben gesteund. Ik ben me altijd bewust geweest van jullie betrokkenheid, die zelfs tot 
uiting kwam door brandende kaarsjes op spannende (examen)momenten. Een goed 
thuisfront, zoals jullie (met Arthur) aan mij hebben gegeven, is van onschatbare waarde. 
Lieve Jack, zoals ik aan het begin al aankondigde, sluit ik dit dankwoord met jou af. Aan het 
einde van een dankwoord is vaak te lezen dat het t.a.v. het werk nu wel rustiger zal worden. 
Voor ons zal dit laatste voorlopig niet opgaan, maar dat staat een fijne, goede toekomst voor 
ons samen niet in de weg. 
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internist werd grotendeels gevolgd in het Universitair Medisch Centrum St Radboud te 
Nijmegen (opleider Prof. Dr J.W.M. van der Meer) en vanaf juli 2002 in het Canisius 
Wilhelmina Ziekenhuis te Nijmegen (opleider Dr. A.S. Dofferhoff). Sinds januari 2004 staat zij 
geregistreerd als internist. In september 2004 startte zij met de opleiding  reumatologie in het 
Universitair Medisch Centrum St. Radboud te Nijmegen (opleider Prof. Dr. P.L.C.M. van 
Riel). Zij woont samen met Jack Wetzels.  
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ADDENDUM CHAPTER  2 :   Figure 2 and 3 (page 24) in color. 
 
 
 
 
 
 
 
 
 
Figure 3. Light and electron microscopic pictures of the third biopsy of the mother.  
(A) Normal-looking glomerulus, methenamine silver staining , x350. (B) Electron microscopy 
of a part of a capillary loop. The foot processes of the podocytes reveal no retraction, x12,000. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Immunofluorescence of the third biopsy of the mother (A and B) and  
a biopsy of a patient with classical minimal change nephropathy (C and D).  
Unchanged presence of (A) heparan sulfate side chains as detected by monoclonal  
antibody (mAb) JM 403, and  (B) core protein as demonstrated by mAb JM 72 of he- 
paran sulfate proteoglycan (HSPG) along the capillary loops. In the biopsy of a patient  
with classical minimal change nephropathy staining of the core protein of HSPG is  
normal (C), while the heparan side chains have completely disappeared (D, x600). 
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ADDENDUM CHAPTER 3 :   Figure 2 and 3 (page 39) in color. 
 
Figure 2.  
Light microscopic pre-
sentation of renal biopsy 
specimens from 2 pat-
ients with IgA nephro-
pathy and differing GST 
iso-enzyme excretion 
Periodic acid-Schiff. x400 
A Specimen from a 
patient with an increased 
urinary level of GST alpha (81 μg/10 mmol creatinine), and a relatively low excretion of GST pi (25 
μg/10 mmol creatinine). Epithelial cells of proximal tubules are damaged (arrows) with loss of brush 
border, whereas distal tubular cells (arrowheads) look normal. B  Specimen from a patient with an 
increased excretion of GST pi (58 μg/10 mmol creatinine) and a slightly elevated level of GST alpha 
(17 μg/10 mmol creatinine). In this patient the distal tubular cells are more severely damaged than the 
proximal tubular cells, as reflected by prominent nuclear and cellular atypia (arrow).  
 
Figure 3. 
Immunofluorescence 
double staining for  GST 
alpha  (A,C) and phalloï-
din (B,D) of renal biopsy 
specimens  from  2  pat-
ients.   A,C   Specimens 
from a  patient with focal 
glomerulosclerosis, 
moderate proteinuria, 
and low levels of both 
GST alpha and pi (17, 
14 μg/10 mmol creat-
inine, respectively). The 
proximal tubules can be 
easily recognized by the 
presence of intact brush 
borders. All proximal 
tubules show homogeneous staining of both GST alpha (A: bright green-colored cells) and of 
phalloïdin (B: bright red-colored brush border, arrow).  C,D  Specimens from the patient with IgA 
A B
A B
C D
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nephropathy shown in fig. 2A. GST alpha excretion was 81 μg/ 10 mmol creatinine. The proximal 
tubules are damaged as indicated by the irregular and sometimes absent brush border staining (arrow 
in D). Staining of the proximal tubules for GST alpha revealed a variable intensity, with clear loss of 
staining in most proximal tubules (C). 
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